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Uterine fibroids are benign tumors that arise from the smooth-muscle uterine cells 
(myometrium) and are the most common uterine disorder occurring in as many as 30% of 
women over 35 years of age. Despite their frequent occurrence, the etiology of uterine 
fibroids is not well elucidated. Several studies have shown that numerous tumors can be 
regulated by cyclooxygenase (COX) enzyme products but their role in uterine fibroids is 
not well established.  
 
The initial aim of the study was to determine the expression level of COX enzymes 
and prostaglandin receptors in fibroids and autologous myometrium samples from women 
with fibroids. Real-Time reverse-transcriptase polymerase chain reaction (RT-PCR) 
revealed that the expression of COX enzymes, EP1, EP2 and EP4 prostanoid receptors and 
prolactin were not significantly altered while the EP3 subtype receptor was significantly 
down-regulated in fibroids compared to adjacent myometrium samples. The EP3 receptor 
has a protective role in tumor development suggesting the role for down-regulation of the 
receptor in uterine fibroids pathology.   
 
In addition, the expression of COX enzymes, prostaglandin receptors and 
prostaglandin-mediated genes were assessed in endometrium samples from women with 
and without uterine fibroids in different stages of the menstrual cycle. COX-2 and 
interleukin-8 (IL-8) mRNA expressions were significantly higher in both proliferative 
stage and early-mid secretory, EP2 receptor and IL-11 were elevated in the proliferative 
stage, vascular endothelial growth factor (VEGF) was highly expressed in the early-mid 
secretory phase while FP receptor was up-regulated in all stages of the menstrual cycle in 
endometrium samples from women with fibroids. These data suggest that up-regulation of 
COX-2 and prostaglandin receptors (EP2 and FP) in endometrium can induce expression 
of angiogenic and mitogenic factors such as VEGF, IL-8 and IL-11 which might act in a 
paracrine manner on neighboring myometrial/fibroid tissue to promote angiogenesis and 











Furthermore, since EP2 and FP receptors were up-regulated in the proliferative 
phase of endometrium from uterine fibroid patients and the receptors are co-expressed in 
endometrial adenocarcinoma (Ishikawa) cells, this study investigated a possible cross-talk 
that influences intracellular signalling by using Ishikawa cells stably expressing the EP2 
and FP receptors (FPEP2 cells) as a model cell line. Real-Time RT-PCR, Western blot 
analysis and immunofluorescence microscopy confirmed stable expression of the EP2 and 
FP receptors in FPEP2 cells localized to the perinuclear and plasma membrane. 
 
Using FPEP2 cells, the integrated effect of Butaprost (EP2 receptor ligand) and 
PGF (FP receptor ligand) co-administration on inositol phosphate (IP3) and adenosine 
3’,5’-cyclic monophosphate (cAMP) release was assessed to study a possible 
heterologous-interaction or cross-talk between the EP2 and FP receptors. The study 
showed that in FPEP2 cells, PGF alone does not alter cAMP production, but in 
combination with Butaprost augments EP2 receptor-mediated cAMP release. PGF-
mediated potentiation of cAMP release was abolished by antagonism of the FP receptor, 
inhibition of phospholipase C (PLC) and IP3-receptor whereas inhibition of protein kinase 
C (PKC) had no effect suggesting the cross-talk is mediated by FP receptor activation of 
IP3 release. Moreover, inhibition of calcium effectors using calmodulin antagonist (W7) 
or Ca
2+
/calmodulin-dependent kinase II (CaMK-II) inhibitor (KN-93) abolished PGF 
potentiation of Butaprost-mediated cAMP release. Using short interfering RNA (siRNA) 
molecules targeted against the adenylyl cyclase 3 (AC3) isoform, the study showed the 
isoform to be responsible for the cross-talk between the FP and EP2 receptors.  
 
In order to determine the integrative effects of the EP2 and FP receptors co-
activation on gene expression, a whole genome array profiling in FPEP2 cells in response 
to Butaprost and/or PGF was performed. The gene array revealed 228 genes that are 
regulated by co-activation of the EP2 and FP receptors that are involved in cell 












In addition, co-activation of EP2 and FP receptors with their respective ligands 
enhanced or repressed a set of EP2 receptor-regulated genes. One of the genes identified, 
SAT1 (Spermidine/ N1-acetyltransferase), was regulated by the EP2 and FP receptors 
cross-talk via the calcium sensitive AC3 isoform. SAT1, with known role in regulation of 
tumorigenesis was also up-regulated in the proliferative stage of endometrium samples 
from women with uterine fibroids suggesting the EP2 and FP receptor cross-talk 
characterized in vitro can also happen in vivo.   
 
In conclusion, this study reports that COX-2, EP2 and FP receptors, VEGF, IL-8, 
IL-11 and SAT1 are up-regulated in endometrium from women with uterine fibroids. 
These genes play a major role in development of fibroids by facilitating angiogenesis and 
cell growth and by inhibiting apoptosis via autocrine/paracrine mechanisms. In addition, 
this study demonstrates that co-activation of the EP2 and FP receptors results in enhanced 
release of cAMP via the FP receptor-Gαq-Ca
2+
-calmodulin pathway by activating the 
calcium-sensitive AC3 isoform and modulates a molecular switch which alters the trans-
activation of a subset single-receptor induced genes that have important functions in the 
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1.1 Introduction  
Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin have been 
widely used for the treatment of a wide spectrum of pathological conditions over the 
last century without understanding the mechanism of their action. Only in 1971, was 
the molecular mechanism of NSAID revealed. Vane (1971) demonstrated that NSAIDs 
reduce inflammation by inhibiting cyclooxygenase (COX) and won a Nobel Prize in 
medicine for this discovery. COX is a rate limiting enzyme that catalyzes the first two 
steps in the biosynthesis of prostaglandins, thromboxanes and leukotrienes 
(collectively called eicosanoids) from the substrate arachidonic acid (Vane et al., 
1998).  
 
1.2 Arachidonic Acid Metabolism  
Arachidonic acid, an essential fatty acid derived from elongation and oxidation 
of linoleic acid is incorporated by ester linkage into membrane phospholipids and 
triglycerides. In response to stimulation by cytokines, growth factors, circulating 
hormones or stress, arachidonic acid gets hydrolyzed by secretory or cytoplasmic or 
both types of phospholipase A2 (sPLA2, cPLA2) and released from the sn-2 position of 
the membrane triglycerides (Marnett, 1992; Wang et al., 2007).  
 
Arachidonic acid gets oxidized by the rate limiting enzyme COX to form 
prostaglandin G2 (PGG2). The hydroxy endoperoxide (PGH2) gets synthesized from 
PGG2 reduction and serves as a substrate for terminal prostanoid synthase enzymes to 
produce specific prostanoids (prostaglandins, prostacyclins and thromboxanes) 
(Marnett, 1992; Smith et al., 2000) (Fig 1.1). The enzymes are named according to 
their respective prostanoids, such that prostaglandin E2 (PGE2) by prostaglandin E 
synthase, prostaglandin F2 (PGF2) by prostaglandin F synthase, prostaglandin D2 
(PGD2) by prostaglandin D synthase, prostacyclin (PGI2) by prostaglandin I synthase 
(PGIS) and thromboxane (TX) by thromboxane synthase (TXS) (Narumiya et al., 
1999; Sales and Jabbour, 2003). The prostanoids formed are released from cytoplasm 
and transported by prostaglandin transporter (PGT) outside of the cells to act on their 
















                      
 
Fig. 1.1: The arachidonic acid metabolism
1  
Arachidonic acid gets hydrolyzed by phospholipase A2 and released from the membrane 
triglycerides. It then gets oxidized and reduced to PGH2 by the rate limiting enzyme COX. 
PGH2 then serves as a substrate for terminal prostanoid synthase enzymes to produce specific 
prostanoids (prostaglandins, prostacyclins and thromboxanes).  
 
1.3 Cyclooxygenase Enzyme Isoforms 
COX, a membrane-bound heme-containing enzyme, was cloned in 1988 and 
has three isoforms termed as COX-1, COX-2 and COX-3 according to the order of 
their discovery. COX-1 and COX-2 are derived from two different genes, while COX-
3 is a splice variant of COX-1. COX-1 is believed to be constitutively expressed, while 
COX-2 is an inducible isoform mostly expressed at sites of inflammation (Fu et al., 
1990; Vane et al., 1998; Davies et al., 2004). COX-3 was suggested to be a third 
physiological form of COX enzyme by Willoughby et al. (2000) after identifying a 
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different form of late-induced COX enzyme that appears 48 hours after the onset of 
inflammation.  
 
COX enzymes catalyze a cyclooxygenase and a peroxidase reaction to 
synthesize PGH2, hence the enzymes are also called PGH2 synthase. The 
cyclooxygenase reaction occurs in a hydrophobic channel in the core of the enzyme 
and can be irreversibly inhibited by acetylation of the site with aspirin, while the 
peroxidase reaction happens at a heme-containing active site that is located near the 
enzyme surface and other NSAIDs like indomethacin produce both reversible and 
irreversible inhibition by competing with the substrate (Vane et al., 1998; Smith et al., 
2000).  
 
1.3.1 Cyclooxygenase-1 (COX-1)  
The human COX-1 gene, approximately 22 kb in length, is located on 
chromosome 9 and is transcribed as 2.8 kb mRNA. COX-1 cDNA encodes a 
glycoprotein that is processed from 576 amino acids with molecular mass of 70 kDa. It 
exists as a homodimer and is preferentially integrated in plasma membrane (Tanabe 
and Tohnai, 2002; Kang et al., 2007). The promoter region for COX-1 lacks TATA or 
CAAT box and contains two Sp1 motifs, two AP-2 sites, a GATA and NF-IL6 motif, 
all characteristics of a “housekeeping” gene. For this reason COX-1 was presumed to 
be only constitutively active. However, COX-1 has been shown to be up-regulated in 
some cells by phorbol myristate acetate (PMA), Interleukin-1β (IL-1β), vascular 
endothelial growth factor (VEGF), bradykinin, estrogen, shear stress and retinoic acid 
(Kang et al., 2007). For example, Gibson et al. (2005) have shown estrogen can up-
regulate COX-1 mRNA expression in endothelial cells mediated by Sp1 functional 
binding site in the promoter of the enzyme. 
 
COX-1 is widely expressed in almost all tissues under basal conditions and it is 
presumed to be involved in providing prostanoid precursors for homeostatic regulation 
(DuBois et al., 1998). COX-1, as the only isoform detectable in platelet is important in 
the blood for a critical role in blood clotting. This was further shown by inhibiting 















aggregation. Induction of COX-1 in platelets has a paracrine effect in adjacent vascular 
endothelial cells by generating prostaglandin that results in vasodilatation (Schafer, 
1995). This physiological phenomenon of COX-1 is also observed in the kidney and 
stomach by acting in different setting to produce prostaglandins and can maintain the 
body homeostatic (Vane et al., 1998; DuBois et al., 1998).  
 
COX-1 has been shown to play a major role in gestation and parturition. 
Trautman et al. (1996) showed COX-1 was constitutively expressed in the amnion, 
chorion and decidua throughout the whole of the third trimester of pregnancy. Another 
study has shown that treatment of human amnion cells by human chorionic 
gonadotropin (hCG) can induce COX-1 mRNA and protein expression suggesting that 
the regulation of COX-1 can help maintain pregnancy (Toth et al., 1996).  
 
1.3.1.1 Cyclooxygenase-1 in Carcinogenesis 
Despite being considered a “housekeeping gene”, several studies have 
demonstrated COX-1 over-expression in numerous pathologies. Gupta et al. (2003) 
showed increased expression of COX-1 in ovarian cancer samples compared to normal 
tissue. COX-1 expression was localized in the epithelial compartment of the tumors 
with higher expression of VEGF in the same compartment. Daikoku et al. (2005) 
extensively studied the role for COX-1 in mouse ovarian surface epithelial (OSE) cells 
lacking the functional tumor suppressor gene p53 with activation of oncogenic 
pathways. The authors reported that tumor and OSE cells derived from these mice 
showed an over-expression of COX-1 but not COX-2. Moreover, they showed a 
decrease in cell proliferation and an increase in apoptosis when OSE cells were treated 
with a specific COX-1 inhibitor sc-560.  
 
COX-1 has been implicated in colon carcinogenesis. Chulada et al. (2000) 
developed COX-1 knockout Min/
+
 mice (mice contain a truncating mutation in the Apc 
gene and are predisposed for developing intestinal adenomas) that showed a significant 
decrease in intestinal tumorigenesis compared to normal mice. A recent study reported 
a decrease in cell proliferation and induction of G0/G1 arrest in colon cancer cells (HT-















resulted in morphological and biochemical changes in the cells characteristics of 
macroautophagy which is a cellular process that degrades organelles through 
lysosomal machinery and may serve as an alternative to the apoptosis pathway (Wu et 
al., 2009). Narko et al. (1997) showed that COX-1 over-expressing immortalized 
endothelial cell lines (ECV) can enhance tumorigenesis when injected subcutaneously 
into the athymic nude mice. Histological analysis of tissue samples from these mice 
revealed that the tumor contained highly malignant ECV cells and vessel-like 
structures demonstrating COX-1 over-expression can induce tumorigenesis and 
exacerbate angiogenesis in endothelial cells. Previous work in our laboratory has 
showed an over-expression of COX-1 enzyme in squamous cell carcinoma and 
adenocarcinoma of cervical cancer and was associated with expression of VEGF and 
other growth factors (Sales et al., 2002). COX-1 up-regulation has also been reported 
in breast cancer, lung tumors and in human prostate cancer (Hwang et al., 1998; Bauer 
et al., 2000; Kirschenbaum et al., 2000). These data show the major role for COX-1 
up-regulation in tumor development by promoting cell proliferation and angiogenesis 
and by inhibiting apoptosis.  
 
1.3.2 Cyclooxygenase-2 (COX-2)  
The human COX-2 gene, approximately 8.3 Kb, is located in on chromosome 1 
and demonstrates a remarkable conservation of exon-intron junction with COX-1 gene. 
Intron 1 of COX-1 is lost in COX-2 and the introns in COX-2 gene are shorter than 
those in COX-1 gene. The COX-2 gene is transcribed as 4.6, 4.0 and 2.8 kb mRNA 
splice variants. The cDNA for COX-2 encodes a 604 amino acids polypeptide before 
cleavage that is 61% identical to COX-1 polypeptide. COX-2 protein has a molecular 
mass of 70 kDa and localizes to the perinuclear envelope (Tanabe and Tohnai, 2002; 
Kang et al., 2007). Unlike COX-1, COX-2 has a TATA box and several transcription 
elements such as NF-IL6 motif, two AP-2 sites, three Sp1 sites, two NF-κB sites, E-
box and an adenosine 3',5'-cyclic monophosphate (cAMP) response element (CRE) 

















COX-2 is usually expressed in low levels in normal tissues and is inducible by 
phorbol esters, pro-inflammatory factors, hormones, several growth factors and 
oncogenes in numerous cell types. The enzyme has been shown to be transcriptionally 
regulated in bones, monocytes/macrophages, fibroblast cells, endothelial cells, smooth 
muscle cells and epithelial cells. These transcriptional activations use several binding 
sites in COX-2 promoter region. For example, lipopolysaccharide (LPS) and PMA act 
synergistically to activate COX-2 expression in bovine arterial endothelial cells via the 
NF-κB sites and CAAT enhancer binding protein (C/EBP) elements. Bradykinin has 
been shown to activate COX-2 expression in smooth muscle cells via the CREB 
binding elements (Kang et al., 2007).  
 
COX-2 expression has been proven to be indispensible in reproductive 
physiology, particularly in female reproduction. For example, follicular levels of COX-
2 have been reported to increase dramatically before ovulation. This robust increase 
was shown in vivo by administration of hCG in rats. In vitro studies have revealed 
robust COX-2 induction by luteinizing hormone (LH), follicle-stimulating hormone 
(FSH) or forskolin stimulation of preovulatory granulosa cells. Administration of 
NSAIDs such as indomethacin blocked ovulation in the granulosa cells (Sirois et al., 
2004; Kang et al., 2007). Morham et al. (1995) developed the first COX-2 knockout 
mice and showed that these mice have renal dysplasia and more importantly the 
females are infertile. This finding is consistent with other reports including those 
mentioned above about the crucial role for COX-2 for successful ovulation (Scherle et 
al., 2000). Lim et al. (1997) also showed COX-2 null mice were impaired in many 
events of female reproductive processes such as ovulation, fertilization, implantation 
and decidualization. These events in early pregnancy are inducible, a fact that mirrors 
the role of the inducible COX-2 role in these events.  
 
1.3.2.1 Cyclooxygenase-2 in Carcinogenesis 
As an inducible gene in response to inflammation, COX-2 has emerged as a 
key player in cancer-related inflammation and tumor progression. COX-2 up-
regulation has been associated with pathogenesis of colon, lung, pancreatic, gastric, 















The role for COX-2 in colorectal cancer was first shown by the ability of 
aspirin to reduce colon cancer incidence and mortality (Marnett, 1992). Other study 
showed COX-2 mRNA expression to be markedly enhanced in 85% of human 
colorectal carcinomas and 50% of colorectal adenomas compared to accompanying 
normal mucosa (Eberhart et al., 1994). Studies using COX-2 null mice showed a 
reduction in intestinal tumorigenesis in Min/
+
 mice compared to normal mice (Chulada 
et al., 2000).  
 
COX-2 over-expression has been reported in human breast cancer. Half et al. 
(2002) reported an induction of COX-2 in 43% of invasive breast cancers and in 63% 
of adjacent ductal carcinoma in situ (DCIS) samples examined. The higher induction 
of COX-2 in DCIS samples might suggest that COX-2 up-regulation affects the early 
stages of mammary carcinogenesis. Furthermore, other studies have shown COX-2 
inhibition can lead to a decrease in tumor progression and metastasis in oncogenic 
mouse models of spontaneous breast cancer. In vivo administration of a selective 
COX-2 inhibitor, celecoxib, caused a significant reduction in mammary gland tumor 
burden in these mice. This tumor reduction was associated with an increase in tumor 
cell apoptosis via the expression of pro-apoptotic protein Bax and down-regulation of 
the anti-apoptotic protein Bcl-2 (Basu et al., 2004).  
 
More importantly COX-2 has been implicated in uterine pathology. Gupta et 
al. (2000) was the first one to report over-expression of COX-2 in prostate 
adenocarcinoma compared to pair-matched benign tissue samples. Expression of 
COX-2 in cancer tissue was higher in surrounding stromal cells and in infiltrating 
inflammatory cells compared to tumor cells. COX-2 up-regulation has been reported in 
cervical cancer. Kulkarni et al. (2001) reported over-expression of COX-2 enzyme in 
cancer of cervix as well as cervical intraepithelial neoplasia (CIN). Sales et al. (2001) 
also showed an up-regulation of COX-2 mRNA in squamous cell carcinoma and in 
adenocarcinoma of the human cervix. The authors also showed over-expression of 
COX-1 enzyme in HeLa cells (cervical adenocarcinoma cells) can induce the 
















These data show COX-2 over-expression can enhance tumor development by 
up-regulation of angiogenic factors, and pro-apoptotic proteins and by down-regulation 
of anti-apoptotic proteins.  
 
1.3.3 Cyclooxygenase -3 (COX-3) 
COX-3, approximately 5.2 Kb, is a splice variant of COX-1. COX-3 gene has 
an addition of intron 1 downstream from the start codon that results in-frame insertion 
of 30 amino acids (Chandrasekharan et al., 2002). COX-3 mRNA has been shown to 
be abundantly expressed in heart and cerebral cortex but it remains controversial 
whether COX-3 protein exists in humans. COX-3 shares all the catalytic and important 
structural features with COX-1 and COX-2. However, it is more sensitive to inhibition 
by acetaminophen than the other isoforms (Davies et al., 2004).   
 
Although COX enzymes are regulators of numerous body functions, it is the 
expression and regulation of the prostanoids that determine the physiology and 
pathology of a cell or a tissue.  
 
1.4 Prostanoids and Prostanoid Receptors  
Prostanoids were first discovered in 1930s, when semen products were shown 
to decrease blood pressure in vivo (Oates, 1982; Versteeg et al., 1999). Prostanoids, 
members of the eicosanoid family, consist of either prostaglandins that contain a 
cyclopentane ring or thromboxanes containing a cyclohexane ring. Prostaglandins 
include the D, E, F and I series while thromboxanes are divided into TXA and TXB 
(Versteeg et al., 1999).  
 
These prostanoids exert their biological function by acting on their cognate 
receptors. There are two classes of prostanoid receptors: G-coupled cytoplasmic 
receptor class and the nuclear PPAR (peroxisome proliferators-activated receptors) 
class consisting of PPAR α, γ and δ. The G-coupled cytoplasmic receptor has eight 
prostanoid receptors (EP1, EP2, EP3, EP4, FP, DP, IP and TP receptors) belonging to 















These prostaglandin receptors have a typical G (guanine nucleotide-binding) 
protein-coupled receptor (GPCR) characteristic with seven hydrophobic 
transmembrane domain structures (Hirata et al., 1991). Within the prostanoid family 
the receptors have an overall homology ranging from 24-44% and have 65 amino acid 
residues that are conserved. Of these conserved residues, 34 amino acids are identical 
between the prostanoid receptors (Versteeg et al., 1999; Breyer et al., 2001). Most of 
the conserved domains lie in the transmembrane regions, although some of the 
residues exist in the second extracellular loop. The ligand binding domain of most 
prostanoid receptors is found in the conserved domain of the transmembrane and the 
extracellular loop (Audoly and Breyer, 1997; Breyer et al., 2001).  
 
A strikingly different feature of prostanoid receptors from other GPCRs is the 
existence of various splice variants. In the prostanoid family, EP1, EP3, FP and TP 
receptors have different splice variants, which mostly differ in the intracellular C-
terminal region of the receptor where most of the splicing occurs. Alternative splicing 
does not have any impact in ligand binding but have an effect on G protein coupling 
specificity, agonist-induced receptor phosphorylation, desensitization/internalization 
and constitutive activity (Breyer et al., 2001).  
 
1.4.1 Prostaglandin E2 (PGE2) and PGE2 Receptors 
PGE2, a major metabolite of COX-initiated arachidonic acid metabolism, is 
biosynthesized in cells from PGH2 by PGES and plays a critical role in regulating renal 
function and facilitating reproduction. PGES, the rate limiting enzyme for PGE2 
production, has two isoforms termed as cytosolic PGES (cPGES) and membrane 
bound PGES (mPGES) (Helliwell et al., 2004). 
 
PGE2 has a well-known role in stimulating myometrial contraction. It also 
plays a major function in tumor progression by promoting angiogenesis, cell 
migration, chronic inflammation and inhibition of apoptosis (Wang et al., 2007; 
Marnett and DuBois, 2002). These roles for PGE2 are mediated by distinct prostanoid 















EP2, EP3 and EP4 receptors and signal through several secondary messengers. EP2 
and EP4 receptors signal via increased levels of cAMP, EP1 signals via activation of 
calcium, while EP3 signals through calcium mobilization and reduction of cAMP (Fig 























Fig. 1.2: Schematic representation of COX-prostanoid biosynthetic and signalling pathway. 
Arachidonic acid (AA) gets released from plasma membrane by phospholipase A2 (PLA2) and 
acts as a substrate for COX enzymes for production of prostanoids. Once prostanoids are 
formed they get transported out of the cytoplasm by prostaglandin transporter (PGT) and act 




1.4.1.1 EP1 Receptor  
The EP1 receptor was cloned and characterized in 1993 from a human 
erythroleukemia (HEL) cells (Funk et al., 1993). The EP1 receptor cDNA encodes a 
protein of 402 amino acids and is highly expressed in the kidney, followed by gastric 
muscularis mucosae and adrenal tissue. The receptor was originally described to act as 
a smooth muscle constrictor (Breyer et al., 2001).  
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There are several agonists for the EP1 receptor with this order of affinity: PGE2 
> PGE1 > PGF2α >> PGD2. However, these agonists also activate other prostanoid 
receptors. Selective agonists for the EP1 receptor include SC15089 or SC53122 and 
their use can facilitate the dissection of the individual receptor signalling 
characteristics (Narumiya et al., 1999; Breyer et al., 2001).  
 
Activation of the EP1 receptor by PGE2 leads to release of intracellular calcium 
in Chinese hamster ovary (CHO) cells. This activation is dependent on extracellular 
calcium without detectable release of inositol-1,4,5-triphosphate (IP3), suggesting the 
receptor might regulate a calcium channel gating via an unidentified G protein 
coupling (Watabe et al., 1993). Another study using the phospholipase C (PLC) 
inhibitor (U73122) showed suppression of the intracellular calcium release without 
affecting the sustained phase of Ca
2+
 influx from extracellular space suggesting the 
presence of receptor-activated Ca
2+
 channel (RACC)-related response following the 
activation of the EP1 receptor (Katoh et al., 1995). A study done on EP1 receptor 
stably expressing Xenopus laevis oocytes showed Ca
2+ 
mobilization was dependent on 
EP1 receptor binding to Gαq/11 and transient receptor potential-5 (TRP5), the latter 
uniquely activating the extracellular calcium influx. These data show EP1 receptor can 
couple to Gαq/11 and TRP5 to activate Ca
2+
 mobilization from the intracellular stores 
via PLC activation and to trigger Ca
2+ 
influx from extracellular space, respectively 
(Tabata et al., 2002).  
 
1.4.1.2 EP2 Receptor 
The first EP2 receptor to be cloned by Bastien et al. (1994) was later found to 
be the EP4 receptor by Nishigaki et al. (1995). The authentic EP2 receptor was cloned 
from human placenta library by Regan et al. (1994b) and the cDNA encodes a 
polypeptide of 358 amino acids. The receptor is abundantly expressed in the uterus, 
lung and spleen but has low expression in the kidney (Breyer et al., 2001).  
 
The EP2 receptor was first characterized in the lung with relaxant/inhibitory 
effect on smooth muscle cells in cat trachea. The authors showed that a selective EP2 















the activation of the receptor (Gardiner, 1986). There are several agonists for the EP2 
receptor in this order of affinity for the receptor. PGE2 > 11-deoxy- PGE2 > Butaprost 
> AH13205 = 19 R OH PGE2 >> sulprostone and PGE1-OH (Kiriyama et al., 1997; 
Breyer et al., 2001). A recent study on osteopenic rat model has reported a new 
selective agonist for the EP2 receptor (CP-533536) that promotes bone formation and 
improves fracture healing in rat models (Cameron et al., 2009). The EP2 receptor is a 
Gαs-coupled receptor and following activation by PGE2, it increases intracellular 
cAMP accumulation. cAMP is produced from adenosine triphosphate (ATP) and this 
reaction is catalysed by the enzymatic activity of members of the adenylyl cyclase 
family (Regan, 2003).  
 
EP2 receptor has the same pharmacological and functional coupling as the EP4 
receptor despite only sharing 38% identity in the transmembrane region. This 
similarity is not appreciably different from the other EP receptors (Toh et al., 1995). 
However, several studies have shown that PGE2 activation of the EP2 receptors 
generates a higher accumulation of cAMP in comparison to the release by PGE2-
activated EP4 receptors despite the cells having a comparable level of receptor 
expression. This is probably dependent in the different downstream signalling pathway 
they use upon PGE2 activation (Regan, 2003).  
 
Following activation of the EP2 receptor by PGE2, the downstream signalling 
is mostly through Protein Kinase A (PKA) activation via the Wnt signalling pathway 
suggesting it is predominantly cAMP mediated. This involves phosphorylation of 
glycogen synthase kinase-3 (GSK-3) by Akt to activate β-catenin-mediated 
transcriptional activation. However, Fujino et al. (2003) showed the EP4 receptor 
pathway primarily uses the phosphatidylinositol 3-kinase (PI3K) and the extracellular 
signal-regulated kinase (ERK) pathway to activate the β-catenin-mediated 
transcriptional activation in addition to partial activation of the cAMP pathway. The 
same group showed EP2 receptor activation does not activate the ERK pathway 
(Fujino et al., 2002). In contrary, studies in our laboratory using stably expressing EP2 
receptor endometrial adenocarcinoma (Ishikawa) cells showed activation of the 















mediated phosphorylation of the epidermal growth factor receptor (EGFR) (Sales et 
al., 2004).  
 
The other major difference between the EP2 and EP4 receptor is that the latter 
undergoes rapid agonist-dependent desensitization and internalization, while the EP2 
receptor does not (Nishigaki et al., 1996). This was demonstrated in transfected CHO 
cells, where the EP4 receptor underwent short term desensitization while the EP2 
receptor did not. In addition, PGE2 treatment of transfected human embryonic kidney-
293 (HEK-293) cells induced internalization of the EP4 receptor, while the EP2 
receptor did not internalize (Desai et al., 2000). 
 
1.4.1.3 EP3 Receptor 
The human EP3 receptor was cloned by Yang et al. (1994) from a human 
kidney library and the cDNA encodes a 367 amino acid polypeptide. The EP3 receptor 
was originally described as smooth muscle constrictor and is highly expressed in 
kidney, uterus, adrenal gland and stomach tissues (Breyer et al., 2001). This receptor 
subtype is unique among the prostanoid family as it has multiple splice variant 
generated with the alternative splicing of the region coding for the C-terminal tail. The 
human EP3 receptor has at least six isoforms that are identical over the first 359 amino 
acids and differ in the C-terminus with the variation ranging from 6 to 65 amino acids 
(Regan et al., 1994a; Pierce and Regan, 1998; Ashby, 1998; Narumiya et al., 1999). 
All the EP3 splice variants bind PGE2 but can also be activated by other agonists with 
this order of affinity to the receptor: Sulprostone = M&B28767 = PGE2 > GR63799X 
> 17-phenyl-PGE2 > misoprostol free acid = enprostil = carbacyclin > misoprostol 
methyl ester. Although not tested in the above studies, EP3 receptor has a selective 
agonist, SC-46275 that has been shown to selectively activate the receptor in several 
animal model cell lines (Savage et al., 1993; Breyer et al., 2001).  
 
EP3 receptor isoforms vary in G protein specificity, receptor phosphorylation 
and desensitization and intracellular trafficking. These splice variants generally can 
couple to Gαi protein and inhibit cAMP generation. However, some splice variants can 

















 release that is appeared to be differentially regulated by their diverse C-
terminal tails (An et al., 1994; Asboth et al., 1996; Breyer et al., 2001).  
 
1.4.1.4 EP4 Receptor 
The EP4 receptor was initially cloned from a human cDNA lung library by 
Bastien et al. (1994) and was described as the EP2 receptor. However, subsequent 
studies showed the receptor does not have similar molecular characteristics compared 
to the EP2 receptor and was named the EP4 receptor (Nishigaki et al., 1995).  
 
The EP4 receptor protein is composed of 488 amino acids and is longer than 
the EP2 receptor, most of the difference coming from the carboxyl terminus of the EP4 
receptor. This variation between the receptors may have an effect on agonist-
dependent desensitization and internalization as the EP2 receptor is insensitive to this 
regulation as mentioned in section 1.4.1.2 (Nishigaki et al., 1996; Desai et al., 2000). 
The EP4 receptor is more abundantly and widely expressed than the EP2 receptor with 
a higher expression in thymus, ileum, lung, spleen, adrenal and kidney tissues (Bastien 
et al., 1994; Breyer et al., 2001). 
 
The EP4 receptor has the following agonists in order of their affinity to the 
receptor; PGE2 = PGE1 > M&B-28767 > misoprostol-free acid >> iloprost > PGF2α > 
PGD2. ONO-AE1-329 agonist has a relative selective specificity for the EP4 receptor 
(Kiriyama et al., 1997; Breyer et al., 2001). PGE2 activation of the EP4 receptor leads 
to coupling of the receptor to Gαs and activates different signalling pathways, the 
PKA-mediated cAMP pathway being one of them. However, the main signalling 
pathway is PI3K-dependent and it leads to either activation of the Akt pathway or 
phosphorylation of ERK to enhance expression of downstream target genes (Fujino et 















1.4.2 Prostaglandin F2α (PGF) and PGF Receptor 
Biosynthesis of PGF2 occurs by the action of PGH 9-, 11-endoperoxide 
reductase, PGE 9-ketoreductase or PGD 11-ketoreductase on PGH2, PGE2 or PGD2, 
respectively. PGD 11-ketoreductase has two isozymes termed as lung type PGFS 
(PGFS I) and liver type PGFS (PGFS II) both responsible for the production of PGF2α 
and 9α-11β-PGF2. PGF2α, together with PGE2 is called a primary prostaglandin and 
this review will refer it as PGF (Sakamoto et al., 1995; Watanabe, 2002; Helliwell et 
al., 2004).  
 
PGF is a group of hormone-like substances that participates in body functions 
such as smooth muscle contraction and relaxation, dilation and constriction of blood 
vessels, blood control pressure and regulation of inflammation. PGF has also a well 
established role in parturition, induction of myometrial contraction and cervical 
relaxation (Helliwell et al., 2004; Wang et al., 2007). A pharmaceutical equivalent of 
PGF, dinoprost, can be used for the induction of abortion and for treatment of 
hydatidiform mole. The role of PGF is mediated by a distinct prostanoid receptor 
named FP receptor (Wang et al., 2007).  
 
1.4.2.1 FP Receptor   
The human FP receptor was cloned by Abramovitz et al. (1994) from uterus 
cDNA library and encodes a protein of 359 amino acid residues. The FP receptor 
endogenous ligand is PGF but it can be activated with the following agonists in order 
of this potency: PGF = fluprostenol > PGD2 > PGE2 > U-46619 > iloprost (Narumiya 
et al., 1999; Breyer et al., 2001).  
 
Several splice variants have been reported for the FP receptor in different 
species. Vielhauer et al. (2004) reported the first human FP receptor variant (hFPs) 
with 71bp exon insertion that created a frame shift mutation resulting in a truncated 
receptor lacking the seventh transmembrane domain. Expression studies using northern 
blots showed the mRNA for the hFPs was present in human heart and skeletal muscle. 















not bind with any significant affinity to the endogenous FP receptor ligand PGF 
(Vielhauer et al., 2004).  
 
Recent studies showed six splice variants of the human FP receptor, each one 
created by an insertion of a different exon between the existing exon 2 and 3. These 
splice variants lack the seventh transmembrane domain and their carboxyl terminal 
was extracellular and the receptors were not functional on their own. The authors 
showed that one of the splice variants (altFP4) can form a heterodimer with the wild 
type FP receptor. The heterodimer was different biochemically compared to the altFP4 
as it responded to PGF treatment in identical manner with the wild type FP receptor. 
However, the heterodimer was highly responsive to the prostamide analogue, 
bimatoprost, compared to the wild type FP receptor. bimatoprost activation of the 
heterodimer expressing HEK-293 cell line gave a rapid transient Ca
2+
 release followed 
by secondary Ca
2+
 waves, the latter being Ca
2+ 
influx from extracellular space. A 
specific prostamide antagonist, AGN211335 inhibited the secondary phase of Ca
2+
 
signalling. As the prostamide receptor has yet to be cloned and characterized there is a 
possibility that the heterodimer may represent the putative prostamide receptor (Liang 
et al., 2008).  
 
FP receptor, a Gαq/11-coupled receptor, triggers the release of IP3 via the PLC 
pathway following activation by PGF (Watanabe et al., 1994). Studies in our 
laboratory using FP receptor stably expressing Ishikawa cells have shown the receptor 
can also activate the ERK pathway via transactivation of the EGFR (Sales et al., 2005).  
 
Thomas et al. (1978) showed co-stimulation of rat luteal cells with LH and 
PGF inhibited LH-mediated progesterone secretion despite PGF itself being able to 
stimulate progesterone production in these cells. This inhibition was reversed by 
addition of dibutyryl cAMP indicating that progesterone secretion inhibition was due 
to a blockage of cAMP production. These data might suggest PGF can inhibit cAMP 
















1.4.3 Other Prostanoids and Their Cognate Receptors  
Prostaglandin D2 (PGD2), a PGD synthase (PGDS) product, is a major 
prostanoid produced in central nervous systems (CNS) in humans. PGD2 is important 
for sedation, sleep induction and regulation of body temperature, all mediated by 
coupling to its cognate DP receptor (Urade and Hayaishi, 1999). The DP receptor was 
the most recent prostanoid receptor to be cloned and it is expressed in leptomeninges, 
retina and mucus-secreting cells of the gastrointestinal tract. DP receptor activation by 
PGD2 leads to accumulation of intercellular cAMP and mobilization of Ca
2+
 (Boie et 
al., 1995; Breyer et al., 2001). 
Prostacyclin (PGI2) was discovered in 1976 when it was found that patients 
with inherited deficiency of PGI2 production tend to develop thrombophilia and were 
predisposed to vascular diseases (Wang et al., 2007). PGI2 synthesis is facilitated by 
prostacyclin synthase (PGIS) and is involved in numerous body functions that include 
antithrombosis and vasodilator actions via interaction with its cell surface IP receptor 
(Helliwell et al., 2004; Breyer et al., 2001). The IP receptor is widely expressed in the 
dorsal root ganglia suggesting the receptor plays a role in mediation of pain. The 
receptor is also expressed in aorta, heart, kidney, lung and liver. The IP receptor has a 
higher affinity to PGE1 than PGE2 and is selectively activated by the agonist cicaprost 
that leads to stimulation of cAMP production (Breyer et al., 2001).  
Thromboxane A2 (TXA2) synthesis is catalyzed by thromboxane synthase 
(TXS) and primarily regulates platelet shape change and aggregation and as such has a 
critical role in blood clotting. In addition it mediates smooth muscle contraction and 
proliferation. The receptor for TXA2 was the first eicosanoid family receptor member 
to be cloned and it has two isoforms designated as TPα and TPβ, differing exclusively 
in their C-terminus amino acid sequence (Breyer et al., 2001). These TP receptors are 
abundantly expressed in the thymus followed by lung, kidney and spleen with lower 
levels in uterus, brain and heart. TPα and TPβ receptors couple to Gαq/11 and activate 
the intracellular calcium/diacylglycerol (DAG) molecular pathway (Breyer et al., 
2001). Hirata et al. (1996) showed TPβ receptors can inhibit adenylyl cyclase by 
coupling to Gi/Go, while TPα receptors can activate cAMP by coupling to Gαs protein 















1.4.4 General Physiological Functions of Prostanoids  
Prostanoids and their cognate receptors have numerous physiological functions 
in the body. These physiological roles have been well studied by either 
pharmacologically inhibiting their action through agents such as NSAIDs or by gene-
knockout mice studies (Kobayashi and Narumiya, 2002). The next three sections will 
discuss the role for prostanoids in allergy, inflammation and pain, vascular hemostasis 
and reproductive functions.  
 
1.4.4.1 Prostaglandins in Allergy, Inflammation and Pain  
Allergic asthma is caused by expression of Th2 cytokines in lung and is 
characterized by infiltration of eosinophils and bronchial hyper-reactivity. Mast cells 
play a role in triggering this disease since they are activated by an immunoglobulin 
(Ig) E-mediated allergic challenge. PGD2 is one of the chemical mediators that is 
released by activated mast cells, and has been proposed to be a marker of mast cell 
activation (Kobayashi and Narumiya, 2002). The role for PGD2 in asthma was well 
characterized by developing DP receptor deficient mice. Using these mice models, the 
authors proposed that PGD2 released in response to allergic challenge can act on its 
cognate receptor DP to recruit lymphocytes to the site of allergy (Matsuoka et al., 
2000).  
 
Studies have shown prostanoids can be mediators of vasodilation and 
inflammatory process by synergizing with other effectors such as histamine and 
bradykinin to increase vascular permeability and edema. These effects are mostly 
mediated by PGE2 and PGI2 since both prostanoids have been shown to be elevated in 
sites of inflammation (Kobayashi and Narumiya, 2002). The role for IP receptor in 
inflammation and pain has been shown using specific knockout mice studies. In IP 
receptor null mice, acetic acid-induced writhing was reduced to the level observed in 
indomethacin-treated wild-type mice (Murata et al., 1997; Bley et al., 1998). The same 
pattern of reduction in writhing was observed in LPS-treated EP3 receptor knockout 
mice demonstrating the role of this PGE2 receptor in pain and inflammation 















Studies using antagonists for E prostanoid receptors in rodents have shown a 
role for these receptors in hyperalgesia (response to stimuli that is painful). PGE2-EP2 
receptor signalling has been shown to be involved in generation of inflammatory pain 
in the zymosan A (a yeast extract that induces inflammatory hyperalgesia) peripheral 
inflammation model. In this study, zymosan A-treated EP2 receptor null mice 
recovered much faster from hyperalgesia compared to wild type mice demonstrating 
the role for EP2 receptor in inflammation and pain (Matsuoka and Narumiya, 2007).  
 
Zymosan-treated peritoneal macrophages derived from IP, EP2 and EP4 
receptors null mice were used to examine the effect of PGE2 and carbacyclin (PGI2 
analogue) on tumor necrosis factor-α (TNF-α) and IL-10 production. Macrophages 
collected from IP null mice showed a down-regulation of TNF-α production and up-
regulation of IL-10 in response to PGE2 but not to carbacyclin, while macrophages 
derived from EP2 and EP4 null mice lacked the response to the specific agonists to the 
EP2 and EP4 receptors, but not to PGE2 or carbacyclin. These data demonstrate that 
PGE2 and PGI2 regulate pro-inflammatory (TNF-α) and anti-inflammatory (IL-10) 
cytokine production redundantly by coupling to their cognate EP2, EP4 and IP 
receptors, respectively via cAMP accumulation (Shinomiya et al., 2001; Kobayashi 
and Narumiya, 2002). 
 
1.4.4.2 Prostanoids in Vascular Hemostasis 
It is well known that most prostanoids elicit contractile and/or relaxant 
activities on vascular smooth muscle cells. Thromboxanes and prostacyclins are 
produced abundantly in vascular endothelial cells and platelets and have an opposing 
action by acting as vasoconstrictor and vasodilator agents, respectively (Kobayashi and 
Narumiya, 2002; Matsuoka and Narumiya, 2007). IP receptor knockout mice show an 
enhanced thrombotic tendency when endothelial damage is evoked showing the 
antithrombotic effect of prostacyclin (Murata et al., 1997). In contrast, TP receptor 
deficient mice show increased bleeding tendencies and are resistant to TP agonist-
















PGE2 has been implicated in contractile and/or relaxant functions on vascular 
smooth muscle cells. Kennedy et al. (1999) studied the role for EP2 receptor in 
regulating blood pressure using EP2 receptor null mice. The authors reported that 
activation of the EP2 receptor by Butaprost induces a hypotensive response in wild 
type mice while this effect is not observed in EP2 receptor null mice. This result 
demonstrates PGE2 elicit arterial dilatation via interaction with its EP2 receptor.  
 
1.4.4.3 Prostanoids in Reproductive Functions 
Prostanoids have been shown to play major roles in reproduction functions 
such as in ovulation, fertilization, luteolysis and parturition. Studies have shown that 
EP1, EP3, EP4, IP and TP receptors null female mice are fertile demonstrating these 
prostanoid receptors are dispensable in reproductive physiology. However, functional 
studies have shown that the EP2 receptor plays an important role in reproductive 
physiology. Kennedy et al. (1999) showed EP2 receptor deficient mice had a reduced 
litter size and deliver few pups compared to wild type mice. The authors also reported 
impaired ovulation and a dramatic decrease in fertilization in EP2 receptor deficient 
mice. Hizaki et al. (1999) reported that EP2 null female mice are normal and can give 
normal birth to their pups in term, but their litter size is significantly smaller. Only 
very few pups are born alive and grow normally, showing the importance of the EP2 
receptor in pregnancy. The authors proposed that the interaction between PGE2 and 
EP2 receptors can induce the oophorus maturation that is required for successful 
fertilization.  
 
Lim and Dey (1997) showed EP2 receptor expression in a temporal manner 
during the pre-implantation period by the effect of ovarian hormones, progesterone and 
estrogen. The authors showed expression of the EP2 receptor mRNA in the mouse 
luminal epithelium on day 3 of pregnancy and a significant increase of the receptor on 
day 4 where both progesterone and estrogen regulate epithelial cell differentiation for 

















In addition, PGF plays a role in ovulation, luteolysis and parturition. Sugimoto 
et al. (1997) showed FP receptor deficient female mice were healthy and were able to 
get pregnant. However, no parturition was found in these mice due to the lack of 
induction of labor even when given exogenous oxytocin. A reduction in progesterone 
by ovariectomy in FP receptor deficient mice resulted in normal delivery of their pups. 
These data demonstrate that FP receptor plays a key role in parturition by diminishing 
progesterone level to induce labor (Sugimoto et al., 1997).  
 
1.4.5 Prostanoid Receptors in Carcinogenesis 
Prostaglandins and their cognate receptors have been implicated in numerous 
cancers. Several studies have reported NSAIDs can prevent incidence of colorectal 
cancer. Giardiello et al. (1998) evaluated the expression of prostanoids in human 
colorectal mucosa and showed an increase in PGE2 and thromboxane production 
compared to control samples. Treatment of patients with sulindac (NSAID) decreased 
the concentration of PGF, PGE2 and PGD2 compared to healthy control subjects. The 
decrease in prostaglandins production was correlated with the reduction of colorectal 
adenomas. A recent study using colonic epithelial cell lines showed an increase in 
motility in response to PGE2 and PGF, suggesting a role for prostaglandin in the 
progression of adenoma by increasing cell motility (Qualtrough et al., 2007). 
Dysregulation of the EP4 receptor has been implicated in colon cancer. Azoxymethane 
(a colon carcinogen)-treated EP4 knockout mice showed a decrease in development of 
putative preneoplastic lesions in the colon compared to wild type mice. The authors 
confirmed involvement of the EP4 receptor in colon cancer by using an EP4-selective 
antagonist (ONO-AE2-227) to decrease the number of putative preneoplastic lesions in 
azoxymethane-treated mice (Mutoh et al., 2002). Others have suggested that EP4 
receptors might be involved in the early stages of colon cancer, while EP2 receptors 
are more important in facilitating the cancer growth (Kawamori et al., 2003; Fujino et 
al., 2007).  
 
Ovarian cancer has been associated with increased synthesis of prostaglandins 
and their receptors. Rask et al. (2006) showed up-regulation of EP1 and EP2 receptors 















was distributed in ovarian surface epithelial cells suggesting a role for these receptors 
in malignant transformation of epithelial cells. Spinella et al. (2004) used human 
ovarian carcinoma cells to show that endothelin-1 can induce PGE2, PGF and PGD2 
production and EP2 and EP4 prostanoid receptor expression via transactivation of 
EGFR. This activation increases matrix metalloproteinases (MMPs) and VEGF 
expression leading to ovarian cancer cell invasion and tumor progression.  
 
Prostanoid receptor up-regulation has been implicated in prostate cancer. 
Miyata et al. (2006) showed an up-regulation of EP1, EP2 and EP4 prostanoid 
receptors in cancer cells compared to non-tumor gland cells. In addition, EP1 and EP2 
receptors were associated with increase in cancer cell proliferation suggesting a role 
for these EP subtype receptors in prostate cancer. In vitro studies by Wang and Klein 
(2007) using PGE2-stimulated prostate cancer cell line (PC-3) showed a significant 
induction of VEGF production via the ERK/Akt signalling pathway mediated by the 
EP2 receptor. Another in vitro study looked at the aldo-keto reductase (AKR) family 
members that are responsible for biosynthesis of PGF from PGD2. The authors showed 
that PGD2 stimulation of AKR expressing PC-3 cells can induce cell proliferation that 
is mediated by increase in PGF accumulation in the culture system. This cell 
proliferation was mediated by PI3K/Akt signalling pathway and was significantly 
decreased by co-stimulation of PGD2 and the FP antagonist AL8810. These data show 
the key role of PGF-FP receptor interaction in mediation of cell proliferation in 
prostate cancer cells (Wang et al., 2008). 
 
Up-regulation of COX enzymes and prostaglandin receptors play a significant 
role in endometrial pathology (Jabbour et al., 2006). Before discussing the implication 
of prostanoids in endometrium pathology it is useful to describe the molecular make 
















1.5 Structure and Function of the Endometrium  
The human endometrium is a complex tissue that lines the uterine cavity and is 
composed of both glandular and stromal elements. This dynamic tissue undergoes 
well-defined cycles of tissue proliferation, differentiation and breakdown. In the 
absence of pregnancy the endometrium is shed and regenerates itself again. This 
cyclical nature of tissue breakdown and remodelling is called the menstrual cycle. The 
endometrium consists of two layers, the upper layer is the one that sheds at 
menstruation and the tissue regenerates itself from the lower layer of the endometrium 
(Critchley et al., 2001; Jabbour et al., 2006a). Earlier studies showed that ovarian 
hormones, estrogen and progesterone are responsible for the changes of endometrial 
structure and functions throughout the menstrual cycle (Markee, 1940; Corner and 
Allen, 1929; Jabbour et al., 2006a).  
 
The menstrual cycle has three classic phases: A proliferative phase that is 
dominated by estrogen, a secretory phase that is dominated by progesterone and a 
menstrual phase following the withdrawal of progesterone and is associated with the 
termination of the corpus luteum. The secretory phase is then divided in two parts. 
Early secretory phase is regulated by both estrogen and progesterone, while the mid 
secretory phase is only regulated by progesterone (Jabbour et al., 2006a). This has 
been suggested by observed down-regulation of the estrogen receptor in the mid 
secretory phase (Snijders et al., 1992). Estrogen plays a major role in promoting the 
proliferation while progesterone controls the differentiation of the glandular and 
stromal components (Jabbour et al., 2006a).  
 
For successful menstruation blood vessels are very essential. It has been shown 
that there are spiral forms of the arterioles in the upper two third of the functional layer 
that are responsible for leukocyte entry and vasoconstriction. The initiation of 
menstruation also consists of a higher expression of various MMPs that would help 
break down the basement membrane comprised of collagen type 4, fibronectin and 
glycosaminoglycans in response to progesterone (Smith, 1998; Osteen et al., 1994; 















endothelial cells in the matrix to promote menstruation (Smith, 1998; Rogers et al., 
1992).  
 
The endometrial proliferation, differentiation and breakdown require 
remodelling of endometrial vasculature. VEGF-A plays an essential role in facilitation 
of new blood vessel formation and triggers proliferation, differentiation and migration 
of the endometrium. Knockout mice studies have shown the binding of VEGF to 
VEGF-receptor 2 (KDR) can trigger endothelial cell recruitment and proliferation, 
while interaction with VEGF-receptor 1 (Flt-1) can induce endothelial cells to form 
tubules with the induction of tight junctions between the endothelial cells (Shalaby et 
al., 1995; Fong et al., 1995; Smith, 1998). The angiopoietins, Ang-1 and Ang-2, have 
been shown to facilitate angiogenesis by stabilising and destabilising blood vessels, 
respectively (Maisonpierre et al., 1997). Other angiogenic growth factors including 
basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), 
thrombospondin-1 and endocrine gland VEGF (EG-VEGF) and their cognate receptors 
are expressed in endometrium, and can stimulate angiogenesis (Smith, 1998; Battersby 
et al., 2004).   
 
1.5.1 Roles for COX Enzymes and Prostanoid Receptors in Endometrium 
Physiology  
Towards the end of the menstrual cycle in the event of progesterone 
withdrawal, expression of COX-2 has been reported to be up-regulated in endometrial 
glandular epithelium cells and lasts through the proliferative phase. Kang et al. (2005) 
showed a higher expression of the human prostaglandin transporter in the luminal, 
glandular epithelial and stromal cells during the menstrual cycle. This was 
accompanied by expression of EP2 and EP4 receptors throughout the stages of 
menstrual cycle, the latter being highly expressed in the late proliferative phase. The 
expression of the EP2 and EP4 receptors was localized to the peri-vascular and 
endothelial cells showing the significance of these receptors in vascular function and 
angiogenesis (Jabbour et al., 2006b; Milne et al., 2001). Milne and Jabbour (2003) 
have reported expression of the FP receptor throughout the menstrual cycle with higher 















glandular epithelial cells. The expression of COX-2 and the prostanoid receptors can in 
turn promote the expression of pro-angiogenic factors (VEGF, bFGF, PDGF, Ang-1 
and Ang-2) or inhibit cathepsin-D, which in turn contributes to inhibition of anti-
angiogenic factor angiostatin (Perchick and Jabbour, 2003; Jabbour et al., 2006b).  
 
There have been several benign endometrial pathologies reported with clinical 
symptoms of pain or bleeding disturbances, such as dysmenorrhoea, endometriosis and 
menorrhagia. COX enzymes and prostaglandins have been implicated in these benign 
endometrial pathologies. However, the most frequently diagnosed and common 
malignancy is endometrial carcinoma (Jabbour et al., 2006b).  
 
1.6 Endometrial Carcinoma   
Endometrial carcinoma is one of the two most common malignancies of the 
female genital tract in the western world, also ranking fourth in incidence among 
invasive tumors in women following breast, lung and colon cancers. Carcinoma of the 
endometrium is more common in post-menopausal women and approximately 80% of 
the patients are over 50 years of age. Most women who undergo hysterectomy to treat 
the non-invasive precursors of endometrial carcinoma will experience morbidity 
related to endometrial neoplasia. The first symptom of endometrial carcinoma is 
abnormal vaginal bleeding and overall, patients have an 86% five-year survival rate 
after diagnosis (Jabbour et al., 2006b; Ellenson and Wu, 2004).   
 
Endometrial carcinoma arises from several types of cells, with endometrial 
cancer from the glandular epithelium being the most common type accounting for 80-
90% of the endometrial cancers. Endometrial carcinoma can be divided in two major 
types termed as type I and II. Type I is generally associated with clinical findings such 
as obesity, diabetes and hypertension. The tumors, usually confined to the uterus, are 
low-grade (well to moderately differentiated) and indolent tumors often associated 
with endometrial hyperplasia. Histology of type I tumors usually resemble normal 
proliferative endometrial glands (Fig 1.3). These tumors are usually treated with 















consists of well and moderately differentiated carcinoma according to histological 
classification (Kurman et al., 1985; Ellenson and Wu, 2004; Di Cristofano and 
Ellenson, 2007).  
 
Type II tumors are poorly differentiated tumors that are aggressive in manner 
and are not associated with unopposed estrogen. The histology of this tumor can be 
classified into two types of carcinoma termed as serous carcinoma and endometrial 
intraepithelial carcinoma (EIC). Serous carcinoma consists of highly atypical cells that 
can grow in papillary, glandular or solid patterns while EIC, precursor of serous 
carcinoma, is composed of similar cells to its precursor carcinoma but do not invade 
the underlying stroma (Ellenson and Wu, 2004; Di Cristofano and Ellenson, 2007).  
 
Fig. 1.3: Histological classification of endometrial cancer: The invasive tumors are shown on 
the right while the precursors are on the left. The genetic alterations associated with the 
lesions are shown below each photomicrograph. SH, simple hyperplasia; CH, complex 
hyperplasia; CAH, complex atypical hyperplasia; G1-G3, Grade 1-3 endometroid carcinoma; 
EIC, endometrial intraepithelial carcinoma; USC, papillary form of serous carcinoma; PTEN, 
phosphatase and tensin homolog on chromosome ten. Type I tumors are associated with 
hyper-estrogenic while type II are not associated with estrogen stimulation (Picture taken from 















1.6.1 Etiology of Endometrial Carcinoma 
The etiology of endometrial carcinoma is yet to be elucidated. However, over 
the last decade several theories have been postulated using gene knockout and over-
expression systems to provide evidence supporting the involvement of several genes 
(Ellenson and Wu, 2004). One of the genes that are highly related to endometrial 
carcinoma is the phosphatase and tensin homolog on chromosome ten (PTEN) tumor 
suppressor gene. This gene is the most altered gene in type I endometrial carcinoma 
and 50% of the tumors contain mutations in this gene (Tashiro et al., 1997). Other 
studies have shown a correlation between mutations in PTEN gene and hyperplastic 
lesions (20%) suggesting a key role for this gene in early stages of the cancer (Levine 
et al., 1998; Ellenson and Wu, 2004).  
 
The other gene associated with endometrial cancer is p53 tumor suppresser 
gene. Mutations in p53 gene account for approximately 10-20% of all endometrial 
carcinoma with higher mutation frequency reported in high-grade tumors (Lax et al., 
2000). The third oncogene associated with endometrial cancer, k-ras, has been shown 
to be mutated in 10-30% of the cases and mutations have been found in all grades of 
endometrial carcinoma (Ellenson and Wu, 2004).  
 
Once the tumor is formed numerous growth factors play a major role in 
promoting its growth and the COX-prostanoid biosynthetic pathway play an active role 
in this process. 
 
1.6.2 Roles for COX Enzymes and Prostanoid Receptors in Endometrial 
Carcinoma   
Several studies have been done to assess the expression of COX enzymes and 
prostanoid receptors in endometrial carcinoma. COX-1 enzyme has been reported to be 
unaltered in endometrial carcinoma compared to normal endometrium despite being 
reported to be involved in other uterine pathologies (Gupta et al., 2003; Tong et al., 
2000; Jabbour et al., 2006b). However, COX-2 has been shown to be up-regulated in 















endometrial carcinoma compared to normal endometrium. It has been shown to be 
expressed in hyperplastic lesions suggesting the enzyme might be involved in early 
pathology and progression of endometrial cancer (Ohno et al., 2005; Tong et al., 
2000).  
 
Studies in our laboratory showed over-expression of COX-2 and PGES enzyme 
that co-localized to endothelial cells and neoplastic epithelial cells in endometrial 
adenocarcinoma suggesting co-regulation of both enzymes. Concomitantly with the 
elevation of COX-2 and PGES expression, the authors showed up-regulation of the 
EP2 and EP4 prostaglandin receptors in secretory phase of adenocarcinoma compared 
with control endometrium samples. These results suggest that COX-2 and PGES 
enhancement can lead to increased production of PGE2 to enhance proliferation of 
epithelial cells in autocrine/paracrine manner via the activation of the EP2 and EP4 
receptors (Jabbour et al., 2001). Moreover, other studies in our laboratory have 
reported dysregulation of the FP receptor in endometrial adenocarcinoma. The authors 
showed an up-regulation of the FP receptor in human endometrial adenocarcinoma that 
was localized to the neoplastic glandular epithelial cells (Sales et al., 2004).  
 
Up-regulation of COX-2, prostaglandins and their cognate receptors can 
influence the growth of endometrial adenocarcinoma by promoting angiogenesis, 
inhibition of apoptosis, control of cell growth and promoting metastasis in 
autocrine/paracrine manner (Ohno et al., 2005).  
 
1.6.2.1 Angiogenesis  
Angiogenesis is very essential for tumor growth in endometrial carcinoma 
since the tumor needs oxygen and nutrients to facilitate growth. COX-2 induces tumor 
angiogenesis through numerous pathways that are regulated by the synthesized 
prostanoids. The angiogenesis process is initiated by PGE2- and PGF-mediated 
production of angiogenic growth factors from tumor, stromal and infiltrating 
inflammatory cells (Ohno et al., 2005). For example, studies in our laboratory have 
shown that PGE2-EP2 receptors and PGF-FP receptors interactions can lead to 















(Sales et al., 2004; Sales et al., 2005). VEGF and other angiogenic growth factors then 
bind to endothelial cell surface receptors that are expressed on pre-existing venules, 
activating intracellular signalling pathways. One of these signalling pathways results in 
release of PGI2 that regulates VEGF-induced vascular permeability (Murohara et al., 
1998). In addition, proteases secreted from proliferating endothelial cells locally 
degrade the vascular basement membrane, followed by vascular sprouting. The 
migration of these developing vessels is mediated by integrins at the endothelial-
extracellular matrix interface and by release of MMPs at the sprouting vascular front. 
TXA2 plays a major role in migration of endothelial cells and PGE2 has been shown to 
interact with its cognate receptors to promote MMP-2 and MMP-9 expression. This 
angiogenic response is sustained by microvascular endothelial cells over-expressing 
the anti-apoptotic protein Bcl-2 regulated by COX-2 and PGE2 (Ohno et al., 2005). 
These data show the COX-2-prostanoid pathway promotes angiogenesis via synthesis 
of various prostaglandins and their receptors to sustain tumor growth.  
 
1.6.2.2 Inhibition of Apoptosis  
Sustainment of tumor growth vastly depends on inhibition of apoptosis. COX-2 
has been shown to inhibit the apoptosis pathway in many cell types and this 
phenomenon can be reversed by the administration of NSAIDs (Ohno et al., 2005). St-
Germain et al. (2004) used different human endometrial cancer cell lines to show the 
involvement of COX-2 in inhibition of apoptosis. The authors showed that COX-2 
inhibition with NS-398 in endometrial cancer cells resulted in the inhibition of Akt 
phosphorylation and induction of apoptosis suggesting that the COX-2 pathway plays 
a key role in control of cell survival. Ohno et al. (2007) used 70 endometrial cancer 
cases to study the role of COX-2 in inhibition of apoptosis. The authors showed that 
apoptotic index was lower in COX-2 positive cancer cells compared to COX-2 
negative cases. Other studies have shown up-regulation of prostaglandin products, 
which in turn inhibit apoptosis through Bcl-2 mediated pathway and by the nitric oxide 
pathway (Ohno et al., 2005). Taking these data in account, up-regulation of Cox-2 can 
















1.6.2.3 Control of Cell Growth and Metastasis 
The prostanoid products of the COX-2 pathway exacerbate tumorigenesis in 
endometrial adenocarcinoma by enhancing cell proliferation and migration. In vitro 
studies using Ishikawa cells as a model showed over-expression and activation of FP 
receptor can induce the expression and secretion of fibroblast growth factor-2 (FGF-2) 
via the ERK pathway. In addition the authors showed that the secreted FGF-2 can 
enhance proliferation of Ishikawa cells (Sales et al., 2007). Further studies by the same 
group showed that activation of prostanoid receptors can modulate cell adhesion and 
invasion. The authors reported FP receptor activation by PGF can lead to adhesion to 
vitronectin and reorganization of the actin cytoskeleton via the recruitment of focal 
adhesion kinase (FAK) to focal adhesion sites. These data suggest a role for PGF-FP 
interaction in regulating cell movement metastasis and adhesion in endometrial 
carcinoma (Sales et al., 2008).  
 
Recent studies showed that leptin, a secreted hormone with role in obesity has 
also a role in the enhancement of cell proliferation in six endometrial adenocarcinoma 
cell lines (Ishikawa, ECC-1, HEC-1A, HEC-1B, RL95-2 and AN3CA cells). The 
authors showed that leptin can activate Janus-activated kinase-2 (JAK2)/signal 
transducers and activators of transcription 3 (STAT3) and the mitogen-activated 
protein kinase (MAPK) pathway to regulate expression of COX-2 and PGE2 
production in different endometrial cancer cell lines. This signalling pathway can in 
turn activate cell proliferation in the cell lines (Gao et al., 2009).  
 
The above mentioned data suggest that prostaglandins synthesized from the 
COX-2 pathway play a major role in development of endometrial carcinoma by acting 
on their cognate receptors to promote angiogenesis, inhibit apoptosis, and facilitate cell 
adhesion and migration. The endometrium can also be affected by the presence of 
















1.7 Uterine Fibroids 
Uterine fibroids (leiomyomas) are benign tumors that arise from the smooth-
muscle uterine cells (myometrium) and are the most common uterine disorder 
occurring in as many as 30% of women over 35 years of age. The prevalence of 
fibroids is two to three times more common in black women than among white women 
in United States of America (USA) and with a higher incidence with increasing age 
(Marshall et al., 1997; Flake et al., 2003).  
 
Most cases of fibroids are asymptomatic but some women have significant 
symptoms warranting therapy. The clinical importance of uterine fibroids is shown by 
the fact that there are no adequate drugs for therapy and most women undergo 
hysterectomy for this disorder, accounting for approximately one-third of 
hysterectomies in USA (Wilcox et al., 1994).  
 
The symptoms of uterine fibroids are related to their local mass effect and can 
be classified in three groups (Stewart, 2001):  
 Abnormal uterine bleeding (menorrhagia; heavy and prolonged menses), 
 Pelvic pressure and severe pain (dysmenorrhea) and   
 Reproductive dysfunction (infertility and repetitive pregnancy loss).  
 
The location of the tumor is an important factor in determining bleeding 
symptoms. As shown in figure 1.4, the three locations of fibroids are submucosal 
(SM), intramural (IM) and subserosal (SS) fibroids with most women presenting with 
a mixed location of fibroids. Submucous fibroids are contained in the uterine cavity 
and intrude to the endometrial cavity and are associated with menorrhagia, while 
intramural fibroids are contained within the wall of the uterus with no cavity 
deformity. Subserosal fibroids extend to the serosal surface and a cause of irregular 

















Fig. 1.4: Different locations of uterine fibroids. A. Submucosal B. Intramural C. Subserosal 
fibroids
3
.   
 
1.7.1 Risk Factors Associated with Fibroids  
Several risk factors have been associated with uterine fibroids, one of them 
being menarche. Marshall et al. (1998) have shown a positive association between an 
early age menarche and hysterectomy-confirmed fibroid diagnosis. The correlation 
with early menarche might be due to increased cell divisions of myometrium 
throughout the reproductive years resulting in increased chance of mutation in genes 
involved in cell proliferation (Marshall et al., 1998).  
 
One of the risk factors associated with fibroids inversely is parity, reports 
showing 20-40% reduced risk in uterine fibroids. The possibility for reduced risk with 
parity could be less time of exposure to unopposed estrogens while reduced fertility 
might be associated with a long term exposure to estrogens from anovulatory cycles. 
Other studies have shown reduced risk of fibroids associated with current smoking 
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with 50% of reduction of uterine fibroids requiring surgery. A diminished risk of 
fibroids requiring surgery has been reported in post-menopausal women showing an 
inverse correlation with menopause. (Ross et al., 1986; Marshal et al., 1997; Samadi et 
al., 1996; Parazzini et al., 1996; Flake et al., 2003).  
 
1.7.2 Etiology of Uterine Fibroids  
The etiology of uterine fibroids is yet to be elucidated. Several theories have 
been postulated, one of them being an increased level of ovarian hormones (estrogen 
and progesterone) resulting in increased mitotic rate of smooth muscle cells that may 
cause somatic mutations resulting in progressive growth dysregulation (Rein, 2000). 
This theory is supported by the observation that early onset of menstruation and 
hormone replacement therapy at menopause increase the risk of symptomatic uterine 
fibroid while treatment with gonadotropin-releasing hormone (GnRH) analogue causes 
a remarkable reduction in tumor burden (Shaw, 1998). The hormonal responsiveness 
of fibroids has been demonstrated in vitro as cells derived from fibroids express 
estrogen and progesterone receptors and are responsive to steroid hormones (Howe et 
al., 1995). Another possible theory is that fibroids may develop due to an abnormal 
myometrium. Studies have shown a significant increase of estrogen receptors in the 
myometrium of fibroid uteri (Richards & Tiltman, 1996).  
 
Genetic background also plays a role in uterine fibroid incidence on the basis of 
familial and ethnic predilections. Several studies show an increased incidence of 
fibroids among the first degree relatives then among the general population, with black 
women more prone to the disorder than white women. Black women diagnosed with 
uterine fibroid have multiple lesions, larger fibroids, greater uterine weight and had 
developed the symptoms at younger age (Schwartz et al., 2000; Marshall et al., 1997; 
Flake et al., 2003).  
 
Inhibition of apoptosis of myometrial smooth muscle cells have been suggested 
to be a cause of uterine fibroid formation as suppression of apoptotic  pathways may 















higher cellular proliferation rate and a lower apoptosis compared to normal 
myometrium. Vu et al. (1998) have shown that fibroid tissue sample from GnRH 
agonist leuprolide acetate (LA)-treated women had a significant decrease in cellular 
proliferation index, estrogen and progesterone receptors compared to untreated control, 
quite likely since treatment decreases the number of cycling cells.  
 
1.7.3 Effectors of Uterine Fibroids   
Once a uterine fibroid is formed, estrogen and progesterone play a major role in 
promoting its growth but their explicit role is yet to be elucidated (Rein, 2000; Flake et 
al., 2003). The effect of ovarian hormones could be partly mediated by the mitogenic 
effects of growth factors and cytokines expressed locally by the smooth muscle cells. 
Numerous molecular studies have been done to investigate the expression level of 
growth factors and cytokines between fibroids and myometrium tissue. Amongst these 
growth factors epidermal growth factor (EGF), insulin growth factor (IGF), basic 
fibroblast growth factor (bFGF) and VEGF play major roles in formation of fibroids 
(Flake et al., 2003).  
 
The level of IGF-I isoform has been shown to be higher in fibroids compared to 
adjacent myometrium sample suggesting it may play a mitogenic role in the 
development and growth of uterine fibroids (Hoppener et al., 1988; Flake et al., 2003). 
Gao et al. (2001) reported IGF promotes growth of fibroids by inhibiting the apoptotic 
pathway through up-regulation of Bcl-2 expression in fibroid cells. They also showed 
IGF-I treatment of fibroid cells markedly increased the expression of proliferating 
nuclear cell antigen (PCNA) that is involved in control of cell proliferation and DNA 
repair and replication (Mangrulkar et al., 1995).  
 
bFGF plays a role in pathology via activating its cognate receptor (FGFR1) to 
initiate remodelling of extracellular matrix (ECM) and regulate angiogenesis. Support 
for the role of bFGF in uterine fibroids is its over-expression in ECM of fibroids 
















EGF has been shown to play a key role in pathologies of uterine fibroids. 
Higher EGF mRNA expression in the secretory phase of menstrual cycle in fibroid 
samples compared to normal myometrium suggests a probable role of EGF in fibroid 
development. In other studies, Maruo et al. (2000) have shown progesterone and 
estrogen up-regulate expression of PCNA and EGF-receptor in cultured fibroid cells.  
 
VEGF is expressed both in myometrium and fibroids, however without 
significant expression level difference (Harrison-Woolrych et al., 1995). Despite this 
finding, VEGF might still be involved in pathologies of fibroids as it promotes 
angiogenesis and is very essential for actively growing tumors. In addition, molecular 
studies have shown that VEGF can exert a biological effect on FGF signalling pathway 
by prompting the release of bFGF which will in turn stimulate angiogenesis (Jonca et 
al., 1997).  
 
1.7.4 Proposed Roles for Cyclooxygenase and Prostaglandins in Uterine Fibroids  
Studies have shown COX-1 to be up-regulated in carcinomas of the uterine 
cervix (Sales et al., 2002), while COX-2 is up-regulated in endometrial (Tong et al., 
2000; Ferrandina et al., 2002) and cervical carcinoma (Ryu et al., 2000; Sales et al., 
2001) but little is known about the role of COX enzymes in uterine fibroids. Cesen-
Cummings et al. (2003), using the Eker rat as a model for human uterine fibroids 
showed fibroids and myometrium expressed the same levels of COX-1 mRNA while 
fibroid cells were deficient in COX-2 expression.  
 
In studies aimed at determining the levels of prostanoids in human 
myometrium and fibroids, it was found that both produce prostanoids. However, the 
levels of these prostanoids were reported to be contradictory (Yamaguchi and Mori, 
1987; Aitokallio-Tallberg, 1990). Recent in vitro studies using cultured fibroid cells 
have shown that letrozole, a specific aromatase inhibitor can inhibit PGE2-regulated 
cell proliferation and induce apoptosis suggesting the key role of prostaglandins in cell 
















Tsibris et al. (2002) screened up to 12,000 genes in uterine fibroids and control 
myometrium tissue homogenates from nine samples in the proliferative and secretory 
stages of the menstrual cycle. Two variants of the EP3 receptors (EP3a1 and EP3-IV 
receptors) and PGD2 synthase were down-regulated in fibroids compared to adjacent 
myometrium tissue samples. Wang et al. (2003) showed the EP3-IV receptor and 
PGD2 synthase to be down-regulated in fibroid samples compared to adjacent 
myometrium in gene array analysis from seven patients in the proliferative stage of 
menstrual cycle. Down-regulation of the EP3 receptor and PGD2 synthase was also 
reported in other independent gene array analyses (Quade et al., 2004; Catherino et al., 
2004; Arslan et al., 2005).  
 
1.7.5 Endometrial Changes Associated with Uterine Fibroids   
It has been reported that the mechanical presence of uterine fibroid can affect 
the endometrium. Early studies have shown that atrophy of the endometrium, as well 
as, elongation and distortion of the endometrium glands came as result of mechanical 
presence of uterine fibroids. This could be a direct effect of the nodular mass of the 
fibroids on the overlying or adjacent endometrium. The authors also reported ovarian 
hormonal change in uterine fibroids can cause cystic glandular hyperplasia, edema, 
polyposis and haemorrhages in endometrium (Deligdish and Loewenthal, 1970).  
 
The only molecular study on the comparison of endometrium from normal and 
women with fibroids was done by Miura et al. (2006). The authors classified fibroids 
samples according to the location of the tumor and compared pattern of macrophages 
infiltration in the tissues. Accumulation of macrophages was significantly higher in 
endometrium of women with submucosal (SM) and intramural (IM) fibroids compared 
to women with subserosal (SS) fibroids and control tissue. Monocyte chemotactic 
protein-1 (MCP-1) and PGF were significantly increased in endometrium of women 
with SM and IM relative to SS or control tissue. The authors proposed an increase in 
inflammation and PGF synthesis could be a possible mechanism in causing either 
pregnancy complications or infertility in women having SM or IM uterine fibroids 















1.8 G Protein-Coupled Receptor (GPCR) Cross-Talk  
Prostanoid receptors, as part of GPCR family, are found to be co-expressed in 
the same cells and co-activation of these receptors might lead to cross-talk between the 
distinct signalling pathways elicited by each receptor. Receptor
 
cross-talk can also 
occur among distinct families
 
of receptors such as tyrosine kinase receptors and 
GPCRs but this review will focus on cross-talk between GPCRs (Ashby, 1998; Selbie 
and Hill, 1998).  
 
Intracellular signalling in a cell expressing multiple GPCRs comprises the 
integration of input from each G proteins coupling (Gs, Gi/o and Gq/11) following ligand 
binding. These signalling outputs may act synergistically or antagonistically to amplify 
or attenuate cell signalling. This leads to a broad spectrum of signalling pathways 
which can alter physiological or pathological make up of a cell or a tissue. These 
heterologous interactions or cross-talks between GPCRs can result in a loss of function 
(desensitization), and also a gain or a potentiation of function (Werry et al., 2003; 
Selbie and Hill, 1998). Since dysregulation of the EP2 and FP receptors in endometrial 
adenocarcinoma is reported and these receptors are co-expressed in endometrial 
adenocarcinoma cells, the next sections will focus on cross-talk between Gαs- and Gαq-
coupled receptors.  
 
1.8.1 Intracellular Calcium in GPCR Cross-Talks  
Alteration of intracellular calcium is a key regulator of many biological 
processes. The release of intracellular calcium can be regulated by either activation of 
a single GPCR or co-activation of multiple GPCRs in the same cell (Werry et al., 
2003). Stimulation of Gαq-coupled receptor can lead to activation of PLC and 
generation of IP3 and a subsequent release of intracellular calcium from cellular stores 
(Watanabe et al., 1994). However, several studies have shown PLC-mediated Ca
2+
 
release can be influenced by co-activation of Gαs-coupled receptors regulating a 
















For example, Jimenez et al. (1999) reported a GPCR cross-talk that involves 
enhancement of intracellular calcium by co-activation of Gαs and Gαq proteins in type 
I cerebellar astrocytes. The authors showed that stimulation of the cells with ATP can 
activate release of intracellular calcium via the P2Y receptors coupled to Gαq protein 
and PLC activation. Furthermore, they showed co-activation of the P2 and P1 
purinoceptors by ATP and adenosine, respectively augmented P2Y receptor-mediated 
intracellular calcium release. This increase was mediated by the activation of A2B 
adenosine receptors that couple to Gαs, suggesting a cross-talk between the P2Y and 
P1 purinoceptors to potentiate PLC-mediated intracellular calcium. Werry et al. (2002) 
showed a cross-talk can happen upon co-activation of the Gαs-coupled β-adrenoceptors 
and Gαq-coupled P2Y receptors to potentiate Gαq-mediated intracellular calcium 
release in HEK-293 cells.  
 
The mechanism by which activation of Gαs can regulate intracellular calcium is 
not well known. A previous study showed that vasopressin-stimulated IP3 production 
was augmented by co-stimulation with a cAMP analogue in cultured rat hepatocytes. 
The authors suggested this could be a direct effect of cAMP on either phosphorylation 
of the vasopressin receptor or the PLC enzyme itself (Pittner and Fain, 1989). Another 
study showed that the increase in Gαq-mediated Ca
2+
 release by Gαs activation could 
be by a direct action of PKA on IP3 receptor/channel to facilitate Ca
2+ 
release from 
endoplasmic reticulum. Another indirect effect of PKA on intracellular Ca
2+
 stores 
could be by stimulation of ATP-dependent Ca
2+ 
pump that in turn modifies the 
functional distribution between the IP3-sensitive and IP3-insensitive Ca
2+
 pools 
(Hajnoczky et al., 1993).  
 
1.8.2 Adenylyl Cyclases (ACs) in GPCR Cross-Talks  
Activation of Gαs-coupled receptor leads to accumulation of intracellular 
cAMP.  The AC family are responsible for this enzymatic reaction by catalyzing the 
synthesis of cAMP from ATP. ACs have been shown to play a major role in mediating 
a Gαs-Gαq cross-talk by forming a critical link between Ca
2+
 and cAMP signalling 
















The first AC was cloned in 1989. The enzyme consists of two hydrophobic 
transmembrane domains (TM1 and TM2 each containing six transmembrane domains), 
two long cytoplasmic domain (C1 and C2) and a short N-terminal region as shown in 
figure 1.5 (Krupinski et al., 1989). The enzyme has two highly conserved ATP-binding 
domains on the cytoplasmic domain that are designated as C1a and C2a. These 
domains are highly homologous and complementary and need to dimerize for complete 
AC activity. C1b and C2b refer to the less conserved domains in AC (Hanoune et al., 





Fig. 1.5: Adenylyl cyclase structure. ACs can be divided in five major domains: The hydroxyl 
terminus, the first six transmembrane group (TM1), the first cytoplasmic loop (C1a and C1b), 
the second group of six transmembrane (TM2) and the second cytoplasmic loop (C2a and 
C2b) (Figure taken and modified from Hanoune et al., 1997; Willoughby and Cooper, 2007).   
 
 
There are multiple AC isoforms (9 membrane-bound and 1 soluble) each with a 
molecular weight about 120-150 kDa, except the soluble isoform which is half the size 
of the others and is found in spermatozoa. This observed high mass is contributed by 
glycosylation of the enzymes that is found in the second transmembrane cluster. The 
AC isoforms differ in their amino acid sequence, tissue distribution and regulation and 
are named in the order of their publication (Krupinski et al., 1989; Bakalyar and Reed, 
1990; Gao and Gilman, 1991; Katsushika et al., 1992; Watson et al., 1994; Defer et 






















Despite their difference in amino acid sequence they share a large sequence 
homology in the primary structure and the same predicted three-dimensional structure. 
All the AC isoforms can be stimulated by Gαs and forskolin. However, ACs can also 
be regulated by several regulatory factors such as calcium, G proteins (Gαi and Gβγ), 
protein kinases (PKA, PKC, calmodulin and calmodulin-kinase) and phosphatases 
(calcineurin). Based on their responsiveness to the above regulatory elements, ACs 
have been classified into four groups. Group 1 consists of enzymes that are stimulated 
by calcium or calmodulin (AC1, AC3 and AC8) while group 2 contains AC enzymes 
that are activated by PKC and βγ subunit (AC2, AC4 and AC7). Group 3 are enzymes 
inhibited by low concentration of calcium (AC5 and AC6) and Group 4 (AC9) is 
insensitive to both calcium and βγ subunit (Hanoune et al., 1997, Willoughby and 
Cooper, 2007). The major source of AC isoforms expression and their response to 
















Table 1.1: Regulation and distribution of adenylyl cyclases (adapted and modified 
from Willoughby and Cooper, 2007; Hanoune and Defer, 2001) 
AC isoform Major source of 
expression 
Response to cAMP signalling pathway component 
Gαs Gαi Gβγ Calcium Protein kinases  
AC1 Brain ↑ ↓ ↓ ↑ (via CaM) ↓ CaMK IV 
↑ RTK 




↑ ↓ → ↑ ?(via CaM) 
↓ ?(CaMKII) 
↓ CaMK II 
AC4 Widespread ↑ → ↑ → ↑ PKC 
AC5 Heart, striatum ↑ ↓ → ↓ ↑ PKC 
↓ PKA 
↑ RTK 
AC6 Heart, kidney, 
widespread 




AC7 Widespread ↑ → → → ↑ PKC 
AC8 Brain, pancreas ↑ ↓ ↓ ↑ (via CaM) → PKC 





Sperm, kidney → →    
 
1.8.2.1 Calcium-Regulated Adenylyl Cyclase Isoforms 
All mammalian ACs are inhibited by high Ca
2+
 concentrations 
(supramicromolar). This effect could be due to the competition of Ca
2+
 on binding to 
metal binding sites on the catalytic domain. Out of the nine membrane-bound AC 
isoforms three of them (AC1, AC3 and AC8) are stimulated by calcium while AC5 
and AC6 are normally inhibited by physiological calcium changes in vivo (Tang et al., 
1991; Choi et al., 1992; Cali et al., 1994). In the next sections this review will discuss 
















1.8.2.2 Adenylyl Cyclase 1 (AC1)  
AC1 was the first AC isoform to be cloned and characterized by Krupinski et 
al. (1989). The characterization of AC1 using Sf9 cells showed accumulation of 
intracellular cAMP regulated by calcium and calmodulin directly without the presence 
of Gαs activator (Tang et al., 1990). Choi et al. (1992) has shown that AC1 can be 
stimulated by extracellular calcium by stably expressing the isoform in HEK-293 cells. 
The authors showed that in the presence of the phosphodiesterase inhibitor IBMX (3-
isobutyl-1-methyl xanthine), extracellular calcium and Ca
2+
 ionophore (A23187) can 
increase the intracellular accumulation of cAMP by 16-fold. They also showed 
forskolin-activated cAMP can be enhanced by the addition of A23187 by about 9-fold 
even in the absence of IBMX (Choi et al., 1992).  
 
Wu et al. (1993) dissected the calmodulin binding domain by mutating specific 
sites that are reported to contribute to calmodulin sensitivity of the enzymes (aromatic 
amino acids in C1b region of the molecule). A specific F503R mutation completely 
abolished calcium stimulated cAMP. This mutation was specific to the regulatory sites 
as neither the basal cAMP level nor the forskolin-stimulated cAMP was altered by the 
mutation showing the mutation had no effect on the catalytic activity of the enzyme 
(Wu et al., 1993).  
 
1.8.2.3 Adenylyl Cyclase 3 (AC3) 
AC3 was cloned by Bakalyar and Reed (1990) from olfactory neurons and was 
presumed to be specific to the sensory system. But other studies have shown the 
enzyme to be expressed in pancreas, heart, vascular smooth muscle, brain and lung 
tissues (Wang and Storm, 2003).   
 
The regulation of AC3 by calcium is not totally clear. Although AC3 is 
generally regarded as calcium stimulable isoform, studies in HEK-293 cells have 
shown direct inhibition of the isoform by physiologically relevant concentrations of 
intracellular calcium. This inhibition was blocked by chemical inhibitor for calmodulin 















studies have shown that increase in intracellular calcium can directly activate CaMK-II 
to phosphorylate AC3 in HEK-293 cells. The authors identified the site of 
phosphorylation on AC3 using a S1076A mutation that completely inhibited 
intracellular calcium inhibition of AC3 (Wei et al., 1996; Wei et al., 1998). However, 
another study has revealed when it is concomitantly activated with Gαs, AC3 can be 
stimulated by intracellular calcium to potentiate cAMP production. The authors 
employing HEK-293 cells stably expressing the AC3 isoform showed an increase in 
intracellular accumulation of cAMP when activated with calcium in the presence of 
forskolin or GppNHp (a nonhydrolyzable guanosine triphosphate (GTP) analogue that 
persistently activate Gαs proteins) while calcium by itself did not have any effect on 
cAMP (Choi et al., 1992).  
 
1.8.2.4 Adenylyl Cyclase 8 (AC8) 
AC8 was the last calcium-regulated isoform to be isolated and it was cloned 
from human newborn brain-stem tissue in 1994 (Defer et al., 1994). The enzymatic 
property of this isoform is very similar to AC1 despite sharing only 28% amino acid 
similarity (Tang et al., 1991). This well studied isoform is activated by calcium and 
calmodulin in HEK-293 cells at almost the same concentration as AC1 (Cali et al., 
1994).  
 
Gu and Cooper (1999) showed two calmodulin binding sites in AC8, located at 
C- and the N-terminus of the enzyme. The complex interaction on how calmodulin 
activates AC8 was studied by Simpson et al. (2006). The authors showed the N-
terminus plays a key role in the activation of the enzyme by calcium as it has an 
amphipathic helix calmodulin binding domain (CaMBD). At resting calcium, AC8 is 
auto-inhibited by the interaction of calmodulin with CaMBD in N terminus. In the 
event of calcium entry, Ca
2+
 binds to the calmodulin and eventually interacts with the 
main regulation site in the COOH terminus then eventually triggers relief 
autoinhibition allowing ATP to bind to the catalytic domain of the enzyme (Simpson et 















1.8.3 Intracellular cAMP Augmentation via GPCR Cross-Talks   
Intracellular calcium and the adenylyl cyclase pathway have been shown to 
play a major part in Gαs-Gαq cross talk by activating cAMP. Meszaros et al. (2000) 
showed a potentiation of isoproterenol (β-adrenergic (β-AR) receptor agonist)-induced 
cAMP production by angiotensin II (ANG-II) activation of AT1 receptors coupled to 
Gαq protein pathway indication of a signalling cross talk between AT1 and β-AR 
receptors in cardiac fibroblasts cells.  
 
The mechanism in which the cross-talk occurs was further studied by Ostrom et 
al. (2003). The authors showed the Gαs-Gαq cross-talk was mediated by the activation 
of PLC and release of intracellular calcium. They further showed Ca
2+
 in turn activate 
the calmodulin-CaMK-II to trigger the cross talk between the receptors probably by 
the activation of calcium stimulable AC3 isoform, since it is the only calcium 
regulated isoform expressed in their model cells.  
 
Zhang et al. (1997) also reported Gαs-Gαq cross talk in cultures vascular 
smooth muscle cells (VSMC). In these cells, Isoproterenol-stimulated cAMP 
accumulation was increased to 2-2.5 fold when it is co-stimulated by arginine 
vasopressin (AVP). Further studies of the molecular pathway underlying this 
augmentation revealed the cross-talk is mediated by the intracellular calcium pathway 
and is independent of PKC. Here too the cross talk between the receptors is probably 
by the activation of calcium-stimulable AC3 isoform, since AC3 is the only calcium 
regulated isoform expressed in these cells (Zhang et al., 1997). 
 
The other Gαs-Gαq cross-talk involves the calcium inhibitable AC6 isoform. 
Studies using AC6 over-expressing HEK-293 cells showed augmentation of 
Isoproterenol and forskolin-stimulated cAMP by carbachol activation of the 
muscarinic receptor. In this study the authors showed AC6 can be regulated in two 
ways as it was inhibited by capacitative calcium entry (CCE) while carbachol activated 
release of intracellular calcium augmented forskolin-stimulated cAMP. The authors 
dissected the pathway involved in this cross-talk and found it to be mediated by the 















over-expressing HEK-293 cell lines also showed a bi-directional regulation of the AC9 
isoform by calcium (Cumbay and Watts, 2005).  
 
1.8.4 Cross-Talks in Eicosanoid Receptors Family  
There have been several reports for cross-talk in the eicosanoid family. The 
most notable is the cross-talks reported between the thromboxane and prostacyclin 
receptors. These two eicosanoid receptors have opposing roles in physiology of 
vascular hemostasis which are mediated via different signalling pathways. As 
mentioned in section 1.4.3, TXA2 binds to TPα and TPβ receptors to activate 
intracellular IP3 release while prostacyclin binds to IP receptor to activate release of 
cAMP from intracellular stores (Breyer et al., 2001).  
 
Walsh et al. (2000) reported a cross-talk between TPα and IP receptors in 
HEK-293 cells stably expressing the TPα receptor. The authors reported stimulation of 
the cells using selective IP agonist (cicaprost) completely desensitized U46619-TP 
mediated PLC activation and Ca
2+
 mobilization. The desensitization of TPα receptors 
by cicaprost was mediated by PKA pathway and inhibition of PKC did not have any 
effect on this heterologous desensitization. However, signalling of the TPβ receptors 
was not affected by stimulation of IP receptors (Walsh et al., 2000).  
 
The other GPCR cross-talk reported in eicosanoid family is between the PGD2 
receptors and TXA2 receptors. The action of PGD2 mimics that of prostacyclin by 
inhibition of platelet aggregation in vascular hemostasis. Activation of the DP receptor 
by BW235C desensitized TPα receptor by inhibiting PLC activation and was mediated 
by the PKA pathway. This effect was limited to the TPα receptor as TPβ was 
unaffected by stimulation of DP receptors in HEK-293 cells over-expressing the TPβ 
receptors (Foley et al., 2001).  
 
Walsh and Kinsella (2000) showed a cross-talk between the TXA2 receptors 
(TPα and TPβ) and the EP1 receptors in HEK-293 cells. The authors showed that 
subjecting TPα and TPβ receptors to 17 phenyl trinor PGE2 (EP1 receptor agonist) 















dependent manner. The authors further indentified the activation of the FP receptor by 
PGF can also mediate desensitization of the TPα and TPβ receptors via the PKC 
pathway in HEK-293 cells (Kelley-Hickie and Kinsella 2004).  
 
In another study, Wilson et al. (2004) showed co-expression of the IP and TPα 
receptors in HEK-293 cells can augment TPα-receptor mediated cAMP without 
activation of the IP receptor. The cAMP augmentation was further increased when 
both receptors were co-activated by their respective ligands. Further studies with the 
receptors showed that heterodimerization can occur between IP and TPα receptors that 
probably leads to augmentation of cAMP production by IP receptors.  
 
1.9 General Aims and Objectives of the Project  
As mentioned in section 1.7, uterine fibroids are an important clinical problem in 
women in the reproductive years. Despite being a major cause of pregnancy related 
complications and gynecological morbidity, the etiology of uterine fibroid are still not 
well elucidated (Marshall et al., 1997; Flake et al., 2003). There is a strong evidence to 
support a role for COX enzymes and prostaglandin receptors dysregulation in 
reproductive pathologies (Lumsden et al., 1983; Karck et al., 1996; Smith et al., 1981; 
Sales et al., 2002; Ryu et al., 2000; Jabbour et al., 2006b). However, there have not 
been sufficient studies to assess the effect of COX and prostaglandin receptors in 
uterine fibroids.  
 
The objectives of this study were two fold. The first aim was to assess the 
expression of COX enzymes and prostaglandin receptors in fibroids, autologous 
myometrium and endometrium samples from women with fibroids. The second aim 
comes from co-expression of prostaglandin receptors in several cell types and tissues 
(Ashby, 1998). For example, EP2 and FP receptors are co-expressed in Ishikawa cells. 
Studies in our laboratory have shown that up-regulation of the EP2 and FP receptors in 
endometrial adenocarcinomas. In addition, the authors have shown elevated expression 
and activation of the EP2 and FP receptors can promote the expression of angiogenic 















This observation suggests that co-activation of prostanoid receptors in the same cell 
could change the physiological/pathophysiological gene expression profile. The second 
aim of this study was to address the integrative signalling effects of the EP2 and FP 
receptors on signal transduction and gene expression. The specific aims of the research 
were to:  
 
1. generate a model cell line co-expressing the EP2 and FP receptors in Ishikawa 
cells (FPEP2 cells)  
2. identify a possible intracellular signalling cross-talk mediated by co-activation 
of the EP2 and FP receptors and to further characterize the molecular 
mechanism underlying the potential cross-talk in FPEP2 cells  
3. identify which genes or cluster of genes are differentially regulated by co-
activation of the EP2 and FP receptors relative to activation of EP2 or FP 
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2.1 Chemicals and Reagents  
All chemicals used were molecular biology grade, and were obtained from Sigma 
(Dorset, United Kingdom (UK) or South Africa (SA) or IBI (Cambridge, UK). Cell 
culture media was purchased from Gibco (Gibco, Paisely, UK). Foetal Calf Serum (FCS) 
and Penicillin-Streptomycin were purchased from PAA Laboratories (PAA Laboratories, 
Middlesex, UK). MycoAlert
®
 Mycoplsma detection kit was purchased from LONZA 
(LONZA, Rockland, USA), while phosphate buffer saline (PBS) and trypsin-EDTA were 
purchased from BioWhittaker (BioWhittaker, Berkshire, UK).  
 
Hygromycin (100mg/ml stock in HEPES (N-2-Hydroxyethylpiperazine-N’-2-
ethanesulfonic acid) buffer) was purchased from Invivogen (Invivogen, Autogen Bioclear 
UK). G418 (100mg/ml stock in PBS), indomethcin (3mg/ml stock in ethanol), Butaprost 
(5mM stock in ethanol), PGE2 (PGE, 100µM stock in ethanol), PGF2α (PGF, 100µM stock 
in ethanol) and IBMX (20mM stock in 50% ethanol) were purchased from Sigma (Sigma 
chemical Co., Nottingham, UK). FP receptor antagonist (AL8810, 50mM stock in 
ethanol), IP3-receptor blocker (2-APB, 40mM stock in dimethyl sulfoxide (DMSO)), PLC 
inhibitor (U73122, 10mM stock in DMSO), Calmodulin antagonist (W7, 25mM stock in 
DMSO), Ca
2+
/calmodulin-dependent kinase II (CaMK-II) inhibitor (KN-93, 50mM stock 
in DMSO) and PKC inhibitor (Ro-31-822, 1mM stock in DMSO) were all purchased from 
Calbiochem (Calbiochem, Nottingham, UK). Inhibitor of Gαq (YM254890, 1mM stock in 
DMSO) was a kind gift from
 
M. Taniguchi, (A stellas Pharmaceuticals Inc., Tokyo, 
Japan).  
 
Pre-cast 4% to 12% Tris-Glycine gels and SeeBlue
®
 Plus2 Pre-stained marker 
were purchased from Novex (Novex, UK). Polyvinylidene difluoride (PVDF) membrane 
was purchased from Millipore (Millipore, Watford, UK). Whatman no. 3 paper was 
obtained from Whatman (Whatman, UK). Odyssey blocking buffer was obtained from Li-
Cor Bioscience (Li-Cor Bioscience, Cambridge,
 
UK). The EP2 and FP receptor primary 
antibodies were purchased from Cayman Chemical Company (Axxora,
 
Nottingham, UK) 
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Cruz, Wiltshire, UK). Fluorescent secondary
 
antibodies were purchased from Li-Cor 
Biosciences (Li-Cor Biosciences, Cambridge,
 
UK). Stealth short interfering RNA (siRNA) 
duplex oligoribonucleotides for AC1 and AC3 were purchased from Invitrogen 
(Invitrogen, Paisley, UK).   
 
2.2 Cellular Investigations 
2.2.1 Cell Culture 
The complete medium used to culture human endometrial adenocarcinoma 
(Ishikawa) cells (Nishida et al., 1985; European Collection
 
of Cell Culture, Centre for 
Applied Microbiology, Wiltshire,
 
UK) was Dulbecco's Modified Eagle Medium 
supplemented with nutrient F-12, glutamax-1 and pyridoxine (DMEM-F12), 10% FCS 
and 1% antibiotics (stock solution of 500IU/ml penicillin and 500µg/ml streptomycin). 
The medium was stored at 4 C, and was warmed at 37 C before use. Monolayer cultures 
of Ishikawa cells were grown in 125 cm
2
 tissue culture (TC) flasks and kept in a 
humidified incubator (37 C , 95% relative humidity and 5% CO2). The cells were checked 
for growth every other day using an inverted microscope. Confluent cells were passaged 
by washing twice with PBS and dissociating with 5ml trypsin-EDTA, for 10 min at 37°C. 
The cell suspension was centrifuged in a fresh tube at 1000 rpm for 5 min and the pellet 
was re-suspended in fresh medium. Cells were seeded into new flasks after 1:10 dilution 
with a new passage number being recorded on each flask. Early passage cells were frozen 
down for later use by re-suspending the trypsinized cells (~1  10
6
 cells/ml) in FCS 
containing 10% DMSO and transferred into small sterile cryogenic vials. The vials 
containing cell aliquots (1ml each) were placed upright in a -80 C freezer and later 
transferred to liquid nitrogen for long term storage. Thawing of frozen vials was done 
quickly at 37 C and cells were suspended in 10ml complete medium to neutralize the 
DMSO. The mix was centrifuged at 1000 rpm for 5 min and cell pellet was re-suspended 
in 10 ml of complete medium and transferred into a 75 cm
2
 flask. The cells were 
frequently checked for Mycoplasma contamination using MycoAlert
®
 Mycoplasma 
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2.2.2 Cell Transfection   
Stable cell lines expressing both EP2 and FP receptors (FPEP2 cells) were 
prepared from Ishikawa cells stably expressing the FP receptor (FPS32 cell lines) (Sales et 
al., 2005). These cells were maintained in a selective medium containing 200µg/ml of 
G418. EP2 receptor cDNA construct was prepared as described in section 2.3.1. The EP2 
receptor cDNA was transfected into the FPS32 cells using SuperFect
®
 transfection reagent 




 FPS32 Ishikawa cells were plated into 100 mm cell culture dishes 
and were allowed to adhere overnight in a humidified incubator. The following day EP2 
receptor cDNA (10µg) in Tris-EDTA buffer (10mM Tris and 1mM EDTA pH 7) was 
added to cell growth medium lacking serum and antibiotics. Subsequently, 60µl of 
SuperFect
®
 transfection reagent was added to the DNA mix and left for 15 min at room 
temperature to allow transfection-complex formation. Cells were then washed with PBS 
and 3 ml of complete growth medium was added to the transfection mix and immediately 
added to the cells. Afters five hrs of incubation under a normal growth condition, the 
medium was aspirated and cells were washed with PBS and incubated in a normal growth 
medium overnight. The following day the cells were passaged (1:5, 1:10, 1:20 and 1:50) 
and were grown in the presence of a selective medium containing 800µg/ml of 
hygromycin. For control, untransfected cells were grown under the same selective media 
in parallel. Once untransfected cells had died, 50 hygromycin-resistant clones were picked 
using sterile cloning cylinders (Sigma) by trypsinizing each colony and were transferred 
into 24-well plates. Single clones were then allowed to grow in the presence of selective 
medium and transferred into 25 cm
2
 flasks. Clones were then screened for the expression 
of the EP2 receptor by Real-time RT-PCR and for the accumulation of intracellular cAMP 
in the presence of the EP2 receptor ligands, PGE2 and Butaprost. All clones were 
maintained in hygromycin and G418 (200µg/ml each) selective for the expression of the 
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2.2.3 Ligand Stimulation and cAMP Assay 
Ligand-induced cAMP accumulation was determined by seeding 2×10
5
 cells in 6-
well plates. The following day, the cells were serum-starved with serum free medium in 
the presence of 3µg/ml of indomethacin (a dual COX enzyme inhibitor used to inhibit 
production of endogenous prostaglandins). After 18 hrs, the cells were pre-treated in 
serum free medium containing the phosphodiesterase inhibitor IBMX (0.2mM) for 30 min 
in humidified incubator. Subsequently, the cells were treated for 5 min with vehicle (0.1% 
ethanol and/or DMSO), PGE2 (100nM), Butaprost (5µM) or PGF (100nM) in the 
presence/absence of different chemical inhibitors as indicated. After the incubation, cells 
were washed twice with cold PBS to stop the reaction and lysed in 200µl of cell lysis 
buffer (R&D Systems, Oxford, UK). Insoluble material was removed from lysates by 
centrifuging the samples at 14000 rpm for 15 min at 4°C. Intracellular accumulation of 
cAMP was determined by an Enzyme-Linked ImmunoSorbent Assay (ELISA) cAMP Kit 
(R&D Systems, Oxford, UK) according to the manufacturer’s protocol.  
 
In short, the ELISA was performed using goat anti-mouse polyclonal antibody-
coated 96-well polystyrene microplates.  The cAMP present in the samples was measured 
by competition with a fixed amount of horse-radish peroxidise (HRP)-labelled cAMP for 
sites on a mouse monoclonal antibody. 100µl of cAMP standards (200pmol/ml to 
1.56pmol/ml) and diluted samples were added to the plate in duplicate. The wells were 
then coated with 50µl/well of mouse monoclonal antibody to cAMP in buffer with blue 
dye™ and cAMP conjugated to HRP with red dye™ and incubated at room temperature 
for 3 hrs on a horizontal orbital microplate shaker (0.12" orbit) set at 550 rpm. Thereafter 
the wells were aspirated and washed four times with 400µl R&D wash buffer™ to remove 
excess conjugate and unbound sample. Subsequently, a substrate solution (a 1:1 ratio of 
Colour Reagent A™ (stabilized hydrogen peroxide) and Colour Reagent B™ (stabilized 
chromogen (tetramethylbenzidine)) was added to determine the bound enzyme activity. 
The colour development was stopped using Stop solution™ (Sulfuric acid) and the 
absorbance was read at 450 nm using Labsystems Multiskan EX plate reader (Thermo 
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Assay Zap computer programe (Biosoft, Cambridge, UK). Data were normalized by the 
respective protein concentration of each sample using the protein assay described in 
section 2.2.8.  
 
2.2.4 Ligand Stimulation and Total Inositol Phosphate (IP3) Assay 
Ligand-induced accumulation of IP3 was determined by plating 50,000 cells in 24-
well plates containing 1ml/well of complete medium. Cells were allowed to attach 
overnight and on the following day, the cells were washed with PBS and then labeled with 
0.5µCi/well myo-[3H]-inositol (Amersham Bioscineces, RSA) in an inositol-free DMEM 
199 medium supplemented with 2% dialyzed FCS overnight. The next day, the medium 
was removed and cells were washed with Buffer I (140mM NaCl, 20mM HEPES, 4mM 
KCL, 8mM Glucose, 1mM MgCl2, 1mM CaCl2, 1mg/ml bovine serum and 10mM LiCl) 
and preincubated for 30 min in Buffer I. Subsequently, cells were stimulated with PGF 
and/or Butaprost at the indicated concentrations in Buffer I for 60 min at 37 C in an 
incubator, while non-stimulated samples served as control for each experiment. After 
aspirating the buffer, the cells were lysed by the addition of 1 ml ice cold 10mM formic 
acid and the plates were placed on ice for 30 min.  
 
Total [3H]-inositol phosphates were separated from cell extracts on AG 1-X8 resin 
by anion exchange chromatography. Briefly, the columns were washed with 3ml of 3mM 
of amonium formate/0.1M formic acid and then with 10ml of distilled water. 
Subsequently, 1ml of sample was added to the columns and columns were rinsed once 
with 10ml of distilled water and 5ml of 0.1M formic acid/ 5mM myo-inositol. The labeled 
inositol phosphates were eluted with 3ml of 1M ammonium formate/0.1M formic acid 
solution and mixed with 16ml of Quick Safe A scintillation fluid (Zinser analytic, 
Frankfurt, Germany). The associated radioactivity was determined by counting each vial 
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2.2.5 Wound Healing Assay (Scratch Assay)  
Ishikawa cells were seeded at a density of 2×10
5
 cells/well into 6-well plates in 
complete media. On the following day cells were serum starved overnight in media 
containing indomethacin (3µg/ml).  Thereafter, the cell monolayer was scraped using a 
p1000 tip to create a straight line. The debris of the smooth edge were removed by 
washing with PBS and cells were treated with vehicle, Butaprost (5µM) and/or PGF 
(100nM). The cells were incubated for 24 hrs in a tissue culture incubator and an image 
was acquired every four hrs. The distance of each scratch closure was measured and 
expressed as fold increase above vehicle treated.  
 
2.2.6 Proliferation Assay  
Ishikawa cells were seeded at a density of 5000 cells/well in a 96-well plate and 
were left to adhere overnight in complete media. The next day the cells were serum 
starved in 1% FCS/DMEM in the presence of 3µg/ml of Indomethacin. Cells were then 
treated with vehicle, Butaprost (5µM) and/or PGF (100nM) for 24, 48 and 72 hrs. After 
each time point, proliferation was assessed by incubating the cells with CellTitre 
96AQueous One Solution reagent (Promega Corp., Madison, WI) for two hrs in a 
humidified incubator. After the incubation the amount of soluble formazan produced by 
cellular reduction of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) was determined by reading the absorbance at 492 nm 
using Labsystems Multiskan EX plate reader (Thermo Labsystems, UK). 
 
2.2.7 Protein Extraction from Cells 
Ishikawa cells were seeded at a density of 2.5×10
5
cells in a 6-well plate and 
cultured in complete media overnight. The cells were lysed by an addition of lysis buffer 
(150mM NaCl, 10% Glycerol, 0.6% (v/v) NP-40, 50mM Tris/HCL pH 7.4 and 10mM 
EDTA containing mini complete tablet cocktail consisting of protease inhibitors 
(chymotrypsin, thermolysin, papain, pronase, pancreatic extract and trypsin inhibitors) 
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at 4°C and the clarified lysate was transferred to a new tube for further protein 
quantification.  
 
2.2.8 Protein Concentration Determination 
Protein concentrations were determined using the standard BIO-RAD DC assay 
(BIO-RAD, UK) as directed by the manufacturer’s instructions. Bovine serum albumin 
(BSA) was used as a protein standard and diluted from 400 to 0 g in 100 l of distilled 
water in tubes. 20 l of standards or samples were loaded into a 96-well plate (in duplicate) 
followed by the addition of 25 l of working reagent (20 l of Reagent S™ in 1ml of 
Reagent A™ (alkaline copper tartrate solution)). Thereafter, 100 l Reagent B™ (Folin 
Reagent) was added to the well and after 15 min incubation the absorbance at 690 nm was 
measured using Labsystems Multiskan EX plate reader (Thermo Labsystems, UK). A 
standard curve was plotted using the program Assay Zap (Biosoft, Cambridge, UK) and 
the unknown protein concentrations were determined from the standard curve.  
 
2.2.9 SDS-PAGE and Western Blotting  
A total of  20-50μg of protein was resuspended in 1 × Laemmli buffer (125mM 
Tris-HCL pH 6.8, 4% SDS, 20% glycerol, 5% 2-mercapthoethanol and 0.05% 
bromophenol blue) and boiled for 5 min at 95°C. Samples and 4 l of SeeBlue
®
 (Novex, 
Invitrogen) pre-stained protein marker were then fractionated by electrophoresis (50mA, 2 
hrs) on a pre-cast 4% to 12% Bis-Tris gels (NOVEX, Invitrogen). The gel and three 
Whatman paper (Whatman, UK) were placed to a protein free tray and equilibrated with 
transfer buffer (25mM Tris/HCL, 0.192M Glycine and 20% Methanol). Millipore 
Immobilon™-FL PVDF membrane (Millipore, Watford, UK) cut to the dimension of the 
gel was equilibrated in transfer buffer after immersing in methanol for 1 min. The blot was 
assembled by overlying three pieces of Whatman paper with a membrane followed by the 
gel and the three layers of Whatman paper. The gel was transferred to the Immobilon™-
FL PVDF membrane at constant voltage of 14V using semi-dry blotter (BIO-RAD) for 90 
min. After incubating the membrane in 10ml of Odyssey blocking buffer (Li-Cor 
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primary antibody at 4°C overnight with gentle shaking. The membrane was then washed 
four times in 10 ml of PBS-Tween (PBS with 0.1% Tween 20) and was incubated with the 
secondary fluorescence antibody for 1 hour. After washing the membrane thrice with 
PBS-Tween, proteins were then viewed using Odyssey Infrared imaging system (Li-Cor 
Bioscience, Cambridge, UK).   
 
2.2.10 Immunofluorescence Microscopy of Cells   
The site of EP2 and FP receptors expression in FPS32 and FPEP2 cell lines were 
localized using an immunofluorescence microscopy. Ishikawa cells (10 ×10
5
 cells/well) 
were plated out in 2-well cell chamber slides and left to adhere overnight. The next day 
the cells were fixed with 4%
 
paraformaldehyde (PFA) for 20 min and washed with PBS, 
before being blocked in 5% BSA diluted in normal goat serum for 2 hrs. Thereafter, the 
cells were incubated with polyclonal rabbit anti-EP2 and FP receptor antibody diluted 
(1:100) in normal goat serum overnight at 4 C. To check the specificity of the signals, the 
primary antibodies were preadsorbed (10 fold in weight) with a specific blocking peptide 
for each receptor and used as control. The next day cells were washed three times with 
PBS for 10 min and incubated with Alexa flour conjugated secondary goat anti-rabbit 
antibody (Molecular probes) for 2 hrs. After three 10 min of PBS washes the nuclear was 
stained using DAPI (1:1000 in PBS; Sigma) for 10 min. Thereafter slides were washed 
and mounted in Permafluor (Immunotech-Coulter,
 
Buckinghamshire, UK) and 
coverslipped for microscopic analysis.  
   
2.3 Molecular Studies  
2.3.1 Construction of EP2 Receptor cDNA Expression Vector  
Total RNA was extracted from proliferative phase of human endometrial
 
tissue and 
reverse transcribed into cDNA using a method described 2.3.3 and 2.3.5, respectively. 
EP2 receptor cDNA was synthesised using forward 5'-CTCTTTTCCAGGCACCCCAC-3'
 
and reverse 5'-TTTTAAACTGACCTCAAAGGTCAGC-3' primers. Subsequently, the 
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2.3.2 Total RNA Extraction from Cells 
Throughout total RNA extraction, a ribonuclease (RNase) free environment was 
maintained by wiping all the surfaces with RNase-Away
TM
 (Gibco-BRL) and by using 
double distilled deionized water that was pretreated with 0.01% diethylpyrocarbonate 
(DEPC; Sigma). Total RNA was extracted from Ishikawa cells using the RNA extraction 
reagent Trizol
TM
 (Invitrogen, Paisley, UK) according to the manufacturer’s protocol. The 
cells were lysed in 1 ml Trizol reagent by pipetting and incubating at room temperature for 
5 min to ensure complete disassociation of nucleoproteins and were then transferred to 
Phase lock gel heavy tubes (5 PRIME). BCP (1-bromo-3-chloropropane (Sigma), 200 l 
per 1ml of Trizol) was added and the sample was shaken vigorously for 15 sec. After 10 
min incubation at room temperature, the tube was centrifuged at 14000 rpm for 15 min at 
4 C for phase separation. The colourless upper aqueous phase that contains RNA was 
transferred to a clean tube and precipitated by the addition of isopropanol (Sigma, 500 l 
per 1ml of Trizol). The tubes were incubated at room temperature for 10 min and 
centrifuged at 14000 rpm for 15 min at 4 C. After discarding the supernatant, the RNA 
precipitate was washed with 1ml of 75% ethanol and centrifuged at 14000 rpm for 5 min 
at 4 C. The RNA pellet was air dried for 5 min and then resuspended in approximately 40-
60 l of DEPC- ddH2O depending on the size of the pellet. The sample was then aliquoted 
to avoid repeated freeze/thaw cycles and stored at -70 C for later use. RNA concentration 
was determined by measuring the absorbance at 260nm and 280nm (OD260 and OD280) 
using NanoDrop
®
 ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies).   
 
2.3.3 Tissue Collection and RNA Isolation 
Fibroids, myometrial and endometrial tissues were collected from women 
undergoing hysterectomy for uterine fibroids. Collected tissues were quickly transferred to 
2ml microfuge tubes with RNAlater and were snap frozen on dry ice after collection. The 
tissue was then disrupted and homogenized twice in RLT™ buffer using a Tissuelyser II 
(QIAGEN, Crawley, UK) for 3 min at 25Hz frequency according to manufacturer’s 
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to a fresh tube and mixed with 70% ethanol. The lysate was transferred into an RNeasy 
spin column (QIAGEN) placed in a 2ml collection tube and was centrifuged for 15 sec at 
10000 rpm at room temperature. The column was then washed with RW1™ buffer 
(QIAGEN) by spinning at 10000 rpm for 15 sec. To eliminate any genomic DNA 
contamination the column was directly treated with DNase I (10µl of DNase I stock in 
70µl of buffer RDD™ (QIAGEN)) for 15 min at room temperature. The column was then 
washed with RW1™ and RPE™ buffer (QIAGEN) by centrifuging for 15 sec at 10000 
rpm at room temperature. Thereafter, the RNeasy spin column was placed on a fresh 1.5ml 
collection tube and 30-50µl of RNase-free water was added to the column directly. The 
column was spun at 1000 rpm for 1 min at room temperature to elute the RNA. The 
concentration and purity of the RNA was determined as described in 2.3.2.  
 
2.3.4 Primer Design  
All primer pairs and probes used in this study were designed using PRIMER 
express program (Perkin Elmer, PE biosystems, Warrington UK) unless otherwise stated. 
At least one primer of each pair spanned an exon-exon junction to prevent amplification of 
genomic DNA during the PCR reaction. The specificity of the designed primers was 
checked by blasting the sequence using a BLASTN program 
(http://www.ncbi.nlm.nih.gov/BLAST/). 
 
2.3.5 cDNA Synthesis  
The cDNA template was synthesized from total RNA by reverse transcription 
(RT). For each 20 l RT reaction, a mix of RNA template (400ng) and primers (Random 
hexamers and/or oligo dT) in a sterile nuclease-free tube was added (the components used 
in the PCR reaction mix are mentioned in table 2.1). Synthesis of cDNA was performed 
using a TaqMan
®
 Reverse Transcription Reagents (PE Applied Biosystems, Warrington, 
UK) in the following conditions; 1 hr 42°C, 5 min 99°C and 5 min at 5°C. A mix with no 
reverse transcriptase
 
was included to control for any genomic DNA contamination. For 
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cDNA template for RT-PCR was synthesized from 1μg total mRNA and both random 
hexamers (1.25µM) and oligo dT (1.25µM) were used for the reaction.  
 
 
Table 2.1: Reverse transcription reaction mix; components and concentrations.  




RT-PCR Reaction Buffer 10  1  
deoxynucleoside triphosphate (dNTP 
Mix) 
10mM  2mM 
MgCl2 25mM 5.5mM 
Random hexamers  50 M 2.5 M 
RNase Inhibitor  20U/ l  0.4U/ul 
MultiScribe™ Reverse Transcriptase 50U/ l 1.25U/µl 
 
 
2.3.6 RT-PCR and Agarose Gel Analysis 
Specific adenylyl cyclase (AC) primers (0.4pmol/ l each; Sequences of primers 
mentioned in table 2.2) were used to amplify individual isoforms of AC in a reaction mix 
containing AmpliTaq Gold
®
 PCR Master Mix (5mM MgCl2 and 400μM each dNTPs, 0.05 
U/μL of AmpliTaq Gold DNA polymerase) and 2µl of cDNA in 20µl final volume. PCR 
reaction was performed for 35 cycles (94, 56, and 72 C for 30, 45 and 60 sec, 
respectively) after 5 min at 95 C unless otherwise stated. After the reaction, 4 l of gel 
tracking dye (Appendix B) was added to increase the density of the PCR product. The 
bromophenol blue in the dye acts as a tracking dye to follow the progress of the 
electrophoresis. The mix was then loaded onto a 2% agarose gel that was melted in tris-
acetate/EDTA (TAE) buffer (Appendix B) with 2 l of ethidium bromide (10mg/dl). To 
check the PCR products, electrophoresis was performed at 100 volts/20cm for 30 min and 














Table 2.2: Primer sequences for all adenylyl cyclase isoforms and Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene
*
   
 
Target gene Sequence ( 5'-3')  
AC1      Forward primer 
                       Reverse primer                      
CCACGTCCTACATCCTCGTT 
AAGTGGTAGGGGCACCTTCT  
AC2               Forward primer 
                       Reverse primer 
GCTCATGTGGCTTTTGAA 
GGAAGTGCTCAGCCACGT 
AC3               Forward primer 
                       Reverse primer 
TACCCAGCTGTCTTCTGCCT 
GAGATGGCCTCCACCATG 
AC4               Forward primer 
                       Reverse primer 
ATGCACAACAGGATGCTGAAC 
GCCCCAATAACTCCAGCTAC 
AC5               Forward primer 
                       Reverse primer 
CGGGCGAGTACACTGCGG 
GGTTCTCTGGCGGTTCAT 
AC6               Forward primer 
                       Reverse primer 
TCGGGCAACACTGCAGTACCTG 
CCCGAGTCCGCTGCAGCTTG 
AC7               Forward primer 
                       Reverse primer 
CTCTCTGTGCTGATGTACGTCGAG 
TCTTGACGTAGAGGCTGTGGAAGT 
AC8               Forward primer 
                       Reverse primer 
TTAGGAACCCCTCCTCCG 
TGCTAGGGGCACAGTCAAG 
AC9               Forward primer 
                       Reverse primer 
GTGGAGCATCTATTTTGCGGTC 
CGAACACCAGCAGGGTGAG 
Soluble AC    Forward primer 
                       Reverse primer 
AAAACCTGTCACCTCCAACG 
TCTAAAGCGTTGAGCCGAAT 
GAPDH         Forward primer 
                       Reverse primer 
GAGTCAACGGATTTGGTCGTATTG 
GCTGTAGCCAAATTCGTTGTC 
                                                 
*
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2.3.7 Real-Time RT-PCR 
The synthesized cDNA was amplified using the specific primers, probes and PCR 
components that are mentioned in table 2.3. Primers and probes for 18S were also added 
in the reaction mix for control. After mixing, 20µl of the reaction mix from each samples 
including a no reverse transcriptase control and a calibrator (positive control) were added 
to Fast optical 96-well MicroAMP PCR plates (PE Applied Biosystems, Warrington, UK) 
in duplicates. The plate was sealed with nuclease free MicroAMP optical adhesion film 
(PE Applied Biosystems, Warrington, UK) and the reaction was run on ABI Prism 7900 
Quantitative PCR machine.  Data were analyzed using sequence detector version 1.6.3 and 
expression of target genes were normalized for each samples using their respective 18S 
rRNA and were expressed as fold increase above vehicle treated samples (Sequences of 
primer and probes are mentioned in table 2.4).  
 
 
Table 2.3: Real time RT-PCR reaction mix; components and concentrations 
 
Component  Stock 
concentration  
Final concentration 
or volume  
Taqman buffer (5.5mM MgCl2 and 
200 m of each dNTPs, 0.025U/µl of 
AmpliTaq
 
Gold DNA polymerase)   
2  1  
Ribosomal 18S primers (forward, 
reverse and probe)  
25 M 50nM each 
Target gene forward and reverse 
primers   
25 M 300nM each 
Target gene probe   5 M 100nM each 
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Table 2.4: Primers and probes for Real Time RT-PCR  
 
Target gene Sequence ( 5'-3')  
COX-1 Forward primer 
                 Reverse primer 




COX-2            Forward primer 
                        Reverse primer 




EP1 Receptor  Forward primer 
                        Reverse primer 




EP2 Receptor  Forward primer 
                        Reverse primer 




EP3 Receptor  Forward primer 
                        Reverse primer 




EP4 Receptor  Forward primer 
                        Reverse primer 




FP Receptor    Forward primer 
                        Reverse primer 
                        Probe (FAM) 
GCAGCTGCGCTTCTTTCAA 
CACTGTCATGAAGATTACTGAAAA AAATAC 
CAC AAC CTG CCA GAC GGA AAA CCG 
VEGF             Forward primer 
                        Reverse primer 




IL-8                 Forward primer 
                        Reverse 




IL-11               Forward primer 
                        Reverse primer 




SAT1              Forward primer 
                        Reverse primer 




AC1                Forward primer 
                        Reverse primer 




AC3                Forward primer 
                        Reverse primer 




Prolactin         Forward primer 
                        Reverse primer 




18S                 Forward primer 
                       Reverse primer 
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2.4 Statistical Analysis 
All data are presented as mean ± standard error of the mean (SEM). Statistical 
significant differences were determined by one-way analysis of variance or unpaired 
student’s t-test using Prism 5.0 software (GraphPad Software Inc., San
 
Diego, CA) (*, 
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Uterine fibroids, myometrium-derived benign tumors, are the most common 
uterine disorder occurring in as many as 30% of women over 35 years of age (Flake et al., 
2003). The etiology of uterine fibroids is unknown but several studies have shown 
estrogen and progesterone play a major role in promoting its growth (Rein, 2000; Flake et 
al., 2003).  
 
Numerous growth factors have been implicated with tumor development of 
fibroids since they are essential elements in controlling the proliferation rate of cells. 
Amongst these growth factors, the role for EGF, IGF and bFGF in uterine fibroids are well 
documented (Hoppener et al., 1988; Flake et al., 2003).  
 
The COX-prostanoid pathway has been implicated in numerous cancers including 
reproductive pathologies (Jabbour et al., 2006b). However, studies on the expression of 




3.2 Aim of the Study  
Previous molecular studies have shown role for genes that are regulated by COX 
enzymes and prostaglandins in reproductive pathology. The aims of this study were to 
compare the expression of  
(a) COX enzymes and prostaglandin receptors between fibroid and adjacent 
myometrium tissue samples.  
(b) COX enzymes, prostaglandin receptors and genes activated by prostaglandins 
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3.3 Materials and Methods 
3.3.1 Tissue Collection and RNA Extraction  
Biopsy specimens from fibroids and adjacent myometrium were collected from 
women undergoing hysterectomy for the disorder (n=14 each). Endometrial tissues were 
collected from women undergoing hysterectomy for uterine fibroids (n=8 proliferative, 
n=11 early-mid secretory and n=2 from late secretory phase). Normal endometrium 
samples from different cycle stages were collected from women undergoing hysterectomy 
for benign gynecological disorders (n=10 proliferative, n=17 from early-mid secretory and 
n=3 from late secretory phase). The cycle stage dates were confirmed by histological 
staging by a pathologist and by blood estrogen and progesterone levels. Samples were 
quickly transferred to microfuge tubes with RNAlater
®
, snap frozen on dry ice and stored 
at -70°C until processing. Total RNA was extracted from cell lysates as described in 
section 2.3.3. The concentration and purity of the RNA were determined by measuring the 
absorbance at 260nm and 280nm (OD260 and OD280) using NanoDrop
®
 ND-1000 UV-Vis 
Spectrophotometer (NanoDrop Technologies).  
 
3.3.2 cDNA Synthesis and Real-Time RT-PCR  
Real-Time RT-PCR was performed to investigate the levels of COX-1, COX-2, 
prostaglandin receptors (EP1, EP2, EP3, EP4 and FP receptors), prolactin, VEGF, IL-8 
and IL-11 mRNA expression in tissue homogenates derived from women with and 
without fibroids. cDNA was synthesized from total mRNA (400ng) by reverse 
transcription in the presence of PCR reaction buffer (1×), dNTPs (0.5mM each), MgCl2 
(5.5mM), random hexamers (2.5µM), RNase inhibitor (0.4U/µl), and MultiScribe™ 
reverse transcriptase
 
(1.25U/µl) (PE Applied Biosystems, Warrington, UK). Thereafter, 
Real-Time RT-PCR was performed using specific primers and probes (300nM and 
100nM, respectively; sequences of the primers used are mentioned in table 2.4) in a 
reaction mix containing Taqman buffer (5.5mM MgCl2 and 200 m of each dNTPs, 
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UK)), ribosomal 18S forward and reverse primers and probe (all at 50nM), and 2µl of the 
cDNA. 
3.3.3 Statistical Analysis  
All data are presented as mean ± SEM. Statistical significant differences were 
determined by unpaired student’s t-test using Prism 5.0 software (GraphPad Software Inc., 
San
 


































3.4.1 Expression of COX-1 and COX-2 in Fibroids and Adjacent Myometrium 
Tissue Samples  
The levels of COX-1 and COX-2 expressions were determined in fibroids and 
adjacent myometrium tissue homogenates obtained from women with fibroids using Real-
Time RT-PCR. As shown in figure 3.1A, level of COX-1 expression was not statistically 
different in fibroids samples (0.18 ± 0.04) compared to adjacent myometrium samples 
(0.33 ± 0.10). The level of COX-2 mRNA expression also showed no significant 
difference between the samples with the following values: Myometrium (0.39 ± 0.14) and 





























































Fig. 3.1: Relative mRNA expression of (A) COX-1 and (B) COX-2 in fibroids (n=7) and adjacent 
myometrium (n=7) tissue homogenates from women with fibroids as determined by Real-Time RT-
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3.4.2 Expression of Prostanoid Receptors and Prolactin in Fibroids and Adjacent 
Myometrium Tissue Samples  
Real-Time RT-PCR was used to assess mRNA expression levels of prostanoid 
receptors (EP1, EP2, EP3, EP4 and FP receptors) and prolactin between fibroids and 
adjacent myometrium tissue homogenates from women with fibroids. As shown in figure 
3.2A and 3.2B, the level of EP1 and EP2 receptors in myometrium were slightly different 
compared to fibroids samples however, the difference was not statistically significant 
(EP1 receptor; 0.31 ± 0.09 vs. 0.58 ± 0.29 and EP2 receptor; 9.94 ± 2.66 vs. 6.09 ± 2.6 
respectively). EP3 receptor mRNA expression was significantly lower (p<0.001) in fibroid 
tissue samples (19.45 ± 4.98) compared to the adjacent myometrium samples (51.43 ± 
7.21) (Fig 3.2C). The values of EP4 and FP receptor mRNA expression were almost 
similar in myometrium and in fibroid samples (EP4 receptor; 1.65 ± 0.39 vs. 1.66 ± 0.53 
and FP receptor; 399.0 ± 99.29 vs. 316.8 ± 103.2 respectively) (Fig 3.2D and 3.2E). 
Prolactin mRNA expression was not statistically different in fibroid tissue samples (3.06 ± 























































































































































































































Fig. 3.2: Relative mRNA expression of prostanoid receptors. (A) EP1 (B) EP2 (C) EP3 (D) EP4 
(E) FP receptors (F) prolactin in fibroids (n=14) and adjacent myometrium tissue (n=14) 
homogenates from women with fibroids as determined by Real-Time RT-PCR. Data are presented 
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3.4.3 Expression of COX-1 and COX-2 in Endometrium from Women with and 
without Fibroids  
The expression of COX-1 and COX-2 was assessed throughout the menstrual 
cycle (proliferative, early-mid secretory and late secretory phase) using cDNA samples 
from endometrium tissue of women with and without fibroids. As shown in figure 3.3A, 
COX-1 mRNA expression did not show any significant difference between endometrium 
from women with fibroid and control samples in all the menstrual cycle stages. The level 
of COX-2 mRNA expression was significantly higher (p<0.0001) in endometrium from 
women with fibroids compared to control samples in both proliferative (4.34 ± 1.09 vs. 
















































































































Fig. 3.3: Relative mRNA expression of (A) COX-1 (B) COX-2 in endometrium tissue of women 
with (n=8 proliferative, n=11 early-mid secretory and n=2 from late secretory phase) or without 
fibroids (n=10 proliferative, n=17 from early-mid secretory and n=3 from late secretory phase) 
as determined by Real-Time RT-PCR across different stages of menstrual cycle. Data are 
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3.4.4 Expression of Prostanoid Receptors in Endometrium from Women with and 
without Fibroids  
Expression of EP2, EP4 and FP receptors was assessed in endometrium tissue 
from normal and of women with fibroids using Real-Time RT-PCR. As shown in figure 
3.4A, the level of EP2 receptor showed a significant increase in endometrium tissue 
derived from women with fibroids in proliferative stage (9.79 ± 3.35 vs. 3.82 ± 0.80; 
p<0.001), while it was lower in the early-mid secretory phase compared to normal 
endometrium (8.67 ± 2.74 vs. 20.34 ± 4.41; p<0.05). FP receptor level was significantly 
higher in all the stages of the menstrual cycle in endometrium from women with fibroids 
compared to normal endometrium with the following values; proliferative (10.11 ± 3.57 
vs. 3.01 ± 0.7; p<0.0001), early-mid secretory (6.74 ± 1.59 vs. 1.91 ± 0.63; p<0.05) and 
late secretory phase (5.61 ± 3.35 vs. 0.73 ± 0.23; p<0.05) (Fig 3.4B). The level of EP4 
receptor expression was not significantly different between endometrium of women with 
















































































































































































Fig. 3.4: Relative mRNA expression of (A) EP2 (B) EP4 (C) FP receptors in endometrium tissue 
of women with (n=8 proliferative, n=11 early-mid secretory and n=2 from late secretory phase) 
or without fibroids (n=10 proliferative, n=17 from early-mid secretory and n=3 from late 
secretory phase) as determined by Real-Time RT-PCR across different stages of menstrual cycle. 
Data are presented as mean ± SEM from three independent experiments (*, p < 0.05; **, p < 
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3.4.5 Expression VEGF, IL-8 and IL-11 in Endometrium from Women with and 
without Fibroids  
Real-Time RT-PCR was used to determine the level of VEGF, IL-8 and IL-11 
mRNA expression in endometrium from women with and without fibroids. As shown in 
figure 3.5A, level of VEGF mRNA expression in early-mid secretory was shown to be 
significantly higher (p<0.001) in endometrium from women with fibroids compared to 
control samples (20.12 ± 3.84 vs. 12.31 ± 1.3) while there was no significant difference 
in the other phases. The Level of IL-8 expression was significantly higher in 
endometrium from women with fibroids in the proliferative phase (99.03 ± 26.63 vs. 3.09 
± 0.86; p<0.0001) and in early-mid secretory phase (56.58 ± 16.26 vs. 3.34 ± 0.77; 
p<0.0001) in comparison to normal endometrium samples (Fig 3.5B). Expression of IL-
11 was significantly higher in endometrium from women with fibroids in the proliferative 
stage (26.33 ± 10.84 vs. 4.48 ± 2.21; p<0.0001), while it was lower in the early-mid 
secretory phase compared to normal samples (10.56 ± 2.24 vs. 23.12 ± 5.66; p<0.0001) 
(Fig 3.5C). Both IL-8 and IL-11 mRNA expression were not altered in the late secretory 
phase.  
 













































































































































































Fig. 3.5: Relative mRNA expression of (A) VEGF (B) IL-8 (C) IL-11 in endometrium tissue of 
women with (n=8 proliferative, n=11 early-mid secretory and n=2 from late secretory phase) or 
without fibroids (n=10 proliferative, n=17 from early-mid secretory and n=3 from late secretory 
phase) as determined by Real-Time RT-PCR across different stages of menstrual cycle. Data are 
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3.5 Discussion  
Uterine fibroids are a fairly frequent occurrence in women in the reproductive age 
group. Despite being a major cause of gynecological morbidity, the etiology of uterine 
fibroid is still not yet elucidated (Marshall et al., 1997). Several studies have shown 
ovarian hormones estrogen and progesterone to play a major role in the development of 
uterine fibroids (Flake et al., 2003). Furthermore, there have been studies showing the 
effectors of uterine fibroids once they are formed. Since uterine fibroids are mostly 
characterized by changes in cell proliferation and differentiation, there has been more 
focus on studying the effect of growth factors in uterine fibroids. As mentioned in the 
introduction numerous growth factors have been implicated with the pathology of uterine 
fibroids (Hoppener et al., 1988; Flake et al., 2003; Gao et al., 2001; Mangrulkar et al., 
1995; Maruo et al., 2000).  
 
There is a compelling evidence to support a role for COX enzymes and 
prostaglandins in reproductive pathologies such as dysmenorrhea, endometriosis, 
menorrhagia, cervical cancer and endometrial adenocarcinoma (Lumsden et al., 1983; 
Karck et al., 1996; Smith et al., 1981; Sales et al., 2002; Ryu et al., 2000; Jabbour et al., 
2006b). However, there haven’t been sufficient studies to assess the effects of 
prostaglandins on the development of uterine fibroids. The objective of this study was to 
assess the expression level of COX enzymes and prostaglandin receptors in fibroids, 
autologous myometrium and endometrium samples from women with fibroids.  
 
The growth of uterine fibroid arises from the myometrium and was practical to 
first compare the expression of target genes between fibroids and adjacent myometrium 
samples. In the first part of this study, fibroids and patient-matched myometrial samples 
from 14 women with uterine fibroids were assessed for mRNA expression of COX 
enzymes (COX-1 and COX-2), prostaglandin receptors (EP1, EP2, EP3, EP4 and FP 
receptors) and prolactin. The expressions of COX-1 and COX-2 were not statistically 
different in fibroids compared to adjacent myometrium samples. Prostanoid receptors 
(EP1, EP2, EP4 and FP receptors) and prolactin also did not show any significance 














However, expression of the EP3 prostanoid receptor showed a significant 
decrease in fibroids compared to myometrium samples. Four independent gene array 
analyses have reported down-regulation of the EP3 subtype receptor in fibroids compared 
to adjacent myometrium samples (Tsibris et al., 2002; Wang et al., 2003; Quade et al., 
2003; Catherino et al., 2004). Down-regulation of the EP3 receptor has been shown to 
play a role in colorectal cancer. Shoji et al. (2004) showed that the EP3 receptor 
decreased markedly in colon cancer tissue compared to normal colon mucosa samples. 
The authors also showed azoxymethane-induced colon cancer was more enhanced in EP3 
receptor knockout mice compared to wild type mice. Cell lines studies by the group also 
revealed EP3 receptor agonist can markedly decrease the number of viable cells in the 
HCA-7 human colon cancer cell lines expressing the EP3 receptor, supporting its role in 
decreasing cell proliferation (Shoji et al., 2004). Based on these observations, down-
regulation of the EP3 receptor might not influence the early stages of uterine fibroids but 
could still play a role in development of the tumor at a later stage once the fibroid is 
formed.  
 
Despite several reports showing up-regulation of prostanoid receptors (mainly 
EP2 and FP receptors) in uterine pathology (Jabbour et al., 2001; Sales et al., 2004; Sales 
et al., 2005; Jabbour et al., 2006b), in this current study there was no significant change 
observed between fibroids and patient-matched myometrium samples. These findings led 
me to the second part the study. As mentioned in the introduction, the growth of fibroids 
can affect autologous endometrium possibly leading to a dysregulated endometrium and 
pregnancy complications. Molecular studies have shown macrophage infiltration, 
concentration of MCP-1 and PGF expression to be higher in endometrium from women 
with fibroids (submucosal and intramural) compared to control endometrium samples 
(Deligdish and Loewenthal, 1970; Miura et al., 2006).   
 
In light of these studies, I decided to look at the expression level of COX enzymes 
prostaglandin receptors, and prostanoids-mediated genes in endometrium from women 
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menstrual cycle stage and women treated with GnRH analog were excluded from the 
study. First, I assessed the expression level of COX-1 and COX-2 since both isoforms of 
COX enzymes have been shown to be involved in reproductive pathology (Sales et al., 
2002; Tong et al., 2000; Ferrandina et al., 2002; Ryu et al., 2000; Sales et al., 2001; Sales 
et al., 2002). The level of COX-1 expression was not altered between the samples but 
COX-2 mRNA expression was significantly higher in both proliferative and early-mid 
secretory phase in endometrium from women with fibroids compared to control samples. 
The level of EP2 receptor was also elevated in the proliferative stage while FP receptor 
was up-regulated in all stages of menstrual cycles in endometrium samples from women 
with fibroids. COX-2 has been shown to play a role in uterine pathologies by promoting 
angiogenesis, inhibiting apoptosis, controlling cell growth and increasing cell migration 
and cell adhesion. This is mainly facilitated by production of prostaglandins all products 
of COX-2 or COX-1 pathway (Ohno et al., 2005; Jabbour et al., 2006b). In the human 
endometrium, production of PGF and PGE2 by separated epithelial cells is higher in 
proliferative phase of menstrual cycle to regulate epithelial cell proliferation (Smith and 
Kelly, 1988; Milne and Jabbour, 2003). PGF and PGE2 can interact with EP2 and FP 
receptors to activate expression of angiogenic and mitogenic genes such as VEGF and 
IL-8 to act in a paracrine manner on neighboring myometrial/fibroid tissue.  
 
Angiogenesis is essential for actively growing tumors as the tumor needs oxygen 
and nutrients to facilitate growth. COX-2, PGE2 and PGF and their cognate receptors 
have been shown to promote expression of angiogenic factors such as VEGF (Jabbour et 
al., 2006b; Sales et al., 2004; Sales et al., 2005). VEGF is a potent angiogenic and 
mitogenic growth factor that plays a great role in the development of reproductive tumors 
by promoting angiogenesis (Leung et al., 1989). Previous studies have shown expression 
of VEGF was not altered between fibroids and matched myometrial samples, despite 
studies showing over-expression of VEGF in other reproductive pathologies (Harrison-
Woolrych et al., 1995; Guidi et al., 1996). In this current study VEGF was highly 
expressed in the early-mid secretory phase of the menstrual cycle in endometrium from 
women with fibroids compared to control samples suggesting its possible paracrine role 














IL-8, a chemoattractant chemokine, was the other gene that was assessed and it is 
involved in angiogenesis and mitogenesis. IL-8 has shown to be over-expressed in cancer 
cell lines including cancer of breast, ovary and prostate (Green et al, 1997; Ivarsson et 
al., 1998; Ferrer et al., 1998). Arici et al. (1998) have shown that IL-8 can play a role in 
the growth and proliferation of endometrium by directly stimulating endometrial stromal 
cell proliferation. Recent study also showed lysophosphatidic acid (LPA)-mediated 
expression of IL-8 can trigger multi-step process of angiogenesis including migration and 
proliferation of endothelial cells (Chen et al., 2008). Comparative studies done on uterine 
fibroids and adjacent myometrium samples showed high level of IL-8 and its receptor in 
myometrium tissue immediately surrounding fibroids. Furthermore, the authors showed 
blocking of IL-8 by neutralizing antibody can inhibit cell proliferation showing its role in 
the growth of fibroids (Senturk et al., 2001). In this study IL-8 mRNA expression was 
significantly higher in the proliferative and early-mid secretory phase in endometrium 
samples from women with fibroids compared to control samples. These data suggest that 
up-regulation of VEGF and IL-8 in endometrium collectively can have a paracrine effect 
on fibroids to promote angiogenesis and sustain tumor development.  
 
This study also showed up-regulation of IL-11 in the proliferative stage of 
endometrium from women with fibroids. IL-11 is a hematopoietic growth factor and can 
affect cell growth, differentiation and proliferation (Du and Williams, 1994). Studies 
done using IL-11 over-expressing transgenic mice showed subepithelial and adventitial 
tissue fibrosis in lung tissue compared to wild type mice. Immunohistochemistry analysis 
of tissue samples from IL-11 over-expressing mice also revealed an enhancement in 
deposition of type I and type III collagen, suggesting a role for IL-11 in the progression 
of fibrotic disorders (Zhu et al., 2001). Luo et al. (2005) showed transforming growth 
factor-β (TGF-β) treated fibroid cells expressed significantly higher IL-11 mRNA 
expression compared to normal myometrial smooth muscle cells using microarray 
analysis. Our findings show an up-regulation of COX-2 and prostanoid receptors (EP2 
and FP) in endometrium of women with fibroids. These prostaglandin receptors can in 
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as VEGF, IL-8 and IL-11 to sustain development of uterine fibroids via paracrine 
manner.  
 
Up-regulation of the EP2 and FP receptors in the proliferative phase of 
endometrium from women with fibroids was also observed in this study. For many years 
it has been known that prostanoid receptors are co-expressed in many cell types (Ashby, 
1998). For example, our laboratory has shown that EP2 and FP receptors are co-
expressed in endometrial adenocarcinoma cells (Sales et al., 2004; Sales et al., 2005). 
However, to my knowledge there have been no studies addressing the integrative 
signalling effects of the two prostanoid receptors on signal transduction and gene 
expression in endometrium. Taking these in account, I decided to investigate a possible 
cross-talk between the EP2 and FP receptors and the molecular mechanism underlying 
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The arachidonic acid cascade produces a family of bioactive lipids including 
prostaglandins, thromboxanes and leukotrienes (collectively called eicosanoids) that 
modulates different physiological and pathophysiological responses in the reproductive 
tract (Marnett, 1992). Arachidonic acid gets hydrolyzed by PLA2 and is released from sn-2 
position of the membrane. Once it is released from cellular stores, arachidonic acid gets 
oxidized by the rate limiting enzyme COX of which there are three isoforms (COX-1, 
COX-2 and COX-3) to form prostaglandin G2 (PGG2). PGG2 then gets reduced and serves 
as the substrate for terminal prostanoid synthase enzymes to produce specific 
prostaglandins (Marnett, 1992; Narumiya et al., 1999).  
 
Prostaglandins have a relatively short half-life and are believed to exert paracrine 
and autocrine effects on target cells by coupling to their specific GPCRs to activate 
intracellular signaling. PGE2 and PGF are the most abundantly biosynthesized 
prostaglandins and are major metabolites of COX enzymes in the human endometrium 
(Narumiya et al., 1999; Jabbour et al., 2006b). COX enzyme expression, prostaglandin 
synthesis and their cognate receptor expression (mainly EP2 and FP) are dysregulated in 
numerous reproductive pathologies including endometrial adenocarcinoma (Lumsden et 
al., 1983; Karck et al., 1996; Smith et al., 1981; Jabbour et al., 2006b). 
 
Researchers have studied the molecular pathway of prostaglandin receptors by 
over-expressing receptors in model cell lines. Studies done in our laboratory have shown 
elevated expression and activation of EP2 and FP receptors, which promote the expression 
of angiogenic genes via the ERK1/2 pathway in Ishikawa cells (Sales et al., 2004; Sales et 
al., 2005). In addition others have shown activation of the EP2 receptors can trigger the 
Wnt signalling pathway that involves phosphorylation of GSK-3 by Akt to activate β-
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EP2 and FP receptors are co-expressed in Ishikawa cells and use different 
intracellular signalling pathways (Sales et al., 2004; Sales et al., 2005). EP2 receptors 
couple to Gαs, resulting in increased formation of cAMP, while FP receptors couple to Gαq 
leading to the accumulation of IP3 and DAG (Watanabe et al., 1994; Jabbour et al., 2001; 
Milne and Jabbour, 2003).  
 
4.2 Aim of the Study 
The EP2 and FP receptors are often co-expressed in numerous types of cells 
including Ishikawa cells. The aim of this study was to generate a model cell line co-
expressing the EP2 and FP receptors in Ishikawa cells in order to study a possible cross-
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4.3 Materials and Methods  
4.3.1 Generation of EP2 and FP Receptors Stable Cell Lines and Selection Procedure  
To generate cells expressing the EP2 and FP receptors (FPEP2 cells), cells stably 
expressing the FP receptor (FPS32) were used as a parental cell line. FPS32 cell lines 
were generated by Sales et al. (2005), which were used for individual FP receptor 
signalling pathway studies. EP2 receptor cDNA was transfected into FPS32 cell lines as 
described in section 2.2.2. Briefly, EP2 receptor cDNA expression construct was ligated 
into the pcDNA3.1 expression vector (Invitrogen) and transfected into the FPS32 cell lines 
using SuperFect
®
 transfection reagent. Transfected cells were selected in a medium 
containing 800µg/ml of hygromycin. Fifty single hygromycin-resistant clones were picked 
and allowed to grow under the selective medium. Clones were then screened for 
expression of the EP2 receptor by Real-Time RT-PCR and by determining intracellular 
accumulation of cAMP in the presence of the EP2 receptor ligands, PGE2 and Butaprost.  
 
4.3.2 cDNA Synthesis and Real-Time RT-PCR  
Real-Time RT-PCR was performed to investigate the levels of E prostanoid 
receptors (EP1, EP2, EP3 and EP4) and FP receptor mRNA expression in parental FPS32 
cell line and selected FPEP2 clones. Total mRNA was extracted from the clones as 
described in section 2.3.2 and cDNA was synthesized from total mRNA (400ng) by 
reverse transcription in the presence of RT reaction buffer (1×), dNTPs (0.5mM each), 
MgCl2 (5.5mM), random hexamers (2.5µM), RNase inhibitor (0.4U/µl), and 
MultiScribe™ reverse transcriptase
 
(1.25U/µl). Thereafter, Real-Time RT-PCR was 
performed using specific EPs and FP receptors primers (300nM) and probes (100nM) in a 
reaction mix containing Taqman buffer (5.5mM MgCl2 and 200 m of each dNTPs, 
0.025U/µl of AmpliTaq Gold DNA polymerase), ribosomal 18S forward and reverse 
primers and probe (all at 50nM), and 2µl of the cDNA (Sequences of the primers used are 
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4.3.3 Ligand Stimulation and cAMP Assay  
In order to determine the functionality of the EP2 receptor, cAMP accumulation 
was determined in response to PGE2 and Butaprost induction. Cells (2×10
5
 cells/well) 
were seeded in 6-well plates and serum starved the following day in the presence of 
3µg/ml of indomethacin. A day later, the cells were pre-treated with 0.2mM of IBMX for 
30 min, before being treated with vehicle (0.1% ethanol), PGE2 (100nM) or Butaprost 
(5µM) for 5 and 10 min in serum free medium. cAMP accumulation was determined by 
ELISA using cAMP Kit (R&D Systems) according to method mentioned in section 2.2.3. 
The concentration of cAMP was calculated using a standard curve by Assay Zap computer 
programe (Biosoft, Cambridge, UK) and was normalized according to the respective 
protein concentration of each sample. Data are presented as mean ± SEM. 
 
4.3.4 Ligand Stimulation and Total IP3 Assay  
PGF induced accumulation of IP3 in FPS32 and FPEP2 cells was determined by 
plating 50,000 cells in 24-well plate containing 1ml/well of complete medium. The 
following day, cells were labeled with 0.5µCi/well myo-[3H]-inositol in an inositol-free 
DMEM 199 medium (2% FCS) overnight. A day later cells were washed and stimulated 




M) in Buffer I (Appendix B) for 1 hr at 37 C. 
After aspirating the buffer, cells were lysed by the addition of 1 ml ice cold 10mM formic 
acid and by placing the plates on ice for 30 min. Total [3H]-inositol phosphates was then 
separated and analyzed by the method described in section 2.2.4. Data were expressed as 
fold increase above non-stimulated samples and presented as mean ± SEM.  
 
4.3.5 SDS-PAGE and Western Blot Analysis  
To assess protein expression level of FP and EP2 receptors, total protein was 
extracted from FPS32 and FPEP2 and quantified as mentioned in section 2.2.7 and 2.2.8, 
respectively. A total of 40μg of protein was resuspended in 1× Laemmli buffer (Appendix 
B) and boiled for 5 min at 95°C. Samples and SeeBlue
®
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(Novex, Invitrogen) were then fractionated by electrophoresis (50mA, 2 hrs) on a pre-cast 
4% to 12% Bis-Tris gels (NOVEX, Invitrogen). The gel was then transferred onto 
Immobilon™-FL PVDF membrane (Millipore, Watford, UK) in a transfer buffer 
(Appendix B) at constant voltage of 14V using semi-dry blotter for 90 min. After 
incubating the membrane in 10ml of Odyssey blocking buffer for 1 hr the membrane was 
either incubated with the rabbit primary antibody raised against the EP2 or the FP receptor 
in combination with goat anti-actin primary antibody (all in 1:1000) at 4°C overnight with 
gentle shaking. The membrane was then washed four times in 10 ml of PBS-Tween and 
was incubated with two fluorescent secondary antibodies, donkey anti-rabbit IgG 
conjugated to Alexa Fluor
 
680 (Invitrogen) and donkey anti-goat IgG conjugated to 
IRDYE 800 (Tebu-bio,
 
Peterborough, UK) for 1 hr in the dark at room temperature. After 
washing the membrane three times with PBS-Tween, proteins were then viewed using 
Odyssey Infrared imaging system (LI-COR biosciences, Cambridge, UK).     
 
4.3.6 Immunofluorescence Microscopy of Ishikawa Cells    
To localize the expression of the EP2 and FP receptors, FPEP2 and FPS32 
Ishikawa cells (1×10
5
 cells/well) were plated out in 2-well chamber slides, fixed with 4%
 
PFA for 20 min and blocked in 5% BSA diluted in normal goat serum for 2 hrs. 
Thereafter, the cells were incubated with rabbit anti-EP2 or FP receptor antibody diluted 
in normal goat serum containing 5% BSA (1:100) overnight at 4 C and washed three 
times in PBS for 10 min, before being incubated with Alexa flour conjugated secondary 
goat anti-rabbit antibody (Molecular probes) for 2 hrs. After three 10 min PBS washes, the 
nuclear was stained using DAPI (1:1000 in PBS; Sigma) for 10 min. Thereafter, slides 
were washed and mounted in Permafluor for microscope analysis. Control cells were 
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4.3.7 Statistical Analysis   
All data are presented as mean ± SEM. Statistical significant differences were 
determined by one-way analysis of variance using Prism 5.0 software (GraphPad Software 
Inc., San
 














4.4.1 Analysis of EP2 and FP Receptors mRNA Expression of the Ishikawa Stably 
Transfected Clones 
FPS32 cells were transfected with the EP2 receptor cDNA and grown under 
selective media containing hygromycin parallel to untransfected cells as controls. After 
control cells have died, 50-hygromycin resistant clones were picked and allowed to grow 
in a selective media. Real-Time RT-PCR was performed on three selected clones (FPEP2 
clone 4, 8 and 10) to check the level of EP2 receptor expression in comparison with the 
parental FPS32 cells. As shown in figure 4.1A, FPEP2 clone 4 and 8 showed higher levels 
of EP2 receptor mRNA expression with a significant fold increase (78.30 ± 5.99 and 83.93 
± 6.70 vs. 1, respectively; p<0.0001), while clone 10 had about 26 fold increase (26.43 ± 
6.98 vs. 1; p<0.05) above the parental FPS32 cells. The expression of EP1, EP3, EP4 and 



































































































































Fig. 4.1: Relative expression of E and F prostanoid receptors in FPS32, FPEP2 clone 4, 8 and 10. 
A. Expression of the EP2 receptor and B. Expression of EP1, EP3, EP4 and FP receptors as 
determined by Real-Time RT-PCR analysis. Expression levels in FPEP2 clones are expressed as 
fold increase above FPS32 cells. Data are presented as mean ± SEM from four independent 
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4.4.2 Production of cAMP by the FPS32 and FPEP2 Clones 
Activation of the EP2 receptor by PGE2 or Butaprost leads to intracellular 
accumulation of cAMP (Jabbour et al., 2001; Regan, 2003). FPEP2 Clone 4 and 8 were 
chosen for cAMP assay as they both express relatively higher EP2 receptor than clone 10. 
In order to assess the functionality of the EP2 receptor in FPEP2 clone 4 and 8, the ability 
to generate cAMP was determined by treating the cells with vehicle (0.1% ethanol) or 
Butaprost (5μM) or PGE2 (100nM) for 5 and 10 min. As shown in figure 4.2, treatment of 
FPEP2 clone 4 cells with Butaprost or PGE2 for 5 min increased intracellular cAMP 
accumulation significantly compared to vehicle treated (348 ± 52.1 and 3539.5 ± 475.2 vs. 
10.7 ± 1.8 pmol cAMP/mg protein, respectively) while clone 8 had a much higher cAMP 
release (1658 ± 326.2 and 5424.2 ± 619.9 vs. 4.6 ± 1.4 pmol cAMP/mg protein, 
respectively). The relative accumulation of cAMP in response to 10 min Butaprost or 
PGE2 induction was 1798.5 ± 392.5; 5468.2 ± 968.8; 3604.2 ± 278.9 and 7956.6 ±1 482.9 
pmol cAMP/mg protein for clone 4 and 8 respectively. PGE2 stimulation of the FPEP2 
cells exhibited a higher cAMP release compared to Butaprost-treated cells. Butaprost 
induction (10min) of the FPS32 cells had no effect while PGE2 stimulation (10min) 
showed a slight increase in intracellular cAMP accumulation compared to treated vehicle 
(9.7 ± 1.8 and 19.8 ± 2.7 vs. 9.6 ± 1.8 pmol cAMP/mg protein, respectively). Since the 
FPEP2 clone 8 directed a higher accumulation of intracellular cAMP in response to EP2 



































































Fig. 4.2: The effect of 5 and 10 min treatment with vehicle, Butaprost (5μM) or PGE2 (100nM) on 
cAMP release in FPS32, FPEP2 clone 4 and 8 cell lines as determined by cAMP ELISA analysis. 
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4.4.3 Production of IP3 by the FPS32 and FPEP2 Clones  
The FP receptor is a Gαq-coupled receptor, which upon PGF activation leads to an 
accumulation of intracellular IP3 (Watanabe et al., 1994). In order to compare the 
functionality of the FP receptors in the parental FPS32 and FPEP2 cell lines, the cells 




M) while control 
samples were left untreated for 1 hr. Both the parental FPS32 and FPEP2 cell line resulted 
in an increase in IP3 release reaching an Emax of 15.7 ± 0.6 and 16.6 ± 2.1, while the EC50 
values for the FPS32 and FPEP2 were 2.3nM ± 0.3 and 1.95nM ± 0.8, respectively. There 
was no significance difference in IP3 release between the parental and FPEP2 cell lines 































M) on IP3 response in FPS32 and FPEP2 
clone 8 cells as determined by an IP assay. Data are expressed as fold increase above non-
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4.4.4 Protein Expression of the FP and EP2 Receptors in FPS32 and FPEP2 Cells   
Western blot analysis was done on the FPS32 and FPEP2 cells to compare the 
expression level of EP2 and FP receptor proteins and to validate the Real-Time RT-PCR 
data shown in figure 4.1. Protein samples (40µg) from both cell lines were subjected to 
Western blot analysis using specific EP2 and FP receptor antibodies. Protein expression 
was normalized using β-actin as a loading control on the same blots.  As shown in figure 
4.4A, the level of FP receptor expression was not different between the parental FPS32 
and FPEP2 cell lines, while figure 4.4B shows the level of EP2 receptor to be higher (4.5 
fold) in the FPEP2 cells relative to the parental clone FPS32, validating the Real-Time 




                              
 
Fig. 4.4: Representative Western blot analysis in FPS32 and FPEP2 protein samples (40µg).  
A. Protein expression of FP receptor B. Protein expression of EP2 receptor as determined by 
Western blot analysis. EP2 and FP receptor protein expression levels were normalized for loading 
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4.4.5 Localization of the FP and EP2 Receptors in FPS32 and FPEP2 Cells   
EP2 and FP receptor expression was visualized in the FPS32 and FPEP2 cells 
using Immunofluorescence microscopy. This was done to investigate if the receptors are 
expressed on the plasma membrane compartment after synthesis. A specific blocking 
peptide to which the antibody was raised against was used as a negative control. As shown 
in figure 4.5 Panel A, FPEP2 cells showed the same level of immunoreactivity to the FP 
receptor antibody in comparison to the FPS32 cells and revealed a strong and clear plasma 
membrane and perinuclear labeling. No EP2 receptor staining is seen in FPS32 cells but 
the FPEP2 cells showed a marked expression with the same distribution pattern shown for 
the FP receptor. Both EP2 and FP receptor signals were almost abolished when the 
antibody for the receptors was preadsorbed with a specific blocking peptide as shown in 
figure 4.5.  
 
 
        
 
      
 
Fig. 4.5: Localization of the FP and EP2 receptor in FPS32 and FPEP2 cells.  
A. localization of the FP receptor B. Localization of the EP2 receptor as determined by 
immunofluorescence microscopy. Control cells (C) were incubated with preadsorbed primary 


















It has been known that prostanoid receptors are co-expressed in many cell types 
and tissues (Ashby, 1998). This observation suggests that co-activation of prostanoid 
receptors in the same cell could alter the signalling cascades which are normally activated 
by each receptors. The altered signalling cascades in turn could change the gene 
expression profile and the physiology of these cells that might be an outcome of receptor 
heterologous interaction or cross-talk.  
 
GPCR cross-talk in the eicosanoid family has been shown in several studies by 
stably expressing the receptors in HEK-293 cell lines. Studies using TPα expressing HEK-
293 cells showed an IP receptor agonist-dependent desensitization of the TPα receptor 
(Walsh et al., 2000). The same isoform of TP receptor has also been shown to be inhibited 
by activation of PGD2 receptor via the PKA pathway in HEK-293 cells (Foley et al., 
2001). Walsh and Kinsella (2000) showed TPα and TPβ receptors are subjected to 17 
phenyl trinor PGE2 (EP1 receptor agonist) mediated desensitization. The authors further 
indentified that the activation of the FP receptor by PGF can also mediate desensitization 
of the TPα and TPβ receptors in HEK-293 cells (Kelley-Hickie and Kinsella, 2004). In 
another study, Wilson et al. (2004) showed that co-expression of IP and TP receptors in 
HEK-293 cells can augment TP-receptor mediated cAMP without activation of the IP 
receptor. The cAMP augmentation was further potentiated when both receptors were co-
activated by their respective ligands. 
 
EP2 and FP receptors are co-expressed in Ishikawa cells (Sales et al., 2004; Sales 
et al., 2005). However, there have been no studies addressing the integrative signalling 
effects of the EP2 and FP receptors. In order to investigate this, EP2 receptor was stably 
transfected into Ishikawa cells expressing the FP receptor stably (FPS32 cells). Out of 50-
hygromycin-resistant clones, three clones (FPEP2 clone 4, 8 and 10) were selected for 
further expression analysis. Expression level of the EP2 receptor in FPEP2 clones was 
compared to the parental FPS32 cells using Real-Time RT-PCR. I found that all the 
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FPS32 cells with clone 10 giving a lower fold increase. Introduction of the EP2 receptor 
had no effect on the expression profile of the other E-series receptors and of FP receptor 
which could be activated by prostanoid ligands in our study.  
 
The EP2 receptor is a Gαs-coupled receptor, which upon PGE2 or Butaprost 
activation leads to an accumulation of intracellular accumulation of cAMP (Jabbour et al., 
2001; Regan, 2003). Due to their higher mRNA expression of the EP2 receptor, FPEP2 
clone 4 and 8 were chosen for functional studies. This was done by assessing the 
accumulation of intracellular cAMP after activation of the EP2 receptor by either PGE2 or 
Butaprost. Both clones gave a significant increase in cAMP accumulation compared to the 
parental cell line FPS32. However, FPEP2 clone 8 showed a robust increase in cAMP 
accumulation that was significantly higher than the FPEP2 clone 4 and was chosen for 
subsequent studies. PGE2 induction of the cells exhibited more intracellular cAMP 
accumulation than Butaprost. Studies have shown the inhibitory constant (Ki) values of 
EP2 receptor and its agonists (PGE2 and Butaprost) to be 10nM and 110nM, respectively 
in CHO cells. This shows PGE2 has about 10 fold increased affinity to bind to the EP2 
receptor than Butaprost, explaining the higher release in cAMP exhibited by PGE2 
activation of the FPEP2 clones (Kiriyama et al., 1997).  
 
Activation of cells by PGF leads to FP receptor-Gαq coupling to trigger IP3 
production (Watanabe et al., 1994). To confirm the similar level of FP receptor mRNA 
expression between FPS32 and FPEP2 clone 8 cells functionally, cells were treated with 
PGF and assessed for IP3 accumulation. There was no significance difference in the Emax 
and EC50 values between PGF treated FPS32 and FPEP2 clone 8 cells, suggesting the 
levels of FP receptor were similar between the two cell lines.  
 
Protein expression level of the EP2 receptor in FPEP2 clone 8 cells was compared 
to the parental FPS32 cells using Western blot analysis. EP2 receptor protein expression 
was higher in FPEP2 cells while FP receptor protein levels were not altered compared to 
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receptor is stably expressed in the FPEP2 clone 8 cells without altering the expression of 
the FP receptor. Both EP2 and FP receptors were localized in the perinuclear and 
cytoplasmic membrane regions, a lower expression observed in cytoplasmic regions. 
Prostaglandin receptors have a short half-life and rapidly cycle between the cell surface 
and the intracellular pool explaining the small fraction of the receptors in the plasma 
membrane (Naor et al., 2007).    
 
In conclusion, FPEP2 clone 8 stably over-expresses the EP2 and FP receptors and 
they are both localized in the perinuclear and cytoplasmic membrane compartments. 
Furthermore, the functionality of EP2 and FP receptors was also confirmed by the release 
of their respective secondary messengers, cAMP and IP3 in the presence of their 
respective ligands. Subsequent studies investigated the intricate signalling system between 
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5.1 Introduction  
Activation of the EP2 receptor by Butaprost leads to intracellular accumulation of 
cAMP (Jabbour et al., 2001; Regan, 2003). cAMP is a prototypical secondary messenger 
that impacts in every aspect of a cellular life, from differentiation and development 
through to cell death. It is generated in cells by the enzymatic activity of the adenylyl 
cyclase (AC) family which catalyses the synthesis of cAMP from ATP. The AC enzyme is 
made of 12 transmembrane spanning domains, extensive amino and carboxyl termini and 
contains two catalytic ATP-binding domains that are found in the cytoplasmic region of 
the enzyme (Krupinski et al., 1989; Willoughby and Cooper, 2007).  
 
There are nine membrane-bound AC isoforms with different amino acid sequence, 
tissue distribution and regulation and are named from AC1-AC9 in the order of their 
identification (Hanoune et al., 1997). All the isoforms of ACs can be stimulated by Gαs 
and forskolin. However, ACs can be subclassified in terms of their responsiveness or not 
to other regulatory factors. Group 1 comprises enzymes that are stimulated by 
physiological concentration of calcium or calmodulin (AC1, AC3 and AC8) while group 2 
contains AC enzymes (AC2, AC4 and AC7) that are activated by PKC and βγ subunit. 
Group 3 are enzymes inhibited by low concentration of calcium and Group 4 (AC9) is 
insensitive to both calcium and βγ subunit (Hanoune et al., 1997, Willoughby and Cooper, 
2007).  
 
PGF-stimulated FP receptor-Gαq coupling leads to activation of PLC that can 
either lead to PKC activation by the release of DAG or trigger the production of IP3, 
which then acts on specific IP3 receptors (IP3R) found at the ER promoting the release of 
intracellular calcium into the cell cytosol (Watanabe et al., 1994). The concentration of 
intracellular calcium in cytoplasm is maintained regularly by different factors. One of 
these regulatory factors is an activation of a calcium buffering protein called calmodulin. 
Activated calmodulin can in turn act on other calcium effectors like CaMK-II to activate 
calcium-sensitive isoforms of AC to alter cAMP production in cells (Persechini and 
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5.2 Aim of the Study  
As described in the previous chapter, I developed an Ishikawa cell line over-
expressing the EP2 and FP receptors (FPEP2 cell line). The aim of this study is to identify 
a possible intracellular signalling cross-talk following co-activation of both receptors and 
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5.3 Materials and Methods 
5.3.1 Ligand Stimulation and cAMP Assay 
In order to determine ligand-stimulated cAMP accumulation, FPEP2 cells (2×10
5
 
cells/well) were plated out in 6-well dishes. The cells were serum starved the following 
day in the presence of 3µg/ml of Indomethacin. A day later, the cells were pre-treated in 
serum free medium containing 0.2mM of IBMX and incubated for 5 min with vehicle 
(0.1% ethanol and/or 0.1% DMSO), Butaprost (5µM) and/or PGF (100nM) in the 
presence/absence of different chemical inhibitors. cAMP release was determined by 
ELISA using cAMP Kit (R&D Systems) according to method mentioned in section 2.2.3. 
The concentration of cAMP released was calculated using a standard curve by Assay Zap 
computer programe (Biosoft) and was normalized according to the protein concentration 
of each sample.  
 
5.3.2 Ligand Stimulation and IP3 assay 
In order to assess ligand-stimulated IP3 release, FPEP2 cells (50,000 cells/well) 
were seeded in 24-well plates overnight. After serum starving the cells overnight, the cells 
were labeled with 0.5µCi/well myo-[3H]-inositol in an inositol-free DMEM 199 medium 









M) and Butaprost (5μM) together in Buffer I for 
60 min at 37 C. Total [3H]-inositol phosphates were separated from cell extracts on AG 
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5.3.3 Knockdown of AC1 and AC3 in FPEP2 Cells with siRNA Transfection 
Three different Stealth siRNA duplex oligoribonucleotides were used to abolish 
the expression and function
 
of AC1 and AC3. FPEP2 Ishikawa cells were seeded in 
complete media at a density of 7.5×10
4 
cells/well in 12-well plates to achieve 60-80% 
confluence on the day of transfection. The next day the cells were transfected with 60nM 
of AC isoform specific siRNA (20nM from each Stealth siRNA) or scrambled sequence 
siRNA in the presence of
 
SuperFect (QIAGEN). After 48 hrs, the cells were subjected to 
RNA extraction for AC1 and AC3 mRNA expression analysis or serum-starved overnight 
in medium
 
containing indomethacin (3µg/ml) for cAMP assay. For cAMP assay, cells 
were then exposed to vehicle (0.1% ethanol), Butaprost (5µM) and/or PGF (100nM) for 5 
min and lysed with lysis buffer and subjected to cAMP analysis
 




Total mRNA was extracted from Ishikawa cells as described in section 2.3.2. The 
cDNA template for RT-PCR was synthesized from total mRNA (1μg) by reverse 
transcription in the presence of RT-PCR reaction buffer (1×), dNTPs (0.5mM each), 
MgCl2 (5.5mM), random hexamers (1.25µM), oligo dT (1.25µM), RNase inhibitor 
(0.4U/µl), and MultiScribe™ reverse transcriptase
 
(1.25U/µl). Thereafter, for PCR 
amplification specific AC primers (0.4pmol/ l each; Sequences of the primers are 
mentioned in table 2.2) were used to amplify individual isoforms of AC in a reaction mix 
containing AmpliTaq Gold
®
 PCR Master Mix (5mM MgCl2 and 400μM each dNTPs, 0.05 
U/μL of AmpliTaq Gold DNA polymerase) and 2µl of cDNA in 20µl final volume. 
Isoforms of AC proved to be difficult to amplify under normal PCR conditions. The 















 DNA Polymerase: This Applied biosystems product has been 
developed for “hot-start” PCR reaction, which provides greater specificity of amplification 
in general and is particularly suited to amplification of difficult templates, such as GC rich 
regions. This enzyme is inactive and has no polymerase activity at ambient temperatures 
and is activated by a 5 min, 95 C incubation step, which can easily be incorporated into 
existing thermal cycling programs. This enzyme was used for the amplification of all the 
AC isoforms (AmpliTaq Gold
®
 PCR handbook).  
 
II. Touchdown PCR: This involves decreasing the annealing temperature (0.5 C 
every second cycle in this case) to a „touchdown‟ annealing temperature, which is then 
used for the remaining cycles. This allows for higher specificity of amplification during 
the initial cycles and preferential amplification of the early templates at the lower 
annealing temperature. Touchdown PCR was performed for AC1 and the soluble AC 
isoforms as shown in table 5.1. For the other AC isoforms, PCR reaction was performed 





Table 5.1: Touchdown PCR reaction conditions for AC1 and Soluble AC 
 
Cycles Denaturation Temp 
( C) /time  
Annealing Temp 
( C)/time  
Extension Temp  
( C)/ time  
First hold  95/5 min - - 
First 10 cycles  95/30 sec 60-55/ 1 min (decreases 0.5 
C per cycle)  
72/ 45 sec  
Second 25 cycles 92/30 sec 55/1 min 72/45 sec 
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5.3.5 Real-Time RT-PCR 
Total mRNA was extracted and cDNA was synthesized from FPEP2 cells after 48 
hrs of siRNA transfection. To assay knockdown efficiency, Real-Time RT-PCR was 
performed with specific AC primers and probes (300nM and 100nM respectively) in a 
reaction mix containing Taqman buffer (5.5mM MgCl2 and 200 m of each dNTPs, 
0.025U/µl of AmpliTaq Gold DNA polymerase), ribosomal 18S forward and reverse 
primers and probe (all at 50nM), and 2µl of the cDNA (Sequences of the primers are 
mentioned in table 2.4). The reaction was run on ABI Prism 7900 Quantitative PCR 
machine.  Data were analyzed using sequence detector version 1.6.3 and expression of AC 
isoforms were normalized for each treatment using their respective 18S rRNA and were 
expressed as fold decrease below control siRNA treated samples.  
 
5.3.6 Statistical Analysis   
All data are presented as mean ± SEM. Statistical significant differences were 
determined by one-way analysis of variance using Prism 5.0 software (GraphPad Software 
Inc., San
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5.4 Results  
5.4.1 Butaprost Does not Affect PGF-Stimulated IP3 Release in FPEP2 Cells 
To study the cross-effects of the two different intracellular signalling pathways 
involved in EP2 and FP receptors activation, FPEP2 cells were treated with Butaprost 
and/or PGF. First, the effect of Butaprost on PGF-mediated IP3 release was assessed by 



















M) had a significant increase in IP3 release (Emax 15.5 ± 0.6). Co-treatment of 




M) and Butaprost (5μM) resulted in an Emax of 16.6 ± 
2.2 which is similar to the Emax achieved with treating the cells with PGF alone (Emax 15.5 
± 0.6). The EC50 value for the co-stimulation with PGF and Butaprost was slightly smaller 
compared to PGF treated, but was not statistically significant (EC50 0.7nM ± 0.5 and 
1.95nM ± 1.04, respectively). These data demonstrate that PGF-mediated IP3 release is 


























-10 -9 -8 -7
Butaprost (10-10 to 10-6M)
PGF (10-10 to 10-6M)
Butaprost (5 M)  +
PGF (10-10 to 10-6M)






















M) and Butaprost (5μM) together for 60 min as determined by an IP3 assay. 
Data are expressed as fold increase above non-stimulated samples (NS). Data are presented as 
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5.4.2 PGF Potentiates Butaprost-Stimulated cAMP Production in FPEP2 Cells 
To assess the effect of FP receptor induction by PGF on Butaprost-stimulated 
cAMP accumulation, FPEP2 cells were treated with vehicle, Butaprost (5µM) and/or PGF 
(100nM) for 5 min. As shown in figure 5.2, treatment of the cells with Butaprost resulted 
in a robust increase in intracellular cAMP accumulation compared with vehicle treated 
(2172 ± 314 vs. 18.6 ± 1.98 pmol cAMP/mg protein; p<0.001), while treatment with PGF 
alone had minimal effect (73.5 ± 4.7 pmol cAMP/mg protein). However, co-treatment of 
the cells with Butaprost and PGF significantly increased (~2 fold) the cAMP response 
compared to treatment with Butaprost alone (4141 ± 511 vs. 2172 ± 314 pmol cAMP/mg 
protein; p<0.001; Fig 5.2). These results demonstrate that co-activation of the EP2 and FP 

























































Fig. 5.2: cAMP accumulation (pmol/mg protein) in FPEP2 cells after treatment with vehicle, 
Butaprost (5μM) and/or PGF (100nM) for 5 min. Data are presented as mean ± SEM from four 
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5.4.3 PGF-Induced cAMP Potentiation is Mediated by FP Receptor-Gαq Coupling in 
FPEP2 Cells  
To investigate whether the augmentation of cAMP release by PGF is mediated by 
either EP2 or FP receptor, the cells were co-treated with specific antagonist for EP2 
receptor (10µM of AH6809 with 3min pretreatment) or FP receptor (50µM of AL8810 
with 3min pretreatment). As shown in figure 5.3, antagonism of the EP2 receptor 
significantly decreased (p<0.001) the Butaprost-induced cAMP in both groups of 
treatment (Butaprost only and Butaprost and PGF) but had no effect on the enhancement 
of cAMP accumulation by PGF (727.1 ± 66.4 and 1397 ± 105.9 pmol cAMP/mg protein, 
respectively). Whereas, the use of FP receptor antagonist completely abolished the 
potentiation of cAMP by PGF without altering Butaprost-stimulated cAMP (4141 ± 510.6 
vs. 2305 ± 116 pmol cAMP/mg protein; p<0.001). To assess if the PGF potentiation of 
Butaprost-stimulated cAMP is mediated by FP receptor-Gαq coupling, FPEP2 cells were 
co-treated with Gαq inhibitor (1µM of YM254890 with 30 min pretreatment). As shown in 
figure 5.3, the use of Gαq inhibitor reduced the level of cAMP release significantly to the 
Butaprost stimulated level (4141 ± 510.6 vs. 1588 ± 137 pmol cAMP/mg protein 
respectively; p<0.001). These data indicate that, PGF potentiation of Butaprost-stimulated 







































































Fig. 5.3: cAMP accumulation (pmol/mg protein) in FPEP2 cells after 5 min treatment with 
Butaprost (5μM) and/or PGF (100nM) in the presence/absence of the EP2 receptor antagonist 
(AH6809; 10μm), FP receptor antagonist (AL8810; 50μm) or Gαq inhibitor (YM-254890; 1μm). 
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5.4.4 The Gαq-Gαs Cross-Talk is Dependent of PLC-Mediated Calcium Release but 
not on PKC Activation  
PGF activated FP receptor-Gαq coupling leads to activation of PLC that results in 
both IP3 release that increases accumulation of intracellular calcium and DAG release that 
activates PKC (Watanabe et al., 1994). Inhibition of PLC using U73122 (10µM with 30 
min pretreatment) abolished the augmentation of cAMP directed by PGF significantly 
(4141 ± 510.6 vs. 2261 ± 236 pmol cAMP/mg protein; p<0.001) demonstrating that the 
Gαs-Gαq cross-talk is mediated by PLC activation. However, in order to determine 
whether intracellular calcium or PKC activation mediate the observed cross-talk, the cells 
were incubated with specific IP3-Receptor blocker (40μm of 2-APB with 15 min 
pretreatment) or PKC inhibitor (1μm of Ro-31-822 with 30 min of pretreatment) in the 
absence/presence of Butaprost (5µM) and/or PGF (100nM). Co-treatment of the cells with 
2-APB inhibited the PGF-mediated potentiation in cAMP release in response to Butaprost 
but had no effect on Butaprost treatment alone (4141 ± 510.6 vs. 2252 ± 327 pmol 
cAMP/mg protein; p<0.001). Whereas inhibition of PKC failed to attenuate the 
potentiation of Butaprost-stimulated cAMP release by PGF (4141 ± 510.6 vs. 3655 ± 416 
pmol cAMP/mg protein) demonstrating that PGF-mediated increase in Butaprost-
stimulated cAMP is via the accumulation of intracellular calcium and not through 



































































Fig. 5.4: cAMP accumulation (pmol/mg protein) in FPEP2 cells after 5 min treatment with 
Butaprost (5μM) and/or PGF (100nM) in the presence/absence of the PLC inhibitor (10µM 
U73122), IP3-R blocker (40μm 2-APB) or PKC inhibitor (1μm Ro-31-822). Data are presented as 
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5.4.5 PGF-Induced cAMP Potentiation is Mediated by Intracellular Ca
2+
 Transients  
Intracellular calcium can modulate calcium sensitive isoforms of AC to enhance 
cAMP via activation of calmodulin-CaMK-II pathway (Wang and Storm, 2003; Hanoune 
and Defer, 2001). To determine whether the PGF-mediated enhancement of Butaprost-
stimulated cAMP is mediated by the calcium-calmodulin pathway, chemical inhibitors 
against two calcium effectors were used. Inhibition of calcium signalling, using 
calmodulin antagonist (25μm W7) or CaMK-II inhibitor (50μm KN-93) in the presence of 
Butaprost and PGF reduced the level of cAMP release significantly to the Butaprost-
stimulated level (2656 ± 181.7 and 2611 ± 179.9 vs. 4130 ± 187.9 pmol cAMP/mg 
protein, respectively; p<0.001) (Fig 5.5). These results indicate that PGF potentiation of 
Butaprost-stimulated cAMP is mediated by the release of Ca
2+
 from intracellular stores 
leading to activation of the calmodulin-CaMK-II pathway.  
 







































Fig. 5.5: cAMP accumulation (pmol/mg protein) in FPEP2 cells after 5 min treatment with 
Butaprost (5μM) and/or PGF (100nM) in the presence/absence of the inhibitors for calmodulin 
(25μm of W7) or CaMK-II (50μm of KN-93). Data are presented as mean ± SEM from four 
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5.4.6 Adenylyl Cyclase Isoforms Expression in FPEP2 Ishikawa cells 
There are ten isoforms of AC, of which three of them are calcium stimulated 
(Willoughby and Cooper, 2007). Since I have shown intracellular calcium has a role in the 
Gαs-Gαq cross-talk system mentioned above, I decided to check the expression of multiple 
AC isoforms in Ishikawa cells. To investigate which isoforms are present in FPEP2 cells, 
total RNA was extracted from Ishikawa cells and RT-PCR was performed using AC 
isoform-specific primers (sequences of the primers used are mentioned in table 2.4). As 
shown in the representative agarose gel in figure 5.6, Ishikawa cells express mRNA for 
AC1, AC3, AC4, AC5, AC6, AC7, AC9 and the soluble AC (SAC). However, AC2 and 
AC8 primers did not yield a PCR product at the expected size indicating they are not 
expressed. Therefore, out of the three calcium regulated isoforms (AC1, AC3 and AC8), 
Ishikawa cells express two of them (AC1 and AC3) and either both or one of them may be 
mediating the cAMP potentiation mentioned above.  
 
1Kb






Fig. 5.6: RT-PCR analysis of AC isoforms mRNA expression in FPEP2 Ishikawa cells. 
Ishikawa cells express mRNA for eight of the ten AC isoforms including the soluble form of AC 
(SAC) among those two of them are calcium stimulated ones (AC1 & AC3) as determined by RT-
PCR and agarose gel (2%) analysis. Arrows indicate the size of the expected PCR product from 
each primer pair and no reverse transcriptase control is designated as B (blank).  PCR product 
size: AC1= 826bp, AC2= 625bp, AC3= 213bp, AC4= 166bp, AC5= 316bp, AC6= 170bp, AC7= 
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5.4.7 siRNA Knockdown of AC1 and AC3 Transcripts in FPEP2 Ishikawa Cells 
Since AC1 and AC3 are the only calcium regulated isoforms that are expressed in 
Ishikawa cells, siRNA designed to these specific isoforms were used to knockdown 
endogenous mRNA expression. After 48 hrs of specific siRNA transfection, Real-Time 
RT-PCR showed that AC1 and AC3 mRNA were reduced by 76% and 70%, respectively 
compared with scrambled sequence siRNA. The specificity of the siRNA was also proven 
as both AC1 and AC3 siRNA inhibited only the expression of their cognate targets 
without altering the other (Fig 5.7).  
 
 




























Fig. 5.7: Real-Time RT-PCR analysis of AC1 and AC3 in FPEP2 cells transfected with isoform 
specific AC siRNA (60nM) compared to the control siRNA (scrambled sequence). Data are 
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5.4.8 siRNA Knockdown of AC3 Abolishes PGF-Potentiation of Butaprost-
Stimulated cAMP in FPEP2 Cells 
To determine which calcium sensitive AC isoform is involved in Gαs-Gαq cross-
talk mentioned above, AC1 and AC3 siRNA transfected cells were exposed to either 
vehicle, Butaprost (5µM) and/or PGF (100nM) for 5min. 
 
Thereafter, cells were lysed and 
subjected to cAMP analysis
 
as described in section 2.2.3 to assess the functional effect of 
the knockdown. As shown in figure 5.8, transfection of FPEP2 cells with AC3 siRNA 
completely abolished the potentiation of Butaprost-stimulated cAMP by PGF (3718 ± 
114.0 vs. 1882 ± 83.66 pmol cAMP/mg protein; p<0.001) while AC1 siRNA transfection 
had no effect on cAMP accumulation compared to Butaprost and PGF treatment (3718 ± 
114.0 vs. 3724 ± 187.0 pmol cAMP/mg protein). Both AC1 and AC3 siRNA did not have 
any significant effect on Butaprost-stimulated cAMP. This result suggests that PGF 
potentiates Butaprost-stimulated cAMP through Ca
2+
-calmodulin pathway by activating 
the calcium sensitive AC3 isoform in FPEP2 cells.  
 





































Fig. 5.8: cAMP accumulation (pmol/mg protein) in AC1 or AC3 knockdown FPEP2 cells after 5 
min treatment with vehicle, Butaprost (5μM) and/or PGF (100nM) as determined by cAMP 
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5.5 Discussion  
Regulation of intracellular calcium plays a major role in heterologous-interaction 
between Gαs- and Gαq–coupled receptors. The intracellular calcium pathway can activate 
calcium-stimulated AC isoforms to augment cAMP production or PKA can regulate either 
the IP3 receptors or the intracellular calcium pump to potentiate production of intracellular 
calcium in cells (Wang and Storm, 2003; Hajonoczky et al., 1993).  
 
For example, Ostrom et al. (2003) showed a potentiation of β-adrenergic (β-AR) 
receptor induced cAMP production by activation of angiotensin II (ANG-II) receptor 
coupled to Gαq protein through calcium/calmodulin pathway indication of a signalling 
cross-talk between ANG -II and β-AR receptors in cardiac fibroblasts cells.  
 
In other study, Jimenez et al. (1999) have shown a cross-talk between the P1 and 
P2 purinoceptors that augments P2 receptor-mediated Ca
2+ 
release. This cross-talk was 
mediated by adenosine activation of the Gαs-coupled P1 receptors demonstrating a Gαs-
Gαq cross-talk that potentiates intracellular calcium in cerebellar cells. Werry et al. (2002) 
have also shown β-adrenoceptors activation can augment P2Y receptor-mediated 
intracellular Ca
2+
 release in HEK-293 cells.  
 
EP2 and FP receptors are co-expressed in Ishikawa cells and a cross-talk between 
these prostanoid receptors has not yet been studied. To identify a possible signalling 
interaction between both receptors, Ishikawa cells that stably express the EP2 and FP 
receptors (FPEP2 cells) were used as a model system. The aim of this study was to assess 
the integrated effect of Butaprost and PGF co-administration on IP3 and cAMP release. 
Using the FPEP2 cells, we showed PGF-stimulated IP3 production was not altered by co-
stimulation with Butaprost suggesting heterologous interaction between the two receptors 
does not have a synergetic effect on IP3 release. However, co-stimulation of FPEP2 cells 
with Butaprost and PGF augmented Butaprost-stimulated cAMP release despite the fact 
that PGF-mediated FP receptor activation on its own had no effect on cAMP 
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et al. (2000) in other receptors with similar fold increase (2 to 2.5 fold) to the one reported 
in this current study.  
 
Using specific receptor antagonists and small molecule chemical inhibitors of cell 
signaling, the molecular pathways mediating the PGF-induced augmentation of cAMP in 
cells treated with the combination of ligands was dissected. The PGF-mediated 
enhancement of cAMP observed in FPEP2 cells treated with Butaprost and PGF was 
mediated via the FP receptor- Gαq-mediated activation of IP3 via PLC and was 
independent of PKC activation. Following its release IP3 could activate its receptors 
(IP3R) present on the endoplasmic reticulum (ER) membrane to promote intracellular 
calcium release and activation of calmodulin and CaMK-II.  
 
The composite of the abovementioned data show PGF potentiation of Butaprost-
stimulated cAMP could be via the adenylyl cyclase pathway since several studies have 
shown that the calmodulin pathway can activate calcium sensitive AC isoforms to regulate 
intracellular cAMP accumulation (Wang and Storm, 2003; Hanoune and Defer, 2001). 
Clearly, identifying the expression of multiple AC isoforms in FPEP2 Ishikawa cells, in 
particular the calcium-stimulated isoforms provides an answer for the intricate cross-talk 
system between the EP2 and FP receptors. With the use of RT-PCR, data were obtained 
that show Ishikawa cells express mRNA for eight of the ten AC isoform (AC1, AC3, 
AC4, AC5, AC6, AC7, AC9 and the soluble AC), AC1 and AC3 being the calcium 
regulated ones. Even if AC3 is generally regarded as a calcium-stimulable isoform, studies 
have shown direct inhibition of the isoform by the phosphorylation of CaMK-II in HEK-
293 cells (Wei et al., 1996; Wei el al., 1998). However, other study has revealed when it is 
concomitantly activated with Gαs, AC3 can be stimulated by intracellular calcium to 
potentiate cAMP (Choi et al., 1992). Zhang et al. (1997) and Ostrom et al. (2003) reported 
AC3 to be the only calcium-regulated isoform that is expressed in their model cells, 
showing the likely involvement of the isoform in the Gαs-Gαq cross-talk reported in their 
studies. Transfection studies using siRNA to abolish expression of AC1 or AC3 in FPEP2 
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potentiation of Butaprost-stimulated cAMP. These data suggest that the Gαs-Gαq cross-
talk reported here is via the calcium sensitive isoform AC3.  
 
Other studies done on brown adipose tissue showed that neural stimulation can 
increase norephrine-stimulated AC activity. This is the only study to determine the Gαs-
Gαq cross-talk between the receptors was followed by a rapid increase in mRNA 
expression level of the AC3 isoform (Granneman, 1995). Using Real-Time RT-PCR 
analysis, regulation of AC3 mRNA by co-activation of the EP2 and FP receptors was 
determined. At all time points (1, 2, 4, 6 and 8 hrs), AC3 mRNA expression was not 
affected by co-activation of the receptors suggesting the cross-talk does not have an effect 
on auto-regulation of the isoform itself (Data not shown). 
 
Interestingly, both AC1 and AC3 siRNA inhibition did not have any significant 
effect on Butaprost-stimulated cAMP suggesting these two isoforms are not regulated by 
Butaprost. In contrast, Wong et al. (2001) showed that AC3 is the principal isoform that is 
activated by PGE2 despite the expression of other AC isoforms in human arterial smooth 
muscle cells (SMC). Another study showed that PGE2 can interact with its cognate 
receptors to activate solely the AC6 isoform when it is over-expressed in rat SMCs while 
it did not couple efficiently to the AC3 isoform. The authors suggested these could be due 
to localization of the AC isoforms in the cells. They showed that AC3 and AC6 are 
expressed in caveolin-rich fractions while the PGE2 receptors EP2 and EP4 were detected 
primarily in the non-caveolin fraction of the membrane. When AC6 isoform is over-
expressed it localizes to non-caveolin fraction explaining why PGE2 solely activates the 
AC6 isoform in RSMCs. Differences in these data might be related to cell-specific or 
different localization of ACs and the components that can activate ACs (Ostrom et al., 
2002). In Ishikawa cells Butaprost stimulation of cAMP accumulation can be mediated by 
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In conclusion, this study demonstrates that co-activation of the EP2 and FP 
receptors results in enhanced release of cAMP via FP receptor-Gαq-Ca
2+
-calmodulin 
pathway by activating the calcium-sensitive AC3 isoform in FPEP2 cells. The effect of 
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In chapter three expression of COX enzymes, prostaglandin receptors and 
prostaglandin-regulated genes were compared in endometrium samples from women 
with and without fibroids. I reported enhancement of COX-2, EP2 receptor, FP 
receptor, VEGF, IL-8 and IL-11 mRNA expression in endometrium from women with 
fibroids compared to control samples.  
 
Interestingly, endometrial samples derived from women with fibroids had 
higher EP2 and FP receptors mRNA expression in the proliferative stage of the 
menstrual cycle compared to normal samples. In order to investigate the integrated 
signalling and the possible cross-talk between the two receptors, I established Ishikawa 
cells over-expressing EP2 and FP receptors cell line as a model. Using this cell line, I 
reported a novel and integrative cross-talk observed following co-activation of the EP2 
and FP receptors. An important question is to determine the integrative effects of these 
receptors co-activation on gene expression profiling.  
 
Gene array analysis has been used in a large number of studies to assess gene 
expression in cell lines and tissue samples with and without exposure to different 
external stimuli. One of the great advantages of this analysis is the ability to use a 
single RNA sample to study the global transcription profile. Another advantage of 
gene array analysis is the reduction of human technical error since the processes are 
mostly automated. 
 
There have been several global gene array studies using Ishikawa cells as 
models to study the genetic signatures underlying endometrial pathologies. Paulssen et 
al. (2008) treated Ishikawa cells with progesterone for 4 hours and compared 
expression of genes to untreated samples using gene array analysis. This analysis 
revealed 247 differentially expressed genes of which 126 were up-regulated. Of the 
genes that were up-regulated some of them were shown to be involved in biological 
processes like apoptosis (7.2%), developmental process (13.9%), immune response 
and defence (11%) and intracellular protein trafficking (10.5%). However, genes 
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structure and motility (15.4%) and developmental process (14%) and transport (7%) 
were down-regulated by progesterone treatment.  
 
Davis et al. (2006) also assessed genes that are temporally regulated by 
progesterone and glucocorticoids in Ishikawa cells using gene array analysis. The 
authors identified unique lists of genes that are hormonally regulated and might be 
involved in the early process of carcinogenesis. Out of these genes, legumain, a gene 
associated with metastasis was down-regulated by progesterone while upstream c-fos 
related transcription factor-2 (USF-2), an anti-proliferative factor was shown to be 
induced by both progesterone and glucocorticoids (Davies et al., 2006).  
 
Another Global gene array analysis studied the effect of estrogen in Ishikawa 
cells. This study reported differentially regulated genes using estrogen receptor 
proficient and deficient Ishikawa cells treated with well-known estrogen active 
compounds. The authors reported up-regulation of novel genes by estrogen involved in 
cell growth, cell migration and tissue remodelling. Most down-regulated genes in 
response to estrogen were related to cell growth inhibition, apoptosis induction and 
estrogen metabolism (Boehme et al., 2009).  
 
Since EP2 and FP receptors are co-expressed, I set out to examine target genes 
that are regulated by co-activation of both receptors in endometrial epithelial cells. 
This was carried out by employing whole genome array profiling in FPEP2 cells in 
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6.2 Aim of the Study 
Previously, I have shown that there is cross-talk between the signalling 
cascades elicited by Butaprost and PGF in FPEP2 Ishikawa cells. This cross-talk can 
culminate in regulation of different target genes. This current study was designed to 
identify which genes or cluster of genes are differentially regulated by co-activation of 
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6.3 Materials and Methods 
6.3.1 Gene Array 
6.3.1.1 Treatment of Cells and RNA Extraction 
For gene array analysis, Ishikawa cells were seeded at a density of 5×10
5
cells 
per 6-cm dishes. The following day the cells were serum-starved for 18 hrs in the 
presence of 3µg/ml of indomethacin. Cells were then treated in serum free media for 8 
hrs by incubation with vehicle (0.1% ethanol), Butaprost (5µM) and/or PGF (100nM). 
Experiments were done four times in triplicates (N=12) for each treatment. After 
treatment, the cells were washed with cold PBS and incubated with Trizol for 5 min at 
room temperature. Cells were scraped from the dish surface and lysed through 0.22 
gauge needle a number of times. The lysate was centrifuged for 3 min at 10000 rpm 
and supernatant was removed to a fresh tube and was then mixed with 70% ethanol. 
The mix was then transferred to RNeasy spin column and total RNA was extracted as 
mentioned on section 2.3.3. The concentration and purity of the RNA were determined 
by measuring the absorbance at 260nm and 280nm (OD260 and OD280) using 
NanoDrop
®
 ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies). The 
criterion for sample inclusion in the gene array was A260/A280> 1.9. The integrity of 
the RNA was further assessed by Agilent 2100 bioanalyzer (Agilent Technologies UK 
Ltd). This automated RNA analyzer determined the quality of RNA by calculation of 
RNA integrity number (RIN) using microcapillary electrophoresis and fluorescence 
detection. The RIN values range from 10 (fully intact RNA) to 1 (totally degraded 
RNA) (Schroeder et al., 2006). Triplicates for each experiment with good RNA quality 
were pooled and sent for Gene array analysis. Hybridization of RNA samples to the 
gene array was carried out by GeneService by Applied biosystems human genome 
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6.3.1.2 Hybridization of RNA Samples and Data Analysis  
The hybridization of RNA samples was done by GeneService (Cambridge, 
UK) employing the method described below. The cDNA template was made by 
reverse transcriptase using in vitro transcription (IVT) reaction. The RT enzyme was 
used to incorporate deoxynucleotides to prepare single stranded DNA while the use of 
T7 poly dT primers enabled addition of the T7 polymerase promoter to the 5' end. To 
synthesise 2
nd
 strand DNA, RNase H was used to expose the priming sites of DNA 
polymerase by degrading the RNA in DNA-RNA duplexes. Thereafter, the double 
stranded cDNA was washed to clear excess buffer and salts and then eluted in suitable 
solution for IVT labelling. During the IVT labelling the T7 polymerase incorporated 
ribonucleotides and digoxigenin (DIG)-UTP to make up to 1000-fold cRNA from 
double stranded cDNA. The cRNA was eventually washed to get rid of excess buffer 
and eluted to a solution suitable for hybridisation to the microarray. Prior to 
hybridisation, the cRNA was fragmented using divalent cations by catalysing the 2' 
hydroxyl cleavage to reduce the secondary structure that interferes with hybridisation 
kinetics. After blocking the microarrays to prevent non-specific binding, the DIG 
labelled cRNA was then hybridised to the microarray chip. The microarray chip was 
then washed to reduce nonspecific hybridisation of the labelled cRNA. The 
chemiluminescent reaction was performed by subjecting the DIG in the cRNA targets 
bound to the microarray to anti-DIG alkaline phosphatase (ALP) conjugated antibody. 
Non-specific antibody binding was then removed by washing prior to adding an 
enhancement solution in the microarray to increase the quantum yield of the 
chemiluminescent reaction. The chemiluminescent substrate was added which reacts 
with the ALP to emit a light signal. The signal was then read by the applied biosystems 
1700 chemiluminescent microarray analyzer. This software excludes the signal 
intensity emitted from the blank features (non-specific signals) and calculates the 
correct amount of chemiluminescent signals on the microarray. In order to exclude 
technical variations and non-specific binding, several controls were used for each step. 
The RT controls, three synthetic mRNAs with bacterial gene sequences, were used to 
assess how well the RT reaction worked. The IVT controls were three synthetic 
double-stranded cDNA with a T7 promoter and bacterial control gene sequences. They 
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three DIG-labelled 60-mer oligo control targets, were used to determine the 
effectiveness hybridization to the microarray. To normalize the chemiluminescent 
signal, a fluorescent doubled 24-mer oligo was used as internal control target to bind 
with internal control probe on the microarray.  
 
Data acquired using ABI technology was preprocessed according to the 
manufacturers’ recommendations (Applied biosystems 1700 chemiluminescent 
microarray analyzer chemistry guide). The data was normalized using variance 
stabilized normalization (Huber et al., 2002). Linear Models for Microarray Data 
(LIMMA) software package was used to analyze the differential expression of genes 
which provides fold change, standard error, t-statistics and P values for the level of 
expression (Smyth, 2004). The P values were adjusted for multiple testing using 
Benjamini and Hochberg method (Benjamini and Hochberg, 1995). The resulting gene 
list included only the genes that had a fold change value of 2.0 or higher and a P of < 
0.05. Bioinformatics was performed using the gene set analysis tool kit (Zhang et al., 
2005). 
  
6.3.2 Gene Ontology Classification   
Gene Ontologys (GO) were assigned to classify Butaprost and/or PGF 
regulated genes for biological processes and molecular functions using a web tool 
provided by the gene ontology database (www.geneontology.org).  
 
6.3.3 Verification of the Gene Array Data  
6.3.3.1 Treatment of Cells 
In order to asses the temporal expression of Butaprost and/or PGF regulated 
genes, FPEP2 cells were treated with vehicle (0.1% ethanol), Butaprost (5µM) and/or 
PGF (100nM) for 4, 6 and 8 hrs. To assess specific molecular pathway FPEP2 cells 
were treated with either FP antagonist (50µM of AL8810 with 3min pretreatment) or 
transfected with AC3 siRNA as mentioned in section 5.3.3 in the presence/absence of 
Butaprost (5µM) and/or PGF (100nM) for 6 hrs. Cells were washed with cold PBS and 
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6.3.3.2 RNA Extraction and cDNA Synthesis  
Total mRNA was then extracted from the treated samples as described in 
section 2.3.2. cDNA was synthesized from 400ng of mRNA by reverse transcription in 
the presence of RT-PCR reaction buffer (1×), dNTPs (0.5mM each), MgCl2 (5.5mM), 





6.3.3.3 Real-Time RT-PCR Analysis  
Real-Time RT-PCR was performed on the cDNA samples (2µl per reaction) 
from treated FPEP2 cells using specific primers (300nM) and probes (100nM) 
respectively) to detect COX-2, VEGF, IL-8 and SAT1 genes in a reaction mix 
containing Taqman buffer (5.5mM MgCl2 and 200 m of each dNTPs, 0.025U/µl of 
AmpliTaq Gold DNA polymerase). Primers and probes for 18S (all at 50nM) were 
also added in the reaction mix as a loading control for the amount of cDNA added in 
each sample (Sequences of the primers is mentioned Table 2.4). The data was analysed 
using the comparative CT method for relative quantification. 
 
6.3.4 Statistical Analysis  
All data are presented as mean ± SEM. Statistical significant differences were 
determined by one-way analysis of variance using Prism 5.0 software (GraphPad 
Software Inc., San
 






















6.4.1 Real-Time RT-PCR Validation of COX-2, VEGF and IL-8 Gene Expression 
in Response to Butaprost and PGF in FPEP2 Ishikawa Cells   
Prior to Gene Array analysis, cDNA made from treated RNA samples were 
validated by measuring the expression of genes that have already been shown to be up-
regulated by prostaglandins. Studies in our laboratory have shown a significant 
increase of COX-2, VEGF and IL-8 mRNA expression level by the induction of 
Ishikawa cells with either PGE2 or PGF (Sales et al., 2004; Sales et al., 2005). To 
assess whether these genes are transcriptionally regulated in FPEP2 cells, cDNA 
samples from FPEP2 cells treated with vehicle, Butaprost and/or PGF were subjected 
to Real-Time RT-PCR analysis. As shown in figure 6.1A, 8 hrs treatment of the cells 
with PGF or Butaprost alone gave a significant increase in COX-2 mRNA expression 
compared to vehicle treated (5.46 ± 0.44 and 5.25 ± 0.69 vs. 1.0, respectively; 
p<0.0001), while treatment with both ligands had an even higher effect (11.35 ± 1.14; 
p<0.0001). Treatment with both ligands (PGF and Butaprost) or Butaprost alone 
elevated VEGF mRNA expression level significantly (5.55 ± 0.90 and 4.45 ± 0.36 vs. 
1.0, respectively; p<0.0001), while PGF induction of VEGF mRNA was slightly lower 
than the former two treatments (3.73 ± 0.38; p<0.001) (Fig 6.1B). As shown in figure 
6.1C, the relative expression of IL-8 mRNA with PGF or both treatments (PGF and 
Butaprost) was 455.20 ± 41.51 and 683.1 ± 56.70 respectively (p<0.0001). Butaprost 
alone gave 154.90 ± 19.63 fold increase (p<0.05) compared to vehicle treated (1.0). 
These results validated the cell treatment experiment and samples were sent for gene 
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Fig. 6.1: Relative mRNA expression of (A) COX-2, (B) VEGF and (C) IL-8 in FPEP2 cells 
after 8 hrs treatment with vehicle, Butaprost (5μM) and/or PGF (100nM) as determined by 
Real-Time RT-PCR. Data are presented as mean ± SEM from four independent 
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6.4.2 Genes Regulated by PGF and/or Butaprost Treatment  
The data from the gene array was analysed by GeneService. Genes were 
considered to be regulated by PGF and/or Butaprost if they showed an increase or 
decrease of 1.5 fold relative to vehicle treated. The analysis revealed 1045 genes that 
are regulated by PGF and/or Butaprost treatment (The complete list of the genes and 
the fold increases are mentioned in Appendix A). Out of these 1045 genes, 704 genes 
were regulated by PGF treatment only, of which 312 genes were transcriptionally up-
regulated and almost half of the genes (309) were only regulated by PGF and not by 
the other treatments. Treatment with Butaprost modulated the transcription of 363 
genes, of which 202 genes were up-regulated and 161 genes were down-regulated.  
However, only 71 were uniquely regulated by Butaprost. Co-treatment with the two 
ligands regulated 631 genes, of which 358 genes were up-regulated and 273 genes 
down-regulated. Co-activation of the EP2 and FP receptor also revealed regulation of 
228 unique genes. Of these, 94 genes were up-regulated while 134 genes were down-
regulated. The list of the genes and the fold increase/decrease are mentioned in table 
6.1 and 6.2 and selected seven genes that are important in endometrial cancer 
development are indicated in bold text. Fold induction of their gene expression by PGF 
and Butaprost co-stimulation was as follows: Basonuclin-1 (3.72 fold more), 
parathyroid hormone like hormone (PTHLH), (3.32 fold more), interleukin-1 receptor 
accessory protein (IL-1RAP), (3.29 fold more), 11β-hydroxysteroid dehydrogenases-2 
(11βHSD-2) (3.27 fold more), CD2 associated protein (CD2AP), (3.08 fold more), 
thrombospondin type I, domain containing 1 gene (THSD1), (3.04 fold less) and tumor 
protein p73 (3.02 fold less). Interestingly, 48 genes were found to be regulated by 
Butaprost and not by PGF and were either enhanced or repressed by co-stimulation 
with PGF (Table 6.3).  These genes are quite likely regulated by the PGF-potentiation 
of the Butaprost induced cAMP accumulation and one of these genes was further 
investigated.  
























     





Fig. 6.2: A Venn diagram highlighting expression profile of differently expressed genes after 8 
hrs treatment with Butaprost and/or PGF in FPEP2 cells as analysed by Applied biosystems 
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Table 6.1: List of genes uniquely up-regulated by co-activation with Butaprost and 
PGF 
 
Gene Symbol Gene Name Fold 
Change 
C3orf23 Chromosome 3 open reading frame 23 137.68 
MYL3 Myosin, light polypeptide 3, alkali ventricular, skeletal, slow 16.69 
CUGBP1 CUG triplet repeat, RNA binding protein 1 9.69 
TRPC6 
Transient receptor potential cation channel, subfamily C, 
member 6 6.69 
ASCC3 Activating signal cointegrator 1 complex subunit 3 5.13 
C14orf28 Chromosome 14 open reading frame 28 4.58 
ZNF545 Zinc finger protein 545 4.46 
CAMSAP1L1 Calmodulin regulated spectrin-associated protein 1-like 1 4.32 
C17orf39 Chromosome 17 open reading frame 39 4.20 
RABGGTB Rab geranylgeranyltransferase, beta subunit 4.19 
PAQR9 Progestin and adipoq receptor family member IX 3.94 
MFAP5 Microfibrillar associated protein 5 3.86 
ISG20 Interferon stimulated exonuclease gene 20kda 3.81 
NBLA00058 Asparagine synthetase domain containing 1 3.80 
KIAA0020 Kiaa0020 3.77 
BNC1 Basonuclin 1 3.72 
IGFBP4 Insulin-like growth factor binding protein 4 3.70 
RGS20 Regulator of G-protein signalling 20 3.63 
ZNF503 Zinc finger protein 503 3.60 
KCNK17 Potassium channel, subfamily K, member 17 3.60 
GOLGA4 Golgi autoantigen, golgin subfamily a, 4 3.55 
ELK4 ELK4, ETS-domain protein (SRF accessory protein 1) 3.53 
C1orf107 Chromosome 1 open reading frame 107 3.52 
SBDS Shwachman-Bodian-Diamond syndrome 3.50 
C6orf75 Chromosome 6 open reading frame 75 3.46 
NKX2-5 NK2 transcription factor related, locus 5 (Drosophila) 3.45 
TAF1A 
TATA box binding protein (TBP)-associated factor, RNA 
polymerase I 3.44 
TEX14 Testis expressed sequence 14 3.43 
RPS6KA3 Ribosomal protein S6 kinase, 90kda, polypeptide 3 3.40 
NAB1 NGFI-A binding protein 1 (EGR1 binding protein 1) 3.35 
PTHLH Parathyroid hormone-like hormone 3.32 
IL1RAP Interleukin 1 receptor accessory protein 3.29 
HSD11B2 Hydroxysteroid (11-beta) dehydrogenase 2 3.27 
NPAL1 NIPA-like domain containing 1 3.27 
GALNT3 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (galnac-T3) 3.27 
ASB2 Ankyrin repeat and SOCS box-containing 2 3.26 
PVR Poliovirus receptor 3.26 
CPOX Coproporphyrinogen oxidase 3.25 
SLC6A15 Solute carrier family 6, member 15 3.25 
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Gene Symbol Gene Name Fold 
Change 
PAK1IP1 PAK1 interacting protein 1 3.16 
CAMK2N1 Calcium/calmodulin-dependent protein kinase II inhibitor 1 3.15 
PHF2 PHD finger protein 2 3.14 
TAF9 
TAF9 RNA polymerase II, TATA box binding protein 
(TBP)-associated factor, 32kda 3.14 
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 3.11 
TRIM51 Tripartite motif-containing 51 3.10 
C9orf72 Chromosome 9 open reading frame 72 3.10 
WDR36 WD repeat domain 36 3.10 
USP15 Ubiquitin specific peptidase 15 3.09 
PLEKHC1 
Pleckstrin homology domain containing, family C (with 
FERM domain) member 1 3.08 
CD2AP CD2-associated protein 3.08 
SLC20A1 Solute carrier family 20 (phosphate transporter), member 1 3.08 
BTG1 B-cell translocation gene 1, anti-proliferative 3.07 
KIFC3 Kinesin family member C3 3.06 
GAN Giant axonal neuropathy (gigaxonin) 3.06 
CD3EAP CD3E antigen, epsilon polypeptide associated protein 3.05 
TTC6 Tetratricopeptide repeat domain 6 3.04 
FOSB FBJ murine osteosarcoma viral oncogene homolog B 3.04 
FAT FAT tumor suppressor homolog 1 (Drosophila) 3.04 
BCL10 B-cell CLL/lymphoma 10 3.03 
NARG1 NMDA receptor regulated 1 3.02 
LARP2 La ribonucleoprotein domain family, member 2 3.01 
MALL Mal, T-cell differentiation protein-like 3.00 
LAMB3 Laminin, beta 3 3.00 
BXDC2 Brix domain containing 2 2.99 
PTDSR Phosphatidylserine receptor 2.98 
RELB 
V-rel reticuloendotheliosis viral oncogene homolog B, 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells 3 (avian) 2.97 
SERPINB1 Serpin peptidase inhibitor, clade B (ovalbumin), member 1 2.96 
BXDC1 Brix domain containing 1 2.96 
C10orf47 Chromosome 10 open reading frame 47 2.96 
MAPK8 Mitogen-activated protein kinase 8 2.95 
C1orf27 Chromosome 1 open reading frame 27 2.95 
LYAR Ly1 antibody reactive homolog (mouse) 2.93 
TIPARP TCDD-inducible poly(ADP-ribose) polymerase 2.93 
RPL22 Ribosomal protein L22 2.93 
USP16 Ubiquitin specific peptidase 16 2.92 
IPLA2(GAMM
A) Patatin-like phospholipase domain containing 8 2.92 
CCDC41 Coiled-coil domain containing 41 2.91 
GADD45B Growth arrest and DNA-damage-inducible, beta 2.91 
PDLIM2 PDZ and LIM domain 2 (mystique) 2.90 
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Gene Symbol Gene Name Fold 
Change 
GLT28D1 Glycosyltransferase 28 domain containing 1 2.89 
UBE2H Ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) 2.88 
ARID5B AT rich interactive domain 5B (MRF1-like) 2.88 
UAP1 UDP-N-acteylglucosamine pyrophosphorylase 1 2.88 
ICHTHYIN Ichthyin protein  2.87 
PRPF38B PRP38 pre-mrna processing factor 38 (yeast) domain  2.87 
MAPKBP1 Mitogen activated protein kinase binding protein 1 2.86 
ARHGAP21 Rho gtpase activating protein 21 2.85 
JOSD3 Josephin domain containing 3 2.85 
C3orf26 Chromosome 3 open reading frame 26 2.85 
CLK1 CDC-like kinase 1 2.85 
SBDSP Shwachman-Bodian-Diamond syndrome pseudogene 2.84 
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Table 6.2: List of genes uniquely down-regulated by co-activation with Butaprost and 
PGF 
 
Gene Symbol Gene Name Fold 
Change 
INMT Indolethylamine N-methyltransferase 0.35 
C17orf62 Chromosome 17 open reading frame 62 0.35 
P2RY6 Pyrimidinergic receptor P2Y, G-protein coupled, 6 0.35 
RECK Reversion-inducing-cysteine-rich protein with kazal motifs 0.35 
UBIAD1 Ubia prenyltransferase domain containing 1 0.35 
SLC27A1 Solute carrier family 27 (fatty acid transporter), member 1 0.35 
PXDN Peroxidasin homolog (Drosophila) 0.35 
EHHADH 
Enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A 
dehydrogenase 0.35 
CRISP1 Cysteine-rich secretory protein 1 0.35 
CASP8 Caspase 8, apoptosis-related cysteine peptidase 0.35 
OR1D2 Olfactory receptor, family 1, subfamily D, member 2 0.35 
CYP2C8 Cytochrome P450, family 2, subfamily C, polypeptide 8 0.34 
WDR71 WD repeat domain 71 0.34 
CCL3L1|CCL3
L3 
Chemokine (C-C motif) ligand 3-like 1|chemokine (C-C 
motif) ligand 3-like 3 0.34 
PRSS33 Protease, serine, 33 0.34 
PCYT1B Phosphate cytidylyltransferase 1, choline, beta 0.34 
CYB561D1 Cytochrome b-561 domain containing 1 0.34 
TNK2 Tyrosine kinase, non-receptor, 2 0.34 
KCND3 
Potassium voltage-gated channel, Shal-related subfamily, 
member 3 0.34 
EXTL1 Exostoses (multiple)-like 1 0.34 
DNAH3 Dynein, axonemal, heavy polypeptide 3 0.34 
ULBP3 UL16 binding protein 3 0.34 
C21orf87 Chromosome 21 open reading frame 87 0.34 
FHL5 Four and a half LIM domains 5 0.34 
ZNF404 Zinc finger protein 404 0.34 
TRFP 
Trf (TATA binding protein-related factor)-proximal homolog 
(Drosophila) 0.34 
SLC16A13 
Solute carrier family 16 (monocarboxylic acid transporters), 
member 13 0.34 
THSD1P Thrombospondin type I, domain containing 1 pseudogene 0.34 
C7orf31 Chromosome 7 open reading frame 31 0.34 
C20orf175 Chromosome 20 open reading frame 175 0.33 
LEFTY1 Left-right determination factor 1 0.33 
DUSP26 Dual specificity phosphatase 26 (putative) 0.33 
OR52K2 Olfactory receptor, family 52, subfamily K, member 2 0.33 
ACBD4 Acyl-Coenzyme A binding domain containing 4 0.33 
KIAA1618 Kiaa1618 0.33 
PSORS1C2 Psoriasis susceptibility 1 candidate 2 0.33 
VIL1 Villin 1 0.33 
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Gene Symbol Gene name Fold 
Change 
PLEC1 Plectin 1, intermediate filament binding protein 500kda 0.33 
TNFAIP8L1 Tumor necrosis factor, alpha-induced protein 8-like 1 0.33 
PKP3 Plakophilin 3 0.33 
FGF6 Fibroblast growth factor 6 0.33 
TCL6 T-cell leukemia/lymphoma 6 0.33 
HIF3A Hypoxia inducible factor 3, alpha subunit 0.33 
RAB11FIP4 RAB11 family interacting protein 4 (class II) 0.33 
C14orf78 Chromosome 14 open reading frame 78 0.33 
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 0.32 
STEAP2 Six transmembrane epithelial antigen of the prostate 2 0.32 
SUHW1 Suppressor of hairy wing homolog 1 (Drosophila) 0.32 
ZP1 Zona pellucida glycoprotein 1 (sperm receptor) 0.32 
H1F0 H1 histone family, member 0 0.32 
FXYD2 FXYD domain containing ion transport regulator 2 0.32 
TP73 Tumor protein p73 0.32 
NOD9 NLR family member X1 0.32 
CNAP1 Non-SMC condensin I complex, subunit D2 0.32 
MAN2C1 Mannosidase, alpha, class 2C, member 1 0.32 
SERINC4 Serine incorporator 4 0.31 
DEPDC4 DEP domain containing 4 0.31 
APOL2 Apolipoprotein L, 2 0.31 
IGFL2 IGF-like family member 2 0.31 
APOBEC3A 
Apolipoprotein B mrna editing enzyme, catalytic 
polypeptide-like 3A 0.31 
EME1 Essential meiotic endonuclease 1 homolog 1 (S. Pombe) 0.31 
TRPV6 
Transient receptor potential cation channel, subfamily V, 
member 6 0.30 
GML GPI anchored molecule like protein 0.30 
PLXDC2 Plexin domain containing 2 0.30 
PARP4 Poly (ADP-ribose) polymerase family, member 4 0.30 
C14orf133 Chromosome 14 open reading frame 133 0.30 
SMP3 Phosphatidylinositol glycan anchor biosynthesis, class Z 0.30 
ZNF610 Zinc finger protein 610 0.30 
ATCAY Ataxia, cerebellar, Cayman type (caytaxin) 0.29 
KIF20A Kinesin family member 20A 0.29 
CDKN2C Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 0.29 
PBX4 Pre-B-cell leukemia transcription factor 4 0.29 
KLC3 Kinesin light chain 3 0.29 
SYNJ1 Synaptojanin 1 0.29 
FERD3L Fer3-like (Drosophila) 0.29 
PLEKHG1 
Pleckstrin homology domain containing, family G (with 
rhogef domain) member 1 0.29 
NFAM1 NFAT activating protein with ITAM motif 1 0.28 
PSRC1 Proline/serine-rich coiled-coil 1 0.28 
C11orf16 Chromosome 11 open reading frame 16 0.28 
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Gene Symbol Gene name Fold 
Change 
SCML4 Sex comb on midleg-like 4 (Drosophila) 0.27 
TLX1 T-cell leukemia homeobox 1 0.27 
SPRR4 Small proline rich protein 4 0.27 
GPR68 G protein-coupled receptor 68 0.27 
USP54 Ubiquitin specific peptidase 54 0.26 
MBL1P1 Mannose-binding lectin (protein A) 1, pseudogene 1 0.26 
ASPA Aspartoacylase (Canavan disease) 0.26 
KLHDC1 Kelch domain containing 1 0.26 
RTP2 Receptor (chemosensory) transporter protein 2 0.25 
C10orf33 Chromosome 10 open reading frame 33 0.25 
C9orf98 Chromosome 9 open reading frame 98 0.25 
ARID3A AT rich interactive domain 3A (BRIGHT- like) 0.25 
C8orf45 Chromosome 8 open reading frame 45 0.24 
BAIAP2 BAI1-associated protein 2 0.24 
PDK2 Pyruvate dehydrogenase kinase, isozyme 2 0.24 
C2orf21 Chromosome 2 open reading frame 21 0.24 
CA1 Carbonic anhydrase I 0.24 
OR2C1 Olfactory receptor, family 2, subfamily C, member 1 0.24 
OKL38 Oxidative stress induced growth inhibitor 1 0.24 
C1orf145 Chromosome 1 open reading frame 145 0.23 
ATOH7 Atonal homolog 7 (Drosophila) 0.23 
C9orf150 Chromosome 9 open reading frame 150 0.23 
TNRC6B Trinucleotide repeat containing 6B 0.22 
REG3G Regenerating islet-derived 3 gamma 0.22 
TSSK3 Testis-specific serine kinase 3 0.22 
PFN4 Profilin family, member 4 0.22 
RAI1 Retinoic acid induced 1 0.22 
FOXB1 Forkhead box B1 0.21 
Sept9 Septin 9 0.21 
UGT2A1 UDP glucuronosyltransferase 2 family, polypeptide A1 0.21 
PHIP Pleckstrin homology domain interacting protein 0.21 
MRVI1 Murine retrovirus integration site 1 homolog 0.20 
GJE1 Gap junction protein, epsilon 1, 29kda 0.19 
TLN2 Talin 2 0.18 
TMEM37 Transmembrane protein 37 0.18 
C3orf18 Chromosome 3 open reading frame 18 0.14 
OR52I2 Olfactory receptor, family 52, subfamily I, member 2 0.14 
MS4A3 
Membrane-spanning 4-domains, subfamily A, member 3 
(hematopoietic cell-specific) 0.13 
SPATA6 Spermatogenesis associated 6 0.12 
WNT1 Wingless-type MMTV integration site family, member 1 0.10 
LRP12 Low density lipoprotein-related protein 12 0.07 
IRGQ Immunity-related gtpase family, Q 0.07 
KLHDC6 Kelch domain containing 6 0.06 
ZNF483 Zinc finger protein 483 0.06 
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Gene Symbol Gene name Fold 
Change 
RGR Retinal G protein coupled receptor 0.04 
RASGEF1B Rasgef domain family, member 1B 0.019 
PRSS3 Protease, serine, 3 (mesotrypsin) 0.019 
C20orf59 Chromosome 20 open reading frame 59 0.010 
GLIS2 GLIS family zinc finger 2 0.008 
MPO Myeloperoxidase 0.006 
PRSS12 Protease, serine, 12 (neurotrypsin, motopsin) 0.004 
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Table 6.3: List of genes differentially expressed by Butaprost treatment only and 




Gene Name Fold change  
Butaprost PGF + 
Butaprost 
PGF enhanced modulation of gene expression   
SAT1 Spermidine/spermine N1-acetyltransferase 5.94 7.47 
RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 3.48 4.05 
FRAS1 Fraser syndrome 1 3.46 6.41 
KCNK5 Potassium channel, subfamily K, member 5 3.20 3.71 
ATP1B3 Atpase, Na+/K+ transporting, beta 3 polypeptide 3.19 4.28 
AQP3 Aquaporin 3 3.03 3.57 
CDC42EP2 CDC42 effector protein  2 3.02 4.16 
LIMS3 LIM and senescent cell antigen-like domains 3 2.98 3.81 
FAM100A Family with sequence similarity 100, member A 2.87 3.55 
ZNF323 Zinc finger protein 323 0.16 0.12 
NR3C2 Nuclear receptor subfamily 3, group C, member 
2 
0.18 0.14 
SPAG8 Sperm associated antigen 8 0.24 0.15 
C10orf91 Chromosome 10 open reading frame 91 0.27 0.14 
DEFB1 Defensin, beta 1 0.32 0.29 
KIAA1305 Kiaa1305 0.32 0.23 
ALDH3B2 Aldehyde dehydrogenase 3 family, member B2 0.33 0.29 
RNF144B Ring finger protein 144B 0.33 0.27 
SYNM Synemin 0.34 0.26 
MS4A2 Membrane-spanning 4-domains, subfamily A, 
mem 2  
0.34 0.29 
RLN1 Relaxin 1 0.35 0.32 
OR6W1P Olfactory receptor, family 6, subfamily W, 
member 1 pseudogene 
0.35 0.29 
TRIM6 Tripartite motif-containing 6 0.35 0.30 
SAMD13 Sterile alpha motif domain containing 13 0.35 0.31 
PGF repressed modulation of gene expression   
CYP26A1 Cytochrome P450, family 26, subfamily A, 
polypeptide 1 
18.03 12.28 
RPRM Reprimo, TP53 dependent G2 arrest mediator 
candidate 
11.90 7.76 
IL1R2 Interleukin 1 receptor, type II 3.98 3.62 
BTBD3 BTB (POZ) domain containing 3 3.30 3.02 
ZNF703 Zinc finger protein 703 3.28 3.04 
ADA Adenosine deaminase 3.15 2.87 
C1orf168 Chromosome 1 open reading frame 168 0.23 0.31 
DDIT4 DNA-damage-inducible transcript 4 0.22 0.26 
LIPC Lipase, hepatic 0.19 0.22 
VWA5A Von Willebrand factor A domain containing 5A 0.17 0.23 
KCNJ5 Potassium inwardly-rectifying channel, 
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6.4.3 Gene Ontology Analysis and Classification of Genes  
Gene ontology classifies genes in terms of their function into three categories 
namely, cellular component, biological process and molecular function. The cellular 
component ontology describes where the gene is located at the level of subcellular 
structure and macromolecular complexes (e.g. endoplasmic reticulum, nucleus or 
cytoplasm). Biological process ontology is a category that shows a series of events by 
one or more ordered assemblies of molecular function (e.g. cellular physiological 
process). The molecular function ontology describes catalytic or binding activities that 
occur at a molecule level. The difference between biological process and molecular 
function is that a biological process must have more than one distinctive step while the 
later is an activity performed by individual gene products (www.geneontology.org). 
All the 1045 genes that are regulated by Butaprost and/or PGF were subjected to gene 
ontology analysis. Application of gene ontology annotation for biological processes to 
Butaprost and/or PGF regulated genes revealed two significant themes of cell 
motility/chemotaxis (5.8%) (shown in red in Table 6.4) and blood vessel 
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Table 6.4: Gene Ontology Classification of the genes that are regulated by Butaprost 
and/or PGF showing biological process and molecular function (Red: Cell 
motility/chemotaxis, Green: blood vessel development/morphogenesis) 












Regulation of body fluids 
Blood coagulation 
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Blood coagulation 








Localization of cell 
Cell growth 
Morphogenesis 
Regulation of body fluids 
Blood coagulation 
Physiological response to wounding 
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cell cycle 
Regulation of cell size 
Negative regulation of cell 
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Cell migration 
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Gap-junction forming channel 
activity 
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6.4.4 PGF Potentiates Butaprost-Regulated SAT1 Gene Expression in FPEP2 
Cells  
Since PGF-potentiation of Butaprost stimulated-cAMP increase was observed, 
I was primarily interested to identify genes that are transcriptionally induced by 
Butaprost and enhanced in combination with PGF treatment while PGF on its own has 
little effect. This array identified 23 genes that are induced by Butaprost and are further 
enhanced by co-treatment with PGF. It is logical to assume that the enhanced 
transcription of these is a consequence of the Gαs-Gαq cross-talk which results in 
potentiation of cAMP production. One of the genes identified is Spermidine/spermine 
N1-acetyltransferase (SAT1) which is known to have roles in growth and proliferation 
of mammalian cells (Pegg, 2008). Interestingly, the SAT1 gene is known to be 
regulated by cAMP via the cAMP response element binding protein (CREB) that is 
located on its promoter region and this can explain its augmentation by co-treatment 
with Butaprost and PGF. I next decided to study the temporal regulation of the SAT1 
gene by treating FPEP2 Ishikawa cells with vehicle, Butaprost and/or PGF for 4, 6 and 
8 hrs. As shown in figure 6.3, Butaprost treatment alone significantly increased 
expression of SAT1 at all time points reaching a maximum level at 8 hrs compared to 
vehicle treated (3.48 ± 0.34, 3.9 ± 0.15 and 4.61 ± 0.15 vs. 1, respectively). No 
significant elevation of SAT1 gene expression was shown by treatment with PGF 
alone. However, co-stimulation of FPEP2 cells with Butaprost and PGF potentiated 
Butaprost stimulated expression of SAT1 significantly at all time points with the 
following fold increase: 4 hrs (5.29 ±0.22; p<0.05), 6 hrs (6.05 ± 0.3; p<0.001) and 8 
hrs (8.28 ± 0.5; p<0.001). These data demonstrate that PGF augments Butaprost-






























































Fig. 6.3: Relative temporal expression of SAT1 in FPEP2 cells after 4, 6 and 8 hrs treatment 
with vehicle, Butaprost (5μM) and/or PGF (100nM) as determined by Real-Time RT-PCR. 
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6.4.5 PGF-Induced SAT1 Potentiation is Mediated by FP Receptor in FPEP2 
Cells 
To determine whether the PGF-mediated potentiation of SAT1 expression is 
mediated by FP receptor, the cells were co-treated with a specific antagonist for FP 
receptor (50µM of AL8810 with 3min pretreatment) in the presence of Butaprost 
(5µM) and/or PGF (100nM) for 6 hrs. As shown in figure 6.4, antagonism of the FP 
receptor completely abolished the potentiation of SAT1 expression by PGF without 
altering Butaprost-stimulated expression of SAT1 (5.82 ± 0.25 vs. 3.00 ± 0.39; 
p<0.001). These data demonstrate that Butaprost-regulated expression of SAT1 is 








































Fig. 6.4: Relative expression of SAT1 in FPEP2 cells after 6 hrs treatment with vehicle, 
Butaprost (5μM) and/or PGF (100nM) in the presence/absence of the FP receptor antagonist 
(AL8810; 50μm) as determined by Real-Time RT-PCR. Data are presented as mean ± SEM 
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6.4.6 siRNA Knockdown of AC3 Abolishes PGF Potentiation of Butaprost-
Stimulated SAT1 in FPEP2 Cells  
In the previous chapter, I have shown that AC3 is involved in the Gαs-Gαq 
cross-talk in FPEP2 cells. In order to determine if AC3 isoform is involved in the 
mediation of SAT1 expression potentiation by PGF, AC3 siRNA-transfected FPEP2 
cells were subjected to vehicle, Butaprost (5µM) and/or PGF (100nM) treatment for 6 
hrs. As shown in figure 6.5, ablation of AC3 endogenous expression reduced SAT1 
mRNA in FPEP2 cells treated with the combination of Butaprost and PGF to the level 
of Butaprost stimulation only (5.26 ± 0.36 vs. 3.46 ± 0.37; p<0.001) but had no effect 
on Butaprost treatment alone (3.46 ± 0.34 vs. 3.25 ± 0.26). These data demonstrate that 
PGF mediated potentiation of SAT1 mRNA expression is regulated by the EP2-FP 
receptor cross-talk via the calcium-sensitive AC3 isoform.  
 
 




































Fig. 6.5: Relative mRNA expression of SAT1 in control and AC3 knockdown FPEP2 cells after 
6 hrs treatment with vehicle, Butaprost (5μM) and/or PGF (100nM) as determined by Real-
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6.5 Discussion  
In the previous chapter it has been shown that co-activation of the EP2 and FP 
receptors can lead to an integrative signalling pathway. Co-activation of both receptor 
resulted in a potentiation of Butaprost-stimulated cAMP by PGF via the calcium-
calmodulin pathway through the calcium-sensitive AC3 isoform in FPEP2 cells. There 
has been other cAMP mediated Gαs-Gαq cross-talk reported (Zhang et al., 1997; 
Beazely and Watts 2005; Ostrom et al., 2003). The Gαs-Gαq cross-talk reported by 
Ostrom et al. (2003) had an important physiological consequence on regulation of the 
extracellular matrix in myocardium. The authors showed ISO-mediated inhibition of 
collagen synthesis was further decreased by co-stimulation with ANG II suggesting the 
cross-talk plays a role in inhibition of fibrosis in heart. In order to determine the 
integrative effects of receptor co-activation on gene expression, human genome 
profiling was performed in FPEP2 cells in response to Butaprost, PGF or the 
combination of Butaprost and PGF.  
 
Prior to gene array analysis the samples were validated using genes that have 
previously been shown to be regulated by prostaglandins using Real-Time RT-PCR. 
Our analysis confirmed the temporal up-regulation of COX-2, VEGF and IL-8 mRNA 
expression. COX-2 expression was up-regulated by Butaprost and PGF to the same 
level while co-activation of the two receptors showed an even higher enhancement in 
gene expression. VEGF mRNA expression was also up-regulated with all sets of 
treatments however there was not any statistical significance between the treatments. 
IL-8 expression by Butaprost was lower than PGF treatment while co-activation by 
Butaprost and PGF gave a higher expression of the gene, validating the cell treatment 
experiments and samples were sent for gene array analysis.  
 
In the gene array analysis, numerous differentially regulated genes in response 
to treatment of FPEP2 Ishikawa cells with Butaprost and PGF were observed. The 
gene array revealed 1045 differentially expressed genes of which 71 were uniquely 
regulated by Butaprost and 309 were PGF-regulated. Co-treatment with Butaprost and 
PGF regulated 228 unique genes that have two major themes. These two themes were 
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processes are highly significant in the development and growth of tumours and play a 
major role in development of endometrial carcinoma.  
 
The gene array analysis revealed 48 genes that are regulated by Butaprost but 
are further modulated by co-stimulation with Butaprost and PGF. I focused on this set 
of genes since I have demonstrated a novel signalling cross-talk between the EP2 and 
FP receptors involving a potentiation of Butaprost stimulated-cAMP by PGF. Analysis 
of the gene list for Gene Ontology annotations indicated functions in cellular 
metabolism, immune response and excretion. One of the genes identified, SAT1 is a 
rate-limiting enzyme of polyamine catabolism. The enzyme adds an acetyl group to 
aminopropyl ends of spermidine and spermine to reduce the charge of polyamines, 
thus hindering their ability to bind acidic macromolecules and influencing their 
function. Acetylated polyamines are then either oxidized which leads to the back-
conversion of higher polyamines to lower polyamines or they are excreted out of the 
cell as a means of lowering intracellular polyamine pool (Tucker et al., 2005; Pegg, 
2008). The promoter region of SAT1 lacks a TATA box but has multiple binding sites 
for transcriptional factors including cAMP response element binding (CREB), 
suggesting it is cAMP pathway regulated (Fogel-Petrovic et al., 1993). The integrative 
signalling mediating the role of prostanoids on SAT1 expression in FPEP2 cells was 
investigated. I found that SAT1 is regulated by the cAMP mediated Gαs-Gαq cross-talk 
via AC3, such that siRNA knockdown of the AC3 isoform completely inhibited the 
potentiation of Butaprost-stimulated SAT1 expression by PGF. SAT1 is a highly 
regulated enzyme and it is inducible by polyamines and has been shown to be involved 
in carcinogenesis (Pegg, 2008). Transgenic mice harbouring the SAT1 gene showed a 
variety of defects like hair loss, female infertility, lipid metabolism and predisposition 
to develop pancreatitis (Janne et al., 2004). Tucker et al. (2005) showed that SAT1-
over producing transgenic mice bred with Apc
min/+
 mice (mice predisposed to intestinal 
tumor formation) had an increase in incidence of intestinal tumors while crosses with 
SAT1 knockout mice led to 75% reduction in tumour load. Another study on mice 
over-expressing SAT1 using the keratin 6 promoter showed an increased susceptibility 
to incidence and development of skin tumor in response to a tumorigenesis protocol 
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All these studies strongly suggest that SAT1 might have a key role in 
promoting tumor growth. Although the role for SAT1 in endometrial pathologies with 
dysregulated prostanoid synthesis is unclear, SAT1 has been shown to have a direct 
effect on cell migration by binding with α9β1-integrin (Chen et al., 2004). Moreover, 
in a recent study, Vlahakis et al. (2007) have demonstrated that α9B1-integrin can bind 
to VEGF to promote angiogenesis and lymphangiogenesis. In light of these studies, 
SAT1 might play a role in the pathology of the endometrium by directly promoting 
cell migration and an indirect enhancement of angiogenesis via VEGF-α9β1-integrin.  
 
Interestingly, we found that co-activation of FPEP2 cells with Butaprost and 
PGF activated a unique subset of genes (228 genes) with known roles in regulating cell 
morphology, proliferation and differentiation (Table 6.1 and 6.2). Seven genes that are 
only regulated by co-activation of the EP2 and FP receptors will be discussed with a 
review of their functions.  
 
Basonuclin-1 
Basonuclin-1 is one of the genes that is uniquely up-regulated by Butaprost and 
PGF. It is a cell-specific transcription factor mainly found in cells of the basal layer 
and it has been shown to be involved in re-epithelisation (Matsuzaki et al., 2004) and 
cell adhesion (Wang et al., 2006). Basonuclin-1 has been also shown to be involved in 
cell proliferation (Tseng, 1998). Cell proliferation and adhesion are amongst the many 
characteristics of growing tumours. Up-regulation of Basonuclin by EP2 and FP 
receptors activation might exacerbate pathologies of endometrial adenocarcinoma by 
regulating genes that are involved in cell proliferation and adhesion.  
 
Interleukin 1 receptor accessory protein (IL1RAP) 
Another gene that is uniquely up-regulated by co-treatment with Butaprost and 
PGF is IL1RAP. IL-1 is an essential inflammatory protein that binds to its cognate 
receptors (IL-1R type I and type II) to initiate numerous biological processes. This 
cytokine is involved in several reproductive functions and play a role in numerous 
dynamic changes occurring in the endometrium through menstrual cycles (Bigonnesse 
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affinity of the ligand binding to its type II receptor (Greenfeder et al., 1995). Studies 
have shown I1RAP is constitutively expressed in endometrium primarily in epithelial 
glands and luminal epithelium and less markedly in the stroma (Bigonnesse et al., 
2001). Singer et al. (2002) have shown the expression of the IL-1 system in 
endometrial malignancies and IL-1 involvement in an invasive nature of the 
endometrial cancer. Taking these studies into account, up-regulation of IL1RAP by 
Butaprost and PGF might play a role in the pathology of endometrium by increasing 
the affinity of IL-1R type II receptor to IL-1.  
 
CD2 associated protein (CD2AP) 
CD2AP was uniquely activated by co-stimulation of the EP2 and FP receptors. 
CD2AP is a widely expressed adaptor protein that facilitates receptor patterning by 
linking specific adhesion receptors to the cytoskeleton (Dustin et al., 1998). Kirsch et 
al. (2001) have shown CD2AP can interact with the proto-oncogene c-Cbl. c-Cbl is a 
substrate of protein tyrosine-kinases that is rapidly phosphorylated by activation with 
growth factors. Other studies have also shown activation of the c-Cbl can in turn 
regulate formation of lamellipodia and cell morphology (Scaife and Langdon, 2000; 
Lehtonen et al., 2002). Collectively, up-regulation of CD2AP by Butaprost and PGF 
can enhance various signalling pathways that regulate cellular adhesion, motility and 
morphology that all play important roles in endometrial pathologies by regulating cell 
movement and metastasis to distant sites of the body.  
 
11β-hydroxysteroid dehydrogenases-2 (11βHSD-2) 
Another gene that has been shown to be uniquely up-regulated by co-activation 
of the EP2 and FP receptors is 11βHSD-2. The family of 11βHSD are known to 
catalyse glucocorticoids metabolisms that are involved in tissue remodelling. As a 
dynamic and constantly remodelling tissue the endometrium expresses the 11βHSD-2 
gene (McDonald et al., 2006; Manolis et al., 2006). A recent study has shown an up-
regulation of 11βHSD-2 gene and down-regulation of the antiangiogenic factor 
thrombospondin-1 (TSP-1) in endometrium from women having heavy menstrual 
bleeding (Rae et al., 2009). Interestingly, in our array study a down-regulation of 
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was observed by co-stimulation with Butaprost and PGF and the function of the gene 
will be discussed below. TSP-1 is regulated by cortisol suggesting the role of 11βHSD-
2 to reduce glucocorticoids and then in turn enhance endothelial cell dysfunction and 
promote angiogenesis (Rae et al., 2009). 11βHSD-2 up-regulation by Butaprost and 
PGF may contribute to down-regulation of antiangiogenic factors and can promote 
angiogenesis in endometrial pathologies.  
     
Parathyroid hormone like hormone (PTHLH) 
The other gene to up-regulated by co-treatment with Butaprost and PGF is 
parathyroid hormone like hormone (PTHLH). PTHLH is an autocrine/paracrine factor 
that binds to its cognate receptor to activate bone formation and resorption (Juppner et 
al., 1991). An in vitro study using breast cancer cell lines has shown the role of 
PTHLH in development of breast cancer by inhibition of apoptosis and regulation of 
cell cycle (Tovar Sepulveda et al., 2002). Dougherty et al. (1999) have shown 
expression of PTHLH in prostate cancer cell lines and its involvement in tumour 
growth and anti-apoptotic effect in vitro. These data may suggest a role for PTHLH in 
endometrial carcinoma pathology by increasing tumour growth and inhibiting 
apoptosis.  
 
Thrombospondin type I, domain containing 1 gene (THSD1) 
THSD1 gene was shown to be down-regulated by co-stimulation with 
Butaprost and PGF compared to basal level and single ligand treatments. THSD1 is a 
newly indentified gene and was mapped to chromosome 13q14 recently by Ko et al. 
(2008). The authors identified several tumour suppressor genes that are associated with 
esophageal squamos cell carcinoma (ESCC), one of them being THSD1 gene. 
Transfection of the THSD1 gene to a human esophageal cancer cell line (SLMT-1) 
resulted a reduction in colony formation ability suggesting a role for the gene in 
growth suppression. In six ESCC cell lines that showed a down-regulation of the gene 
compared to NE1 (immortalized normal esophageal epithelial cell line), methylation of 
THSD1 gene was highly observed. The function of this gene is not well elucidated but 
the gene encodes for a transmembrane molecule containing a thrombospondin type I 
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thrombospondin type I motif have antiangiogenic activities (de Fraipont et al., 2001). 
Hence, up-regulation and activation of the EP2 and FP receptors in endometrial 
carcinoma can lead to a reduced expression of the tumour suppressor THSD1 gene.  
 
Tumor protein p73 
Tumor protein p73, a protein that shares considerable homology with p53, was 
mapped to chromosome 1p36 and the region is frequently deleted in neuroblastoma 
and most tumors (Kaghad et al., 1997). Soon after its mapping, Jost et al. (1997) 
showed that over-expression of p73 can activate p53-mediated genes and acts as a 
growth suppressor. Another study has shown that expression of p73 can be induced by 
the transcription factor E2F-1 which in turn induces apoptosis. The authors used p73 
homozygous knockout mice to show that apoptosis was reduced in embryonic 
fibroblasts cells derived from these mice compared to wild-type mice (Irwin et al., 
2000). In this current study p73 was down-regulated by co-activation of EP2 and FP 
receptor suggesting a role for p73 down-regulation in development of endometrial 
pathologies by inhibiting apoptosis.  
 
In conclusion, I have identified sets of genes that are uniquely activated by co-
activation of the EP2 and FP receptors that are involved in cell morphology, migration, 
invasion and angiogenesis. Moreover, I demonstrated that AC3 mediated Gαs-Gαq 
cross-talk can activate a unique gene, SAT1, which is involved in cell migration and 
angiogenesis. Therefore the data suggest that in pathologies where both EP2 and FP 
receptor are elevated, co-activation of prostanoid receptors and alteration in integrative 
signalling may alter the pathophysiological outcome of the cell via a molecular switch 
which promotes the activation of a subset of genes uniquely different from that 
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7.1 General Discussion  
Uterine fibroids are the most common tumors found in women in the reproductive 
age group. Despite their frequent occurrence, little attention has been given to the cause 
and pathology of uterine fibroids because of the rarity of their transformation to malignant 
tumors. Due to their local mass, uterine fibroids can cause excessive uterine bleeding, 
pregnancy related complications such as infertility and repetitive pregnancy loss (Flake et 
al., 2003; Haney, 2000). Ovarian hormones (estrogen and progesterone) play a major role 
in early tumorigenesis of uterine fibroids by increasing mitotic rate and the possibility of 
somatic mutations while several growth factors have been implicated as effectors of 
uterine fibroids once they are formed (Rein, 2000; Flake et al., 2003).  
 
There is mounting evidence to support a role for COX enzymes, prostaglandins 
and their cognate receptors in reproductive pathologies such as dysmenorrhoea, 
endometriosis, menorrhagia, cervical cancer and endometrial adenocarcinoma (Lumsden 
et al., 1983; Karck et al., 1996; Rees et al., 1984; Smith et al., 1981; Sales et al., 2002; 
Ryu et al., 2000; Tong et al., 2000; Jabbour et al., 2006b). However, their role in uterine 
fibroids is not well studied.  
 
In this study, expression of COX enzymes and prostaglandin receptors was 
assessed in fibroids and adjacent myometrium tissue samples from women with fibroids. 
The data obtained showed that expression of the EP3 receptor was down-regulated in 
fibroids compared to adjacent myometrium samples. These findings were in agreement 
with observations from gene array analyses on tissues from uterine fibroid samples in 
which the EP3 subtype receptor was found to be down-regulated in fibroids while all the 
other prostanoids and their cognate receptors were not altered compared to patient-
matched myometrium samples (Tsibris et al., 2002; Wang et al., 2003; Quade et al., 2003; 
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Down-regulation of the EP3 prostanoid receptor could play a key role in 
development of fibroids since the receptor has been shown to have a protective role in 
tumor growth. Over-expression and activation of the EP3 subtype receptors have been 
shown to decrease proliferation in human colon cancer cell lines (Shoji et al., 2004). 
Another study has shown enhanced expression of aromatase in fibroids compared to 
adjacent myometrium samples suggesting a role for this enzyme and the estrogen 
synthesized in situ by the enzyme in tumorigenesis of uterine fibroids (Sumitani et al., 
2000). PGE2 has been shown to increase aromatase activity in human breast stromal cells 
via the EP1 and EP2 receptors. However, co-treatment of cells with a selective EP3 
agonist completely inhibited PGE2-induced aromatase activity suggesting an inhibitory 
effect of the EP3 receptor pathway on aromatase activity (Richards and Brueggemeier, 
2003). These data suggest that EP3 down-regulation in uterine fibroids might result in 
tumor growth of uterine fibroids possibly by dysregulation of the aromatase-estrogen 
pathway.  
 
Despite several studies showing over-expression of prostaglandins and their 
cognate receptors in numerous tumors, in this current study expression of COX enzymes, 
EP1, EP2, EP4 and FP receptors were not significantly altered between fibroids and 
adjacent myometrium samples. These data led me to evaluate a possible paracrine 
regulation of prostaglandin receptors from tissues surrounding myometrium such as the 
endometrium on uterine fibroids. This was done by assessing the expression of COX 
enzymes, prostaglandin receptors and COX pathway-regulated genes in endometrium 
from women with and without uterine fibroids. Interestingly, up-regulation of COX-2, 
EP2 and FP receptors, VEGF, IL-8 and IL-11 were observed in endometrium samples 
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7.1.2 Roles for Epithelial Cell-Derived COX-2, EP2 and FP Receptors in Uterine 
Fibroids  
The progression of every tumor needs activation of the so-called “angiogenic-
switch”. This molecular switch involves over-expression of pro-angiogenic factors or 
down-regulation of anti-angiogenic mediators. COX-2 is one of the main factors that 
regulate the angiogenic pathway suggesting that over-expression of COX-2 in 
endometrium from women with fibroids could serve as the “angiogenic-switch” for 
uterine fibroid progression (Chang et al., 2004; Hanahan and Folkman, 1996). Over-
expression of COX-2 in endometrium from patients with uterine fibroids can trigger up-
regulation of prostaglandin synthesis mainly PGE2 and PGF which act on EP2 and FP 
receptors in an autocrine manner. Indeed studies in our laboratory have shown up-
regulation of the EP2 and FP receptors and their interactions with their respective ligands 
can lead to activation of angiogenic genes in endometrial adenocarcinoma cells (Sales et 
al., 2004; Sales et al., 2005). Elevation of prostaglandins and their cognate receptors 
might not be sufficient to have a direct influence on the regulation of uterine fibroids but 
can play major roles by inducing mitogenic and angiogenic genes such as VEGF, IL-8 and 
IL-11 to act in a paracrine manner on neighbouring myometrial/fibroid tissue.  
 
7.1.3 Paracrine Role of VEGF, IL-8 and IL-11 in Uterine Fibroids Development   
Once the “angiogenic-switch” is triggered by the up-regulation of COX-2 and 
prostaglandins the resulting angiogenesis is brought about by the action of several 
regulatory factors. VEGF is one of the main regulatory factors since it is a potent 
angiogenic and mitogenic growth factor. Charnock-Jones et al. (1993) showed VEGF 
expression in endometrial glandular epithelial and stromal cells with strong expression 
observed at the myometrium/endometrium boundary in the proliferative stage of 
menstrual cycle suggesting a possible paracrine role for VEGF in tumor development. 
Albrecht et al. (2003) showed that estrogen can up-regulate VEGF expression in cultured 
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cultured with human myometrial microvascular endothelial cells (HMMECs), it can 
regulate HMMEC tube formation and thus angiogenesis in a paracrine manner.  
 
IL-8, a chemoattractant chemokine, has been shown to induce proliferation, 
chemotaxis and angiogenesis in endothelial cells (Koch et al., 1992). It also has been 
shown to stimulate migration and proliferation in vascular smooth muscle cells (Yue et al., 
1994). Senturk et al. (2001) showed the expression of IL-8 and its receptors to be higher 
in the myometrium adjacent to fibroid tissue compared with fibroid itself. This study was 
in agreement with the observation from Kumar et al. (1998) in experimental tumor animal 
models in which they showed the expression of IL-8 in tumors were restricted to the 
periphery of large tumors. This high level of IL-8 expression in the peripheral regions, 
where cells are actively dividing and are in contact with normal cells might explain the 
paracrine role of IL-8 in mitogenesis (Senturk et al., 2001).  
 
IL-11 is a hematopoietic growth factor and can affect cell growth, differentiation 
and proliferation (Du and Williams, 1994; Leng and Elias, 1997). Tang et al. (1996) used 
the CC10 promoter to over-express IL-11 in the murine airway and showed that IL-11 can 
induce airway remodelling with subepithelial fibrosis and local accumulation of 
fibroblasts, smooth muscle cells and myofibroblasts, suggesting that IL-11 is a fibrogenic 
cytokine. Similar studies by Zhu et al. (2001) also showed that mice over-expressing IL-
11 had an enhancement in deposition of type I and type III collagen that caused airway 
fibrosis in these mice. Nakayama et al. (2007) showed a correlation between higher 
expression of IL-11 receptor and invasive grade tumors in places with venous invasion in 
gastric carcinomas. In vitro administration of recombinant human IL-11 to gastric cancer 
cells (MKN-28 and SCH) enhanced cell migration and invasion in these cells suggesting a 
role of this chemokine in promoting tumorigenesis.  
 
Taken together, these data suggest that the process of tumorigenesis in uterine 
fibroids may be facilitated following over-expression of COX-2 in neighbouring epithelial 
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PGE2-EP2 and PGF-FP receptor interactions can in turn up-regulate expression of 
angiogenic and mitogenic factors such as VEGF, IL-8 and IL-11 that can act on paracrine 
manner on adjacent myometrium/fibroid tissue to initiate neovascularisation, 
angiogenesis, cell migration and proliferation and formation of fibrosis as depicted 





























Fig. 7.1: Autocrine/Paracrine regulation of COX-2 and prostaglandin receptors and their possible 
downstream effects on uterine fibroids development. PGE2 and PGF synthesized by the COX-2 
enzyme pathway activate their cognate receptors EP2 and FP receptors in epithelial cells from 
endometrium to initiate target gene expression such as COX-2, VEGF, IL-8 and IL-11 genes. 
COX-2 can in turn auto-regulate a positive feedback loop to activate prostaglandin signalling 
while VEGF, IL-8 and IL-11 can couple to their specific receptors on myometrial or fibroids tissue 
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7.1.4 EP2 and FP Receptors Cross-Talk and its Proposed Role in Uterine Pathology    
Interestingly, EP2 and FP receptors up-regulation was also observed in the 
proliferative stage of endometrium samples from women with fibroids. The expression of 
these prostanoid receptors has also shown to be up-regulated in endometrial 
adenocarcinoma (Sales et al., 2004; Sales et al., 2005). EP2 and FP receptors are co-
expressed in Ishikawa cells. This observation suggests that co-activation of these 
prostaglandin receptors in the same cell can lead to heterologous interactions that could 
alter the physiological/pathophysiological gene expression profile and outcome.  
 
Heterologous interactions or cross-talks in the eicosanoid family have been shown 
in several studies. Walsh and Kinsella (2000) showed a cross-talk between thromboxane 
A2 (TPα and TPβ) and EP1 receptors in HEK-293 cells that leads to desensitization and 
inhibition of signalling of the TP receptors in a PKC-dependent manner. The same group 
further indentified that the activation of the FP receptor by PGF can also mediate 
desensitization of the TPα and TPβ receptors via the PKC pathway (Kelley-Hickie and 
Kinsella, 2004). In another study, Wilson et al. (2004) showed that heterodimerization can 
occur between the human receptors for prostacyclin (IP) and TPα that leads to 
augmentation of TPα receptor-mediated accumulation of cAMP by IP receptor when they 
are co-expressed in HEK-293 cells.   
 
Although EP2 and FP receptors are found to be co-expressed in numerous cell 
types such as Ishikawa cells, there have been no studies addressing the integrative 
signalling effects of these two receptors on signal transduction and gene expression (Sales 
et al., 2004; Sales et al., 2005). In order to investigate prostanoid integrative signalling, 
Ishikawa cells expressing both the EP2 and FP receptors (FPEP2 cell line) were 
successfully established. Expression level of the EP2 receptor in FPEP2 cells was 
compared to the parental FPS32 cells using Real-Time RT-PCR, Western blot analysis 
and immunofluorescence microscopy confirming stable expression of the EP2 receptor in 
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Using the FPEP2 cells as a model system, I showed that PGF-stimulated IP3 
production was not altered by co-stimulation with Butaprost suggesting that heterologous 
interaction between the two receptors does not have a synergistic effect in PLC-mediated 
IP3 release. However, co-stimulation of FPEP2 cells with Butaprost and PGF augmented 
Butaprost-mediated cAMP release despite PGF-mediated FP receptor activation on its 
own having no effect on cAMP accumulation. Using specific receptor antagonists and 
small molecule chemical inhibitors of cell signalling, I dissected the signalling pathways 
mediating the PGF-induced potentiation of Butaprost-stimulated cAMP in FPEP2 cells 
and have shown that it was mediated via the FP receptor- Gαq-mediated activation of IP3 
via PLC. Subsequently, IP3 could activate its receptors (IP3R) present on the endoplasmic 
reticulum membrane to promote intracellular calcium release and activation of calmodulin 
and CaMK-II as depicted schematically
 
in figure 7.2.  
 
Numerous studies have shown that the CaMK-II pathway can activate calcium 
sensitive AC isoforms to regulate intracellular cAMP accumulation (Zhang et al., 1997; 
Beazely and Watts, 2005; Ostrom et al., 2003). For example, Ostrom et al. (2003) showed 
a potentiation of β-adrenergic (β-AR) receptor induced cAMP production by activation of 
angiotensin II (ANG-II) receptor coupled to Gαq protein through calcium/calmodulin 
pathway demonstrating cross-talk between ANG-II and β-AR receptors in cardiac 
fibroblasts cells. The authors also identified AC3 to be the only calcium-stimulated 
isoform in cardiac fibroblast cells suggesting that this isoform could be regulating the 
cross-talk reported. In FPEP2 Ishikawa cells, I identified AC1 and AC3 as calcium-
regulated targets by RT-PCR analysis. Transfection studies using siRNA to abolish 
expression of AC1 or AC3 in FPEP2 cells revealed that the calcium-sensitive AC3 

























Fig. 7.2: Gαq-mediated Potentiation of Butaprost induced cAMP release.   
Butaprost activates Gαs-coupled EP2 receptors resulting in a rapid increase in intracellular 
cAMP accumulation, while PGF by itself does not alter cAMP production. However, co-treatment 
of the cells with both ligands leads to the Gαq-mediated activation of PLC and release of IP3 from 
the plasma membrane. Subsequently, IP3 via the IP3 receptor (IP3R) mediates the release of Ca
2+
 
from endoplasmic reticulum (ER) leading to calmodulin-CaMK-II dependent potentiation of cAMP 
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In order to determine the integrative effects of the EP2 and FP receptors co-
activation on gene expression, whole genome array profiling was performed in FPEP2 
cells in response to Butaprost and/or PGF treatment. Out of 1045 genes that are regulated 
by PGF and/or Butaprost treatment, 228 genes are uniquely regulated by co-activation of 
the EP2 and FP receptors (Table 6.1 and 6.2). Gene ontology annotations revealed that the 
genes are involved in cell morphology, proliferation and differentiation. The list contained 
several genes with an important function in pathogenesis or control of cancer such as 
basonuclin-1, IL1RAP, CD2AP, 11βHSD-2, PTHLH, THSD1 and tumor protein p73.  
 
Basonuclin-1, a cell specific transcription factor, was up-regulated by co-activation 
of the EP2 and FP receptors and it has been shown to play a role in cell proliferation and 
adhesion (Tseng, 1998; Wang et al., 2004). IL1RAP, a receptor for a very essential 
inflammatory protein (IL-1), is another gene to be up-regulated by this unique pathway 
and over-expression of this gene has been associated with an invasive nature of 
endometrial cancer (Singer et al., 2002). CD2AP, an adaptor protein for adhesion 
receptors and proto-oncogenes, was also up-regulated by co-activation of the EP2 and FP 
receptors and can affect cellular adhesion, motility and morphology (Kirsch et al., 2001; 
Scaife and Langdon, 2000; Lehtonen et al., 2002). 11βHSD-2 and PTHLH were also 
uniquely up-regulated in response to Butaprost and PGF and they have been shown to 
enhance angiogenesis by down-regulating anti-angiogenic factors and inhibit apoptosis 
and regulation of cell cycle, respectively (Rae et al., 2009; Tovar Sepulveda et al., 2002).  
 
Down-regulation of two tumor suppressor genes by co-activation of the EP2 and 
FP receptors was also observed. THSD1 gene encodes for a transmembrane molecule 
containing a thrombospondin type I repeat and has anti-angiogenic activities (Ko et al., 
2008; de Fraipont et al., 2001), while over-expression of tumor protein p73 can activate 
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Taken together, these data demonstrate up-regulation of genes that are implicated 
in cell proliferation, cytoskeleton regulation and angiogenesis and down-regulation of 
genes that are involved in anti-angiogenic and apoptotic proteins by co-activation of the 
EP2 and FP receptors. This may exacerbate pathologies of endometrial adenocarcinoma.  
 
Co-activation of FPEP2 Ishikawa cells with Butaprost and PGF enhanced or 
repressed a unique subset of Butaprost (EP2 receptor) regulated genes that are involved in 
cellular metabolism, immune response and excretion (Table 6.3). SAT1, an important 
enzyme in polyamine metabolism, was one of the genes identified and it adds an acetyl 
group to aminopropyl ends of spermidine and spermine that leads to lowering of 
intracellular polyamine pool (Casero and Pegg, 1993). The data obtained in this current 
study showed that SAT1 was regulated by the Gαs-Gαq cross-talk between the EP2 and FP 
receptors via the calcium stimulated AC3 isoform. 
 
Over-expression of this specific enzyme has been implicated in the pathology of 
intestinal tumors and in development of skin tumor (Pegg 2008; Tucker et al. 2005; 
Coleman et al., 2002). SAT1 has also been shown to have a direct effect on cell migration 
by binding with α9β1-integrin (Chen et al., 2004). Moreover, in a recent study, Vlahakis 
et al. (2007) have demonstrated that α9β1-integrin can bind to VEGF and promote 
angiogenesis and lymphangiogenesis. These data suggest that SAT1 might play a role in 
the pathology of endometrium by directly promoting cell migration or by indirect 
enhancement of angiogenesis via α9B1-integrin.  
 
Since EP2 and FP receptors are up-regulated in the proliferative phase of 
endometrium from women with uterine fibroids and SAT1 is regulated by the cross-talk 
between the EP2 and FP receptors in an endometrial epithelial cell line, I decided to assess 
SAT1 mRNA expression in endometrium from women with and without fibroids. 
Interestingly, Real-Time RT-PCR revealed that the level of SAT1 expression was 
significantly higher in the proliferative stage of endometrium from women with fibroids 
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that the EP2 and FP receptors cross-talk reported in FPEP2 Ishikawa cells in vitro can also 
happen in vivo and can regulate downstream gene expression such as SAT1. It is not clear 
how SAT1 over-expression can cause tumor development. However, it is clear that up-
regulation of SAT1 has a direct or indirect effect in development of tumors by promoting 
cell growth and migration. In the light of these studies, SAT1 produced by epithelial cells 
from endometrium might have a paracrine effect on myometrial/fibroids tissue by 
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7.2 Conclusion  
In conclusion, this study confirms the elevated expression of COX-2, EP2 and FP 
receptors, VEGF, IL-8 and IL-11 in endometrium from women with fibroids 
predominantly in the proliferative stage of the menstrual cycle. In addition, this study 
demonstrates that co-activation of the EP2 and FP receptors results in enhanced release of 
cAMP in a Gαq-calcium-dependent manner in endometrial adenocarcinoma cells stably 
expressing the EP2 and FP receptors. Moreover, the Gαs-Gαq cross-talk between the EP2 
and FP receptors was mediated via the calcium-sensitive AC3 isoform and modulates 
expression of genes involved in regulating cell morphology, proliferation, differentiation 
immune response and excretion.  
 
Taken together, these data suggest that in pathologies where both EP2 and FP 
receptors are elevated, such as in endometrial adenocarcinomas and endometrium from 
women with uterine fibroids, co-activation of these prostanoid receptors can lead to 
integrative signalling pathway that may change the pathophysiological outcome of the cell 
via a molecular switch which either alters the trans-activation of a subset of single 
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7.3 Future Studies   
The whole genome profiling done on FPEP2 cells in response to Butaprost and 
PGF revealed interesting lists of genes that are uniquely regulated by either the EP2 or FP 
receptor activation. These genes will be further analyzed in our laboratory and studies on 
PGF-FP receptor regulated genes that are involved in endometrial pathologies are already 
underway.  
 
In this current project, I have tried to study the role for SAT1 in proliferation and 
migration of Ishikawa cells by employing siRNA knockdown studies. These studies were 
not successful because knockdown studies using siRNA are transient. The role for SAT1 
in endometrial pathology could be an interesting aspect to look at by employing 
MicroRNA (miRNA) stable knockdown techniques in FPEP2 Ishikawa cells.  
 
In addition, studies in our laboratory are underway to determine the role for FP 
receptor over-expressing cell line in tumor growth in vivo. Another interesting aspect for a 
future study will be to assess the biological function of the EP2 and FP receptors in 
various features of endometrial cancer progression such as tumour growth, invasion, 
angiogenesis and metastasis by employing in vivo studies.  
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Appendix A: List of genes differentially expressed by PGF and/or Butaprost 
treatment. Fold increases are above/below vehicle treated and #N/A are treatments 




Gene Name Fold Change 
PGF Butaprost PGF & 
Butaprost 
A1BG alpha-1-B glycoprotein 0.347 #N/A #N/A 
AADACL1 arylacetamide deacetylase-like 1 4.898 #N/A 4.162 
AADAT aminoadipate aminotransferase 0.214 0.181 0.192 
ABAT 4-aminobutyrate aminotransferase 0.267 #N/A #N/A 
ABCA1 ATP-binding cassette, sub-family A (ABC1), 
member 1 
#N/A #N/A 0.323 
ABCC13 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 13 
0.327 #N/A #N/A 
ABCG8 ATP-binding cassette, sub-family G (WHITE), 
member 8 (sterolin 2) 
0.283 #N/A 0.283 
ABHD2 chromosome 11 open reading 
frame2|abhydrolase domain containing 2 
3.667 #N/A 4.451 
ACBD4 acyl-Coenzyme A binding domain containing 4 #N/A #N/A 0.332 
ACOT11 acyl-CoA thioesterase 11 #N/A 0.307 #N/A 
ACTG2 actin, gamma 2, smooth muscle, enteric 7.663 4.859 7.625 
ACTR2 ARP2 actin-related protein 2 homolog (yeast) 0.342 #N/A #N/A 
ACYP2 acylphosphatase 2, muscle type 0.295 #N/A 0.281 
ADA adenosine deaminase #N/A 3.154 2.867 
ADAMTS1 ADAM metallopeptidase with thrombospondin 
type 1 motif, 1 
12.529 10.563 16.481 
ADAMTS10 ADAM metallopeptidase with thrombospondin 
type 1 motif, 10 
0.341 #N/A #N/A 
ADAMTS13 ADAM metallopeptidase with thrombospondin 
type 1 motif, 13 
0.263 #N/A #N/A 
ADAMTS5 ADAM metallopeptidase with thrombospondin 
type 1 motif, 5 (aggrecanase-2) 
3.622 4.033 3.769 
ADM adrenomedullin 29.454 11.512 63.131 
ADORA1 adenosine A1 receptor 0.301 #N/A 0.155 
ADORA2B adenosine A2b receptor 3.100 #N/A #N/A 
ADRB2 adrenergic, beta-2-, receptor, surface 5.023 #N/A 5.602 
AGPS alkylglycerone phosphate synthase 3.283 2.834 4.630 
AGRN agrin 0.125 #N/A #N/A 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
AKAP12 A kinase (PRKA) anchor protein (gravin) 12 10.525 5.446 8.782 
AKR1C3 aldo-keto reductase family 1, member C3 (3-
alpha hydroxysteroid dehydrogenase, type II) 
#N/A 0.334 #N/A 
ALDH3A2 aldehyde dehydrogenase 3 family, member A2 0.278 #N/A 0.272 
ALDH3B2 aldehyde dehydrogenase 3 family, member B2 #N/A 0.326 0.293 
ALOXE3 arachidonate lipoxygenase 3 5.379 3.065 #N/A 
ALPK1 alpha-kinase 1 0.144 0.272 0.131 
ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 46.341 5.878 40.996 
ANKRD19 ankyrin repeat domain 19 0.347 #N/A #N/A 
ANKRD22 ankyrin repeat domain 22 #N/A 0.305 #N/A 
ANKRD25 ankyrin repeat domain 25 0.156 0.258 0.166 
ANKRD34 ankyrin repeat domain 34 0.197 #N/A #N/A 
ANKRD5 ankyrin repeat domain 5 0.317 #N/A #N/A 
APOBEC3A apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3A 
#N/A #N/A 0.306 
APOBEC3B apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3B 
#N/A 0.318 #N/A 
APOL2 apolipoprotein L, 2 #N/A #N/A 0.310 
AQP3 aquaporin 3 #N/A 3.025 3.567 
AREG amphiregulin (schwannoma-derived growth 
factor) 
93.528 39.034 175.938 
ARG2 arginase, type II 4.731 5.432 5.209 
ARHGAP21 Rho GTPase activating protein 21 #N/A #N/A 2.855 
ARHGAP29 Rho GTPase activating protein 29 3.826 #N/A 4.344 
ARHGEF15 Rho guanine nucleotide exchange factor (GEF) 
15 
0.228 0.321 0.296 
ARHGEF2 rho/rac guanine nucleotide exchange factor 
(GEF) 2 
3.059 #N/A 3.250 
ARID3A AT rich interactive domain 3A (BRIGHT- like) #N/A #N/A 0.248 
ARID5B AT rich interactive domain 5B (MRF1-like) #N/A #N/A 2.878 
ARMC3 armadillo repeat containing 3 0.337 #N/A #N/A 
ARNTL aryl hydrocarbon receptor nuclear translocator-
like 
2.920 #N/A 4.299 
ARNTL aryl hydrocarbon receptor nuclear translocator-
like 
2.920 #N/A 4.299 
ARRDC3 arrestin domain containing 3 #N/A 0.245 #N/A 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
ASB2 ankyrin repeat and SOCS box-containing 2 #N/A #N/A 3.259 
ASCC3 activating signal cointegrator 1 complex 
subunit 3 
#N/A #N/A 5.130 
ATAD4 ATPase family, AAA domain containing 4 0.091 0.082 0.106 
ATCAY ataxia, cerebellar, Cayman type (caytaxin) #N/A #N/A 0.295 
ATF3 activating transcription factor 3 14.512 8.033 10.936 
ATOH7 atonal homolog 7 (Drosophila) #N/A #N/A 0.231 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) 
polypeptide 
0.222 0.308 0.287 
ATP1B3 ATPase, Na+/K+ transporting, beta 3 
polypeptide 
#N/A 3.188 4.284 
ATP2B4 ATPase, Ca++ transporting, plasma membrane 
4 
0.331 #N/A #N/A 
ATP6V1C2 ATPase, H+ transporting, lysosomal 42kDa, 
V1 subunit C isoform 2 
5.384 4.085 5.962 
ATP6V1G2 ATPase, H+ transporting, lysosomal 13kDa, 
V1 subunit G isoform 2 
0.261 #N/A #N/A 
AVPI1 arginine vasopressin-induced 1 3.492 #N/A #N/A 
AXL AXL receptor tyrosine kinase 3.690 #N/A #N/A 
AXUD1 AXIN1 up-regulated 1 5.505 #N/A 5.351 
BAG1 BCL2-associated athanogene 3.111 4.693 4.245 
BAIAP2 BAI1-associated protein 2 #N/A #N/A 0.244 
BASP1 brain abundant, membrane attached signal 
protein 1 
0.317 #N/A 0.285 
BAZ2B bromodomain adjacent to zinc finger domain, 
2B 
#N/A 0.292 #N/A 
BCAR3 breast cancer anti-estrogen resistance 3 3.033 #N/A 3.829 
BCL10 B-cell CLL/lymphoma 10 #N/A #N/A 3.031 
BCMP11 anterior gradient homolog 3 (Xenopus laevis) 0.200 0.330 0.228 
BDNF brain-derived neurotrophic factor 32.281 13.650 27.802 
BHLHB2 basic helix-loop-helix domain containing, class 
B, 2 
5.699 3.707 4.562 
BIK BCL2-interacting killer (apoptosis-inducing) 3.225 #N/A #N/A 
BMP2K BMP2 inducible kinase 3.051 #N/A #N/A 
BMP4 bone morphogenetic protein 4 3.926 5.094 4.870 
BNC1 basonuclin 1 #N/A #N/A 3.719 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
BOMB WW and C2 domain containing 2 #N/A 2.954 #N/A 
BTBD3 BTB (POZ) domain containing 3 #N/A 3.304 3.018 
BXDC2 brix domain containing 2 #N/A #N/A 2.993 
C10orf137 chromosome 10 open reading frame 137 3.137 #N/A #N/A 
C10orf33 chromosome 10 open reading frame 33 #N/A #N/A 0.253 
C10orf47 chromosome 10 open reading frame 47 #N/A #N/A 2.955 
C10orf48 chromosome 10 open reading frame 48 4.374 3.456 4.498 
C10orf63 chromosome 10 open reading frame 63 0.223 #N/A 0.315 
C10orf79 chromosome 10 open reading frame 79 0.191 0.290 0.316 
C10orf91 chromosome 10 open reading frame 91 #N/A 0.272 0.135 
C11orf16 chromosome 11 open reading frame 16 #N/A #N/A 0.276 
C11orf2|ABH
D2 
chromosome 11 open reading 
frame2|abhydrolase domain containing 2 
3.667 #N/A 4.451 
C14orf113 chromosome 14 open reading frame 113 0.293 0.298 #N/A 
C14orf133 chromosome 14 open reading frame 133 #N/A #N/A 0.299 
C14orf139 chromosome 14 open reading frame 139 #N/A 0.200 #N/A 
C14orf140 chromosome 14 open reading frame 140 0.182 #N/A 0.267 
C14orf148 chromosome 14 open reading frame 148 0.337 #N/A #N/A 
C14orf28 chromosome 14 open reading frame 28 #N/A #N/A 4.585 
C14orf39 chromosome 14 open reading frame 39 0.248 #N/A #N/A 
C14orf58 chromosome 14 open reading frame 58 0.353 #N/A #N/A 
C14orf78 chromosome 14 open reading frame 78 #N/A #N/A 0.326 
C14orf93 chromosome 14 open reading frame 93 0.307 #N/A 0.324 
C15orf26 chromosome 15 open reading frame 26 0.322 #N/A #N/A 
C16orf52 chromosome 16 open reading frame 52 2.870 #N/A 3.161 
C17orf39 chromosome 17 open reading frame 39 #N/A #N/A 4.203 
C17orf62 chromosome 17 open reading frame 62 #N/A #N/A 0.352 
C18orf25 chromosome 18 open reading frame 25 4.258 #N/A 3.982 
C18orf56 chromosome 18 open reading frame 56 0.336 #N/A #N/A 
C19orf9 chromosome 19 open reading frame 9 0.175 0.313 #N/A 
C1orf101 chromosome 1 open reading frame 101 0.248 #N/A #N/A 
C1orf102 chromosome 1 open reading frame 102 0.229 #N/A #N/A 
C1orf105 chromosome 1 open reading frame 105 0.342 #N/A #N/A 
C1orf107 chromosome 1 open reading frame 107 #N/A #N/A 3.518 
C1orf116 chromosome 1 open reading frame 116 10.656 3.501 7.275 
C1orf145 chromosome 1 open reading frame 145 #N/A #N/A 0.233 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
C1orf178  chromosome 1 open reading frame 178 0.200 #N/A #N/A 
C1orf26 chromosome 1 open reading frame 26 0.180 #N/A #N/A 
C1orf27 chromosome 1 open reading frame 27 #N/A #N/A 2.946 
C1orf38 chromosome 1 open reading frame 38 0.350 #N/A #N/A 
C20orf12 chromosome 20 open reading frame 12 0.335 #N/A #N/A 
C20orf175 chromosome 20 open reading frame 175 #N/A #N/A 0.335 
C20orf26 chromosome 20 open reading frame 26 0.332 #N/A #N/A 
C20orf59 chromosome 20 open reading frame 59 #N/A #N/A 0.010 
C20orf94 chromosome 20 open reading frame 94 0.325 #N/A #N/A 
C21orf63 chromosome 21 open reading frame 63 3.186 3.574 4.307 
C21orf87 chromosome 21 open reading frame 87 #N/A #N/A 0.338 
C21orf91 chromosome 21 open reading frame 91 #N/A #N/A 2.839 
C21orf99 chromosome 21 open reading frame 99 0.336 #N/A #N/A 
C22orf15 chromosome 22 open reading frame 15 0.304 #N/A #N/A 
C2orf21 chromosome 2 open reading frame 21 #N/A #N/A 0.240 
C3orf18 chromosome 3 open reading frame 18 #N/A #N/A 0.140 
C3orf23 chromosome 3 open reading frame 23 #N/A #N/A 137.676 
C3orf26 chromosome 3 open reading frame 26 #N/A #N/A 2.846 
C3orf32 chromosome 3 open reading frame 32 3.049 3.228 3.070 
C5R1 complement component 5 receptor 1 (C5a 
ligand) 
0.209 0.258 0.255 
C6orf114 chromosome 6 open reading frame 114 3.014 #N/A 3.021 
C6orf117 chromosome 6 open reading frame 117 0.314 #N/A #N/A 
C6orf157 chromosome 6 open reading frame 157 3.302 3.618 4.865 
C6orf165 chromosome 6 open reading frame 165 0.280 #N/A #N/A 
C6orf203 chromosome 6 open reading frame 203 0.345 #N/A #N/A 
C6orf75 chromosome 6 open reading frame 75 #N/A #N/A 3.464 
C6orf85 chromosome 6 open reading frame 85 0.333 #N/A #N/A 
C7orf31 chromosome 7 open reading frame 31 #N/A #N/A 0.336 
C8orf22 chromosome 8 open reading frame 22 0.245 #N/A #N/A 
C8orf45 chromosome 8 open reading frame 45 #N/A #N/A 0.245 
C8orf48 chromosome 8 open reading frame 48 #N/A 0.230 #N/A 
C8orf51 chromosome 8 open reading frame 51 #N/A 0.320 0.332 
C9orf130 chromosome 9 open reading frame 130 #N/A 0.350 #N/A 
C9orf150 chromosome 9 open reading frame 150 #N/A #N/A 0.230 
C9orf72 chromosome 9 open reading frame 72 #N/A #N/A 3.103 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
CA1 carbonic anhydrase I #N/A #N/A 0.239 
CABLES1 Cdk5 and Abl enzyme substrate 1 4.341 3.702 4.962 
CACNG5 calcium channel, voltage-dependent, gamma 
subunit 5 
0.319 0.328 0.197 
CALB1 calbindin 1, 28kDa 3.211 3.182 3.966 
CALCOCO1 calcium binding and coiled-coil domain 1 0.271 #N/A #N/A 
CALCRL calcitonin receptor-like #N/A 0.321 #N/A 
CALD1 caldesmon 1 4.948 #N/A 4.933 
CAMK2N1 calcium/calmodulin-dependent protein kinase II 
inhibitor 1 
#N/A #N/A 3.154 
CAMKK1 calcium/calmodulin-dependent protein kinase 
kinase 1, alpha 
0.274 0.324 #N/A 
CAMSAP1L1 calmodulin regulated spectrin-associated 
protein 1-like 1 
#N/A #N/A 4.318 
CAPSL calcyphosine-like 0.204 #N/A #N/A 
CARD15 caspase recruitment domain family, member 15 0.283 0.261 #N/A 
CARD9 caspase recruitment domain family, member 9 0.345 #N/A #N/A 
CASP6 caspase 6, apoptosis-related cysteine peptidase 0.346 0.340 0.289 
CASP8 caspase 8, apoptosis-related cysteine peptidase #N/A #N/A 0.346 
CCDC11 coiled-coil domain containing 11 0.300 #N/A #N/A 
CCDC15 coiled-coil domain containing 15 0.235 #N/A 0.276 
CCDC19 coiled-coil domain containing 19 0.250 #N/A 0.218 
CCDC41 coiled-coil domain containing 41 #N/A #N/A 2.915 
CCK cholecystokinin 3.292 #N/A 2.927 
CCL20 chemokine (C-C motif) ligand 20 134.923 175.585 358.544 
CCL23 chemokine (C-C motif) ligand 23 0.342 0.325 #N/A 
CCL3L1|CCL
3L3 
chemokine (C-C motif) ligand 3-like 
1|chemokine (C-C motif) ligand 3-like 3 
#N/A #N/A 0.343 
CD2AP CD2-associated protein #N/A #N/A 3.081 
CD3EAP CD3E antigen, epsilon polypeptide associated 
protein 
#N/A #N/A 3.045 
CD44 CD44 antigen (homing function and Indian 
blood group system) 
3.437 #N/A 3.637 
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 
2 
#N/A 3.020 4.157 
CDC42EP3 CDC42 effector protein (Rho GTPase binding) 
3 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
CDK2AP2 CDK2-associated protein 2 3.423 4.350 3.316 
CDKN2C cyclin-dependent kinase inhibitor 2C (p18, 
inhibits CDK4) 
#N/A #N/A 0.291 
CDR2 cerebellar degeneration-related protein 2, 
62kDa 
3.234 #N/A #N/A 
CDX1 caudal type homeobox transcription factor 1 #N/A 0.333 #N/A 
CEBPB CCAAT/enhancer binding protein (C/EBP), β 3.162 #N/A #N/A 
CEP1 centrosomal protein 1 0.184 #N/A #N/A 
CES7 carboxylesterase 7 3.491 3.494 #N/A 
CETN1 centrin, EF-hand protein, 1 0.221 #N/A 0.238 
CFHL4 complement factor H-related 4 0.278 #N/A 0.321 
CGA glycoprotein hormones, alpha polypeptide 76.564 149.509 222.226 
CGN cingulin 0.296 0.283 0.259 
CHAC1 ChaC, cation transport regulator-like 1 (E. coli) 2.987 #N/A #N/A 
CHML choroideremia-like (Rab escort protein 2) 0.318 #N/A #N/A 
CHMP1B chromatin modifying protein 1B 3.987 4.940 5.226 
CHRM3 cholinergic receptor, muscarinic 3 0.337 #N/A #N/A 
CITED1 Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 1 
3.556 3.052 3.712 
CITED2 Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 2 
12.750 5.698 10.603 
CKLF chemokine-like factor 0.304 #N/A #N/A 
CLASP1 cytoplasmic linker associated protein 1 #N/A 0.323 0.337 
CLCF1 cardiotrophin-like cytokine factor 1 59.310 20.474 48.934 
CLCN4 chloride channel 4 0.301 #N/A 0.288 
CLDN1 claudin 1 5.709 3.546 4.540 
CLDN4 claudin 4 0.214 0.095 0.176 
CLEC2L C-type lectin domain family 2, member L 0.305 #N/A #N/A 
CLIC5 chloride intracellular channel 5 9.904 6.537 5.846 
CLIPR-59 CAP-GLY domain containing linker protein 3 0.241 #N/A 0.234 
CLK1 CDC-like kinase 1 #N/A #N/A 2.846 
CMIP c-Maf-inducing protein  4.705 3.660 4.124 
CMTM1 CKLF-like MARVEL transmembrane domain 
containing 1 
0.325 #N/A #N/A 
CNAP1 non-SMC condensin I complex, subunit D2 #N/A #N/A 0.316 
CNFN cornifelin 0.230 0.265 #N/A 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
COL16A1 collagen, type XVI, alpha 1 0.328 #N/A 7.398 
COL9A1 collagen, type IX, alpha 1 0.239 #N/A #N/A 
CORO1C coronin, actin binding protein, 1C 4.348 #N/A 3.228 
CPN1 carboxypeptidase N, polypeptide 1, 50kD #N/A #N/A 0.275 
CPOX coproporphyrinogen oxidase #N/A #N/A 3.249 
CREM cAMP responsive element modulator 3.661 6.572 8.599 
CRISP1 cysteine-rich secretory protein 1 #N/A #N/A 0.346 
CRISPLD1 cysteine-rich secretory protein LCCL domain 
containing 1 
3.101 #N/A #N/A 
CRMP1 collapsin response mediator protein 1 0.333 #N/A 0.308 
CRYAA crystallin, alpha A #N/A 3.468 #N/A 
CRYAB crystallin, alpha B 3.631 10.143 9.950 
CSMD2 CUB and Sushi multiple domains 2 0.249 #N/A #N/A 
CSRP1 cysteine and glycine-rich protein 1 3.069 #N/A #N/A 
CTAG2 cancer/testis antigen 2 0.160 #N/A #N/A 
CTGF connective tissue growth factor 184.520 30.535 80.159 
CTSG cathepsin G 0.174 0.249 0.227 
CTSO cathepsin O 0.347 #N/A 0.280 
CUGBP1 CUG triplet repeat, RNA binding protein 1 #N/A #N/A 9.686 
CX3CL1 chemokine (C-X3-C motif) ligand 1 0.228 #N/A #N/A 
CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma 
growth stimulating activity, alpha) 
20.981 9.825 19.383 
CXCL3 chemokine (C-X-C motif) ligand 3 34.744 16.627 43.660 
CXCR4 chemokine (C-X-C motif) receptor 4 9.397 10.939 11.964 
CXorf23 chromosome X open reading frame 23 0.286 #N/A #N/A 
CXorf40B chromosome X open reading frame 40B 3.142 2.865 3.181 
CXXC5 CXXC finger 5 0.274 #N/A 0.251 
CYB561D1 cytochrome b-561 domain containing 1 #N/A #N/A 0.341 
CYP1A1 cytochrome P450, family 1, subfamily A, 
polypeptide 1 
0.141 0.154 0.161 
CYP26A1 cytochrome P450, family 26, subfamily A, 
polypeptide 1 
#N/A 18.032 12.278 
CYP2C8 cytochrome P450, family 2, subfamily C, 
polypeptide 8 
#N/A #N/A 0.345 
CYP39A1 cytochrome P450, family 39, subfamily A, 
polypeptide 1 
0.326 #N/A #N/A 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
DCBLD2 discoidin, CUB and LCCL domain containing 2 3.151 #N/A 2.860 
DDIT3 DNA-damage-inducible transcript 3 5.546 #N/A #N/A 
DDIT4 DNA-damage-inducible transcript 4 #N/A 0.224 0.260 
DEFB1 defensin, beta 1 #N/A 0.323 0.287 
DEFB119 defensin, beta 119 #N/A #N/A 0.052 
DEFB126 defensin, beta 126 #N/A 0.249 #N/A 
DEPDC4 DEP domain containing 4 #N/A #N/A 0.313 
DEPDC6 DEP domain containing 6 0.215 0.325 0.235 
DGCR5 DiGeorge syndrome critical region gene 5 
(non-coding) 
0.309 #N/A #N/A 
DHRS3 dehydrogenase/reductase (SDR family) 
member 3 
0.323 #N/A #N/A 
DIRAS3 DIRAS family, GTP-binding RAS-like 3 #N/A 3.234 #N/A 
DIRC2 disrupted in renal carcinoma 2 6.534 3.927 4.619 
DKK1 dickkopf homolog 1 (Xenopus laevis) 333.177 299.203 639.096 
DLC1 deleted in liver cancer 1 5.875 4.368 6.444 
DMN desmuslin #N/A 0.342 0.261 
DNAH3 dynein, axonemal, heavy polypeptide 3 #N/A #N/A 0.339 
DNAI1 dynein, axonemal, intermediate polypeptide 1 0.327 #N/A 0.331 
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 
9 
3.954 3.745 4.353 
DNAL4 dynein, axonemal, light polypeptide 4 0.346 #N/A #N/A 
DNM1 dynamin 1 0.294 #N/A 0.280 
DOCK8 dedicator of cytokinesis 8 #N/A 0.339 #N/A 
DOK2 docking protein 2, 56kDa 0.252 #N/A #N/A 
DPCR1 diffuse panbronchiolitis critical region 1 0.324 #N/A 0.327 
DRG2 developmentally regulated GTP binding protein 
2 
0.312 #N/A #N/A 
DSCR8 Down syndrome critical region gene 8 0.217 #N/A #N/A 
DUSP1 dual specificity phosphatase 1 56.217 15.377 40.019 
DUSP14 dual specificity phosphatase 14 3.350 #N/A 3.273 
DUSP19 dual specificity phosphatase 19 0.253 #N/A 0.288 
DUSP26 dual specificity phosphatase 26 (putative) #N/A #N/A 0.333 
DUSP4 dual specificity phosphatase 4 45.065 39.449 58.084 
DUSP5 dual specificity phosphatase 5 67.080 23.248 52.013 
DUSP6 dual specificity phosphatase 6 4.173 5.130 3.603 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
DYDC1 DPY30 domain containing 1 0.307 #N/A #N/A 
DZIP3 DAZ interacting protein 3, zinc finger 0.344 0.342 #N/A 
EBF early B-cell factor 0.306 #N/A 0.232 
EDG2 endothelial differentiation, lysophosphatidic 
acid G-protein-coupled receptor, 2 
3.502 4.174 3.822 
EDG5 endothelial differentiation, sphingolipid G-
protein-coupled receptor, 5 
0.273 #N/A #N/A 
EDN1 endothelin 1 7.331 5.579 25.355 
EDN2 endothelin 2 278.419 66.082 280.207 
EDN3 endothelin 3 0.327 #N/A #N/A 
EFHB EF-hand domain family, member B 0.314 0.216 0.284 
EFHC2 EF-hand domain (C-terminal) containing 2 0.317 #N/A #N/A 
EGFL6 EGF-like-domain, multiple 6 0.170 0.221 0.326 
EGR1 early growth response 1 9.123 #N/A 9.378 
EHHADH enoyl-Coenzyme A, hydratase/3-hydroxyacyl 
Coenzyme A dehydrogenase 
#N/A #N/A 0.348 
EIF1 eukaryotic translation initiation factor 1 2.998 #N/A 3.055 
EIF2AK3 eukaryotic translation initiation factor 2-alpha 
kinase 3 
4.435 #N/A #N/A 
ELF3 E74-like factor 3 (ets domain transcription 
factor, epithelial-specific ) 
0.312 0.211 0.194 
ELK4 ELK4, ETS-domain protein (SRF accessory 
protein 1) 
#N/A #N/A 3.525 
ELN elastin (supravalvular aortic stenosis, Williams-
Beuren syndrome) 
0.287 #N/A #N/A 
ELSPBP1 epididymal sperm binding protein 1 0.325 #N/A 0.297 
EME1 essential meiotic endonuclease 1 homolog 1 (S. 
pombe) 
#N/A #N/A 0.306 
EMILIN1 elastin microfibril interfacer 1 0.308 #N/A 0.283 
ENC1 ectodermal-neural cortex (with BTB-like 
domain) 
3.770 #N/A 4.149 
ENPP3 ectonucleotide 
pyrophosphatase/phosphodiesterase 3 
0.353 #N/A #N/A 
EPHA2 EPH receptor A2 6.052 3.682 6.728 
EPN3 epsin 3 0.278 #N/A #N/A 
EPPK1 epiplakin 1 4.886 #N/A 3.290 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
ERRFI1 ERBB receptor feedback inhibitor 1 18.905 8.985 20.883 
ESR1 estrogen receptor 1 0.191 0.337 0.228 
ETV5 ets variant gene 5 (ets-related molecule) 3.739 #N/A #N/A 
EVC Ellis van Creveld syndrome 0.323 #N/A 0.344 
EXT1 exostoses (multiple) 1 5.025 #N/A #N/A 
EXTL1 exostoses (multiple)-like 1 #N/A #N/A 0.339 
F2RL1 coagulation factor II (thrombin) receptor-like 1 2.994 #N/A 3.368 
F3 coagulation factor III (thromboplastin, tissue 
factor) 
15.651 12.660 31.494 
FABP5 fatty acid binding protein 5 (psoriasis-
associated) 
4.009 4.423 6.069 
FABP5L3 fatty acid binding protein 5-like 3 3.170 3.495 4.462 
FAM100A family with sequence similarity 100, member A #N/A 2.868 3.553 
FAM102A family with sequence similarity 102, member A 5.214 #N/A 3.999 
FAM102B family with sequence similarity 102, member B 0.237 #N/A #N/A 
FAM27L family with sequence similarity 27-like 0.295 #N/A #N/A 
FAM40B family with sequence similarity 40, member B 0.280 0.337 #N/A 
FAM48A family with sequence similarity 48, member A 0.288 0.341 #N/A 
FAM60A family with sequence similarity 60, member A 3.971 3.128 3.759 
FAM62C family with sequence similarity 62 (C2 domain 
containing), member C 
0.330 #N/A #N/A 
FAM79B family with sequence similarity 79, member B 3.906 #N/A 5.068 
FAM81B family with sequence similarity 81, member B 0.291 #N/A #N/A 
FAM92A3 family with sequence similarity 92, member A3 0.149 0.327 #N/A 
FANCB Fanconi anemia, complementation group B 0.200 #N/A #N/A 
FANK1 fibronectin type III and ankyrin repeat domains 
1 
0.303 #N/A #N/A 
FAS Fas (TNF receptor superfamily, member 6) 2.990 #N/A 4.389 
FAT FAT tumor suppressor homolog 1 (Drosophila) #N/A #N/A 3.035 
FAT2 FAT tumor suppressor homolog 2 (Drosophila) 0.248 0.294 0.194 
FBP2 fructose-1,6-bisphosphatase 2 #N/A 0.285 #N/A 
FERD3L Fer3-like (Drosophila) #N/A #N/A 0.286 
FGD5 FYVE, RhoGEF and PH domain containing 5 0.272 #N/A #N/A 
FGF2 fibroblast growth factor 2 (basic) 6.148 #N/A 7.736 
FGF6 fibroblast growth factor 6 #N/A #N/A 0.326 
FGFBP1 fibroblast growth factor binding protein 1 2.850 4.168 4.955 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
FLNC filamin C, gamma (actin binding protein 280) 2.973 #N/A #N/A 
FMO5 flavin containing monooxygenase 5 0.239 #N/A 0.316 
FOS v-fos FBJ murine osteosarcoma viral oncogene 
homolog 
5.344 4.606 5.926 
FOSB FBJ murine osteosarcoma viral oncogene 
homolog B 
#N/A #N/A 3.036 
FOXA1 forkhead box A1 4.333 4.093 5.096 
FOXB1 forkhead box B1 #N/A #N/A 0.214 
FOXI1 forkhead box I1 0.183 0.319 0.347 
FOXJ1 forkhead box J1 0.163 #N/A 0.234 
FOXN1 forkhead box N1 0.351 #N/A #N/A 
FRAS1 Fraser syndrome 1 #N/A 3.461 6.408 
FXR2 fragile X mental retardation, autosomal 
homolog 2 
3.030 #N/A 3.081 
FXYD2 FXYD domain containing ion transport 
regulator 2 
#N/A #N/A 0.318 
G1P2 interferon, alpha-inducible protein (clone IFI-
15K) 
3.111 #N/A 3.384 
GAD2 glutamate decarboxylase 2 (pancreatic islets 
and brain, 65kDa) 
0.332 #N/A #N/A 
GADD45A growth arrest and DNA-damage-inducible, 
alpha 
2.844 2.902 5.504 










0.322 #N/A #N/A 
GAN giant axonal neuropathy (gigaxonin) #N/A #N/A 3.058 
GBE1 glucan (1,4-alpha-), branching enzyme 1 
(glycogen branching enzyme, Andersen 
disease, glycogen storage disease type IV) 
4.249 #N/A 4.275 
GBX2 gastrulation brain homeobox 2 0.332 #N/A #N/A 
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  PGF Butaprost PGF & 
Butaprost 
GEM GTP binding protein overexpressed in skeletal 
muscle 
9.015 4.340 13.802 
GIT2 G protein-coupled receptor kinase interactor 2 0.286 #N/A #N/A 
GJA1 gap junction protein, alpha 1, 43kDa (connexin 
43) 
0.309 #N/A #N/A 
GJA7 gap junction protein, alpha 7, 45kDa (connexin 
45) 
2.992 #N/A 4.180 
GJB6 gap junction protein, beta 6 (connexin 30) 5.251 #N/A 5.469 
GJE1 gap junction protein, epsilon 1, 29kDa #N/A #N/A 0.190 
GLI1 glioma-associated oncogene homolog 1 (zinc 
finger protein) 
0.145 #N/A #N/A 
GLIPR1 GLI pathogenesis-related 1 (glioma) 13.521 4.862 13.309 
GLIS1 GLIS family zinc finger 1 0.346 #N/A #N/A 
GLIS2 GLIS family zinc finger 2 #N/A #N/A 0.008 
GLT28D1 glycosyltransferase 28 domain containing 1 #N/A #N/A 2.890 
GML GPI anchored molecule like protein #N/A #N/A 0.304 
GOLGA4 golgi autoantigen, golgin subfamily a, 4 #N/A #N/A 3.550 
GON4 gon-4 homolog (C.elegans) #N/A 0.241 #N/A 
GPBP1L1 GC-rich promoter binding protein 1-like 1 0.315 #N/A #N/A 
GPR126 G protein-coupled receptor 126 3.541 #N/A 3.343 
GPR162 G protein-coupled receptor 162 0.296 #N/A 0.264 
GPR19 G protein-coupled receptor 19 0.328 #N/A #N/A 
GPR68 G protein-coupled receptor 68 #N/A #N/A 0.268 
GPRC5A G protein-coupled receptor, family C, group 5, 
member A 
26.893 17.643 22.859 
GPRC5D G protein-coupled receptor, family C, group 5, 
member D 
0.241 #N/A 0.331 
GPX2 glutathione peroxidase 2 (gastrointestinal) 0.299 #N/A #N/A 
GRAMD2 GRAM domain containing 2 0.179 #N/A #N/A 
GRB7 growth factor receptor-bound protein 7 0.285 #N/A #N/A 
GRHL3 grainyhead-like 3 (Drosophila) 0.286 #N/A #N/A 
GRK1 G protein-coupled receptor kinase 1 0.119 0.189 0.122 
GRK5 G protein-coupled receptor kinase 5 2.942 3.109 3.424 
GSPT2 G1 to S phase transition 2 0.334 #N/A #N/A 
GUCY1B3 guanylate cyclase 1, soluble, beta 3 0.339 #N/A #N/A 
H1F0 H1 histone family, member 0 #N/A #N/A 0.319 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
HCRTR1 hypocretin (orexin) receptor 1 0.186 #N/A #N/A 
HDAC2 histone deacetylase 2 0.305 #N/A #N/A 
HEMGN hemogen 0.271 #N/A #N/A 
HERPUD1 homocysteine-inducible, endoplasmic 
reticulum stress-inducible, ubiquitin-like 
domain member 1 
3.612 #N/A #N/A 
HES4 hairy and enhancer of split 4 (Drosophila) 4.719 3.730 4.941 
HIF3A hypoxia inducible factor 3, alpha subunit #N/A #N/A 0.326 
HINT1 histidine triad nucleotide binding protein 1 0.319 #N/A #N/A 
HIST1H2BA histone 1, H2ba #N/A 0.323 #N/A 
HIST1H2BC histone 1, H2bc 0.272 #N/A #N/A 
HIST1H3G histone 1, H3g 0.264 0.288 0.347 
HIST1H4A histone 1, H4a #N/A 0.303 #N/A 
HIVEP1 human immunodeficiency virus type I enhancer 
binding protein 1 
2.928 2.953 4.318 
HK2 hexokinase 2 7.060 5.412 6.421 
HNRPA3 heterogeneous nuclear ribonucleoprotein A3 0.305 #N/A #N/A 
HOMER1 homer homolog 1 (Drosophila) 3.641 #N/A 4.638 
HS3ST1 heparan sulfate (glucosamine) 3-O-
sulfotransferase 1 
0.302 #N/A #N/A 
HS6ST1 heparan sulfate 6-O-sulfotransferase 1|heparan 
sulfate 6-O-sulfotransferase 1 pseudogene 
0.320 #N/A #N/A 
HS6ST3 heparan sulfate 6-O-sulfotransferase 3 0.352 #N/A #N/A 
HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 #N/A #N/A 3.273 
HSPA2 heat shock 70kDa protein 2 3.092 2.994 #N/A 
HSPA5 heat shock 70kDa protein 5 (glucose-regulated 
protein, 78kDa) 
3.634 #N/A #N/A 
HTR4 5-hydroxytryptamine (serotonin) receptor 4 #N/A 0.352 #N/A 
HYOU1 hypoxia up-regulated 1 3.287 #N/A #N/A 
HYPE Huntingtin interacting protein E 3.075 #N/A #N/A 
IBRDC2 IBR domain containing 2 #N/A 0.335 0.274 
IBRDC3 IBR domain containing 3 3.868 3.211 4.288 
IBTK inhibitor of Bruton agammaglobulinemia 
tyrosine kinase 
5.409 4.859 8.699 
ICHTHYIN ichthyin protein  #N/A #N/A 2.871 
ID2B inhibitor of DNA binding 2B, dominant 
negative helix-loop-helix protein 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
IER2 immediate early response 2 3.407 #N/A 3.649 
IER3 immediate early response 3 28.451 17.779 20.647 
IFIH1 interferon induced with helicase C domain 1 0.323 #N/A #N/A 
IFIT1 interferon-induced protein with 
tetratricopeptide repeats 1 
0.278 0.348 0.269 
IFITM5 interferon induced transmembrane protein 5 0.305 0.258 0.351 
IFT74 intraflagellar transport 74 homolog 
(Chlamydomonas) 
0.311 #N/A #N/A 
IFT80 intraflagellar transport 80 homolog 
(Chlamydomonas) 
0.174 #N/A #N/A 
IFT81 intraflagellar transport 81 homolog 
(Chlamydomonas) 
0.338 #N/A #N/A 
IFT81 intraflagellar transport 81 homolog 
(Chlamydomonas) 
#N/A #N/A 0.331 
IFT88 intraflagellar transport 88 homolog 
(Chlamydomonas) 
#N/A 0.354 #N/A 
IGFBP1 insulin-like growth factor binding protein 1 4.727 #N/A 5.336 
IGFBP4 insulin-like growth factor binding protein 4 #N/A #N/A 3.702 
IGFL2 IGF-like family member 2 #N/A #N/A 0.307 
IGSF9 immunoglobulin superfamily, member 9 #N/A 0.338 #N/A 
IHPK3 inositol hexaphosphate kinase 3 0.221 0.127 0.245 
IKBKE inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase epsilon 
#N/A 0.336 #N/A 
IL11 interleukin 11 40.751 10.255 59.307 
IL13RA2 interleukin 13 receptor, alpha 2 0.249 #N/A #N/A 
IL15 interleukin 15 #N/A 0.317 #N/A 
IL1R2 interleukin 1 receptor, type II #N/A 3.984 3.624 
IL1RAP interleukin 1 receptor accessory protein #N/A #N/A 3.295 
IL3 interleukin 3 (colony-stimulating factor, 
multiple) 
0.299 #N/A 0.161 
IL6 interleukin 6 (interferon, beta 2) 70.472 14.355 29.138 
IL8 interleukin 8 66.669 28.640 109.802 
INMT indolethylamine N-methyltransferase #N/A #N/A 0.353 
IPLA2(GAM
MA) 
patatin-like phospholipase domain containing 8 #N/A #N/A 2.917 
IRF8 interferon regulatory factor 8 0.270 #N/A #N/A 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of 
VLA-2 receptor) 
4.011 #N/A 7.875 
JAK3 Janus kinase 3 (a protein tyrosine kinase, 
leukocyte) 
0.323 #N/A #N/A 
JOSD3 Josephin domain containing 3 #N/A #N/A 2.847 
JUN v-jun sarcoma virus 17 oncogene homolog 
(avian) 
5.800 3.187 6.753 
JUNB jun B proto-oncogene 3.019 3.035 3.532 
KATNAL2 katanin p60 subunit A-like 2 0.305 #N/A #N/A 
KCND3 potassium voltage-gated channel, Shal-related 
subfamily, member 3 
#N/A #N/A 0.339 
KCNE3 potassium voltage-gated channel, Isk-related 
family, member 3 
0.301 #N/A 0.322 
KCNJ5 potassium inwardly-rectifying channel, 
subfamily J, member 5 
#N/A 0.157 0.222 
KCNK17 potassium channel, subfamily K, member 17 #N/A #N/A 3.597 
KCNK5 potassium channel, subfamily K, member 5 #N/A 3.204 3.713 
KCNK6 potassium channel, subfamily K, member 6 3.835 2.838 #N/A 
KCTD12 potassium channel tetramerisation domain 
containing 12 
2.897 #N/A 2.900 
KIAA0020 KIAA0020 #N/A #N/A 3.770 
KIAA0408 KIAA0408 #N/A 0.305 #N/A 
KIAA1212 KIAA1212 0.295 #N/A #N/A 
KIAA1217 KIAA1217 0.228 0.308 0.209 
KIAA1305 KIAA1305 #N/A 0.323 0.227 
KIAA1328 KIAA1328 #N/A 0.281 #N/A 
KIAA1618 KIAA1618 #N/A #N/A 0.332 
KIAA1622 KIAA1622 0.320 #N/A #N/A 
KIAA1949 KIAA1949 3.400 #N/A #N/A 
KIF20A kinesin family member 20A #N/A #N/A 0.291 
KIFC3 kinesin family member C3 #N/A #N/A 3.061 
KLC3 kinesin light chain 3 #N/A #N/A 0.287 
KLF5 Kruppel-like factor 5 (intestinal) 4.030 3.707 6.948 
KLF6 Kruppel-like factor 6 3.104 #N/A 4.350 
KLHDC1 kelch domain containing 1 #N/A #N/A 0.255 
KLHDC6 kelch domain containing 6 #N/A #N/A 0.063 
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keratin 16 (focal non-epidermolytic 
palmoplantar keratoderma)|keratin 14 
(epidermolysis bullosa simplex, Dowling-
Meara, Koebner) 
5.141 #N/A #N/A 
KRT17 keratin 17 217.379 46.443 99.745 
KRT6C|KRT6
A 
keratin 6C|keratin 6A 37.403 22.714 79.461 
KRT6E keratin 6E 46.094 27.267 97.668 
KRTAP1-3 keratin associated protein 1-3 0.341 #N/A #N/A 
KRTAP1-3 keratin associated protein 1-3|keratin associated 
protein 1-1 
#N/A 0.191 #N/A 
KRTAP2-
1|KRTAP2-4 
keratin associated protein 2-1|keratin associated 
protein 2-4 




keratin associated protein 2-2|keratin associated 
protein 2-1|keratin associated protein 2-4 
2.983 #N/A #N/A 
KRTAP6-2 keratin associated protein 6-2 0.332 #N/A #N/A 
KRTAP9-8 keratin associated protein 9-8 0.302 0.322 0.329 
KRTHB5 keratin, hair, basic, 5 0.265 #N/A #N/A 
KUB3 XRCC6 binding protein 1 0.298 0.336 0.305 
LALBA lactalbumin, alpha- 0.165 #N/A #N/A 
LAMA3 laminin, alpha 3 13.742 5.586 8.519 
LAMB3 laminin, beta 3 #N/A #N/A 3.001 
LAMC2 laminin, gamma 2 4.030 #N/A 3.566 
LARP2 La ribonucleoprotein domain family, member 2 #N/A #N/A 3.007 
LATS2 LATS, large tumor suppressor, homolog 2 
(Drosophila) 
5.913 3.237 5.405 
LBH limb bud and heart development homolog 
(mouse) 
21.975 15.981 20.322 
LCP1 lymphocyte cytosolic protein 1 (L-plastin) 2.946 #N/A #N/A 
LEFTY1 left-right determination factor 1 #N/A #N/A 0.335 
LEFTY2 left-right determination factor 2 0.233 #N/A #N/A 
LIMS3 LIM and senescent cell antigen-like domains 3 #N/A 2.982 3.807 
LIPC lipase, hepatic #N/A 0.186 0.221 
LIPF lipase, gastric 0.348 #N/A #N/A 
LMBRD2 LMBR1 domain containing 2 0.300 #N/A #N/A 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
LMO7 LIM domain 7 #N/A 0.312 #N/A 
LOH11CR2A loss of heterozygosity, 11, chromosomal region 
2, gene A 
#N/A 0.170 0.234 
LOH12CR2 loss of heterozygosity, 12, chromosomal region 
2 
0.275 #N/A 0.309 
LOH3CR2A loss of heterozygosity, 3, chromosomal region 
2, gene A 
0.260 #N/A #N/A 
LOX lysyl oxidase 3.807 #N/A #N/A 
LOXL4 lysyl oxidase-like 4 3.336 #N/A #N/A 
LRFN5 leucine rich repeat and fibronectin type III 
domain containing 5 
0.213 #N/A #N/A 
LRP12 low density lipoprotein-related protein 12 #N/A #N/A 0.074 
LRRC50 leucine rich repeat containing 50 0.262 #N/A #N/A 
LRRC8C leucine rich repeat containing 8 family, 
member C 
3.874 #N/A 5.124 
LTBP2 latent transforming growth factor beta binding 
protein 2 
0.166 0.338 0.333 
LYAR Ly1 antibody reactive homolog (mouse) #N/A #N/A 2.934 
LYZL1|LYZL
2 
lysozyme-like 1|lysozyme-like 2 0.284 #N/A #N/A 
MAFK v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog K (avian) 
11.846 11.478 13.376 
MAK male germ cell-associated kinase 0.294 #N/A #N/A 
MALL mal, T-cell differentiation protein-like #N/A #N/A 3.002 
MAN2C1 mannosidase, alpha, class 2C, member 1 #N/A #N/A 0.316 
MAP1A microtubule-associated protein 1A 0.146 0.290 0.179 
MAP1B microtubule-associated protein 1B 2.875 #N/A #N/A 
MAP2K3 mitogen-activated protein kinase kinase 3 5.796 3.231 4.884 
MAP2K7 mitogen-activated protein kinase kinase 7 #N/A 0.337 #N/A 
MAPK8 mitogen-activated protein kinase 8 #N/A #N/A 2.951 
MAPK8IP2 mitogen-activated protein kinase 8 interacting 
protein 2 
3.134 #N/A #N/A 
MAPKAPK2 mitogen-activated protein kinase-activated 
protein kinase 2 
3.748 #N/A 3.264 
MAPKBP1 mitogen activated protein kinase binding 
protein 1 
#N/A #N/A 2.855 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
MCTP2 multiple C2 domains, transmembrane 2 3.572 #N/A #N/A 
MDH1B malate dehydrogenase 1B, NAD (soluble) 0.326 #N/A 0.262 
MEIS1 Meis1, myeloid ecotropic viral integration site 
1 homolog (mouse) 
0.323 0.344 0.300 
MEOX1 mesenchyme homeobox 1 0.067 0.052 0.059 
MEOX2 mesenchyme homeobox 2 0.345 #N/A 0.286 
METRNL meteorin, glial cell differentiation regulator-like 4.234 #N/A 3.997 
MFAP5 microfibrillar associated protein 5 #N/A #N/A 3.864 
MICAL1 microtubule associated monoxygenase, 
calponin and LIM domain containing 1 
#N/A 0.342 #N/A 
MICALCL MICAL C-terminal like 5.695 #N/A 6.063 
MMP10 matrix metallopeptidase 10 (stromelysin 2) 11.120 8.434 31.984 
MN1 meningioma (disrupted in balanced 
translocation) 1 
0.289 #N/A #N/A 
MPEG1 macrophage expressed gene 1 #N/A 0.325 #N/A 
MPFL MPF-like  0.329 #N/A 0.253 
MPO myeloperoxidase #N/A #N/A 0.006 
MPPED2 metallophosphoesterase domain containing 2 0.211 #N/A 0.332 
MRPS16 mitochondrial ribosomal protein S16 0.263 #N/A #N/A 
MRVI1 murine retrovirus integration site 1 homolog #N/A #N/A 0.204 
MS4A2 membrane-spanning 4-domains, subfamily A, 
member 2 (Fc fragment of IgE, high affinity I, 
receptor for; beta polypeptide) 
#N/A 0.344 0.290 
MS4A3 membrane-spanning 4-domains, subfamily A, 
member 3 (hematopoietic cell-specific) 
#N/A #N/A 0.135 
MTHFD1L methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
3.198 #N/A #N/A 
MTHFR 5,10-methylenetetrahydrofolate reductase 
(NADPH) 
0.277 #N/A 0.269 
MXD3 MAX dimerization protein 3 0.213 0.301 0.253 
MYC v-myc myelocytomatosis viral oncogene 
homolog (avian) 
4.273 3.425 3.883 
MYH9 myosin, heavy polypeptide 9, non-muscle 3.329 #N/A #N/A 
MYL3 myosin, light polypeptide 3, alkali; ventricular, 
skeletal, slow 
#N/A #N/A 16.689 
MYL7 myosin, light polypeptide 7, regulatory 4.930 #N/A 3.960 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
NAPSA napsin A aspartic peptidase 0.286 #N/A #N/A 
NARG1 NMDA receptor regulated 1 #N/A #N/A 3.021 
NAT6|HYAL3 N-acetyltransferase 
6|hyaluronoglucosaminidase 3 
#N/A 4.549 4.564 
NAT8 N-acetyltransferase 8 (camello like) 0.247 #N/A 0.240 
NBLA00058 asparagine synthetase domain containing 1 #N/A #N/A 3.797 
NCF1 neutrophil cytosolic factor 1 (47kDa, chronic 
granulomatous disease, autosomal 1) 
0.277 #N/A 0.257 
NCOA2 nuclear receptor coactivator 2 0.308 #N/A 0.336 
NDEL1 nudE nuclear distribution gene E homolog like 
1 (A. nidulans) 
3.194 #N/A 3.046 
NDRG1 N-myc downstream regulated gene 1 10.275 9.694 12.636 
NDRG4 NDRG family member 4 0.329 #N/A #N/A 
NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 3, 12kDa 
0.297 #N/A #N/A 
NEDD4L neural precursor cell expressed, 
developmentally down-regulated 4-like 
4.202 #N/A 4.766 
NEIL3 nei endonuclease VIII-like 3 (E. coli) 0.347 #N/A #N/A 
NEU2 sialidase 2 (cytosolic sialidase) 0.202 #N/A #N/A 
NFAM1 NFAT activating protein with ITAM motif 1 #N/A #N/A 0.284 
NFATC1 nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 1 
4.202 #N/A 3.817 
NFKBIZ nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, zeta 
3.194 #N/A 3.104 
NID2 nidogen 2 (osteonidogen) 2.933 #N/A #N/A 
NIP dual oxidase maturation factor 1 0.334 #N/A #N/A 
NKX2-5 NK2 transcription factor related, locus 5 
(Drosophila) 
#N/A #N/A 3.447 
NKX6-1 NK6 transcription factor related, locus 1 
(Drosophila) 
#N/A #N/A 0.004 
NMNAT1 nicotinamide nucleotide adenylyltransferase 1 0.287 #N/A #N/A 
NOD9 NLR family member X1 #N/A #N/A 0.318 
NOX1 NADPH oxidase 1 0.251 #N/A #N/A 
NOXA1 NADPH oxidase activator 1 0.297 #N/A #N/A 
NPAL1 NIPA-like domain containing 1 #N/A #N/A 3.267 
NR3C2 nuclear receptor subfamily 3, group C, member 
2 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
NR4A2 nuclear receptor subfamily 4, group A, member 
2 
9.097 18.751 20.220 
NR4A3 nuclear receptor subfamily 4, group A, member 
3 
23.907 9.223 14.894 
NRBP2 nuclear receptor binding protein 2 0.228 #N/A #N/A 
NRCAM neuronal cell adhesion molecule 3.397 #N/A 3.118 
NRG1 neuregulin 1 3.216 #N/A #N/A 
NRIP1 nuclear receptor interacting protein 1 3.090 2.915 5.682 
NRP2 neuropilin 2 4.482 7.933 10.570 
NT5E 5'-nucleotidase, ecto (CD73) 11.756 7.268 13.481 
NUDT13 nudix (nucleoside diphosphate linked moiety 
X)-type motif 13 
#N/A 0.354 #N/A 
NUDT7 nudix (nucleoside diphosphate linked moiety 
X)-type motif 7 
0.174 #N/A 0.296 
NUPL1 nucleoporin like 1 2.851 2.902 4.311 
NXF5 nuclear RNA export factor 5 0.207 #N/A #N/A 
NYD-SP14 tetratricopeptide repeat domain 29 #N/A 0.341 #N/A 
NYD-SP17 coiled-coil domain containing 54 0.016 0.022 0.010 
OACT1 O-acyltransferase (membrane bound) domain 
containing 1 
#N/A 0.342 0.353 
ODF2L outer dense fiber of sperm tails 2-like 0.308 0.270 #N/A 
OKL38 oxidative stress induced growth inhibitor 1 #N/A #N/A 0.236 
OLFML3 olfactomedin-like 3 0.353 #N/A #N/A 
OR10G3 olfactory receptor, family 10, subfamily G, 
member 3 
0.242 #N/A #N/A 
OR10W1 olfactory receptor, family 10, subfamily W, 
member 1 
3.592 2.857 #N/A 
OR1D2 olfactory receptor, family 1, subfamily D, 
member 2 
#N/A #N/A 0.346 
OR1F2 olfactory receptor, family 1, subfamily F, 
member 2 
0.249 #N/A #N/A 
OR2C1 olfactory receptor, family 2, subfamily C, 
member 1 
#N/A #N/A 0.239 
OR2F1 olfactory receptor, family 2, subfamily F, 
member 1 
0.318 #N/A 0.179 
OR2F2 olfactory receptor, family 2, subfamily F, 
member 2 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
OR4B1 olfactory receptor, family 4, subfamily B, 
member 1 
0.332 #N/A #N/A 
OR51T1 olfactory receptor, family 51, subfamily T, 
member 1 
0.343 #N/A 0.275 
OR52I2 olfactory receptor, family 52, subfamily I, 
member 2 
#N/A #N/A 0.139 
OR52K1 olfactory receptor, family 52, subfamily K, 
member 1 
0.267 #N/A #N/A 
OR52K2 olfactory receptor, family 52, subfamily K, 
member 2 
#N/A #N/A 0.333 
OR5AU1 olfactory receptor, family 5, subfamily AU, 
member 1 
0.178 #N/A #N/A 
OR5B21 olfactory receptor, family 5, subfamily B, 
member 21 
0.344 #N/A #N/A 
OR6W1P olfactory receptor, family 6, subfamily W, 
member 1 pseudogene 
#N/A 0.348 0.291 
OR7D4 olfactory receptor, family 7, subfamily D, 
member 4 
0.187 0.346 #N/A 
OTOS otospiralin 0.336 #N/A #N/A 
OVOS2 ovostatin 2 0.346 #N/A 0.338 
P2RXL1 purinergic receptor P2X-like 1, orphan receptor 0.266 #N/A #N/A 
P2RY6 pyrimidinergic receptor P2Y, G-protein 
coupled, 6 
#N/A #N/A 0.352 
PABPC5 poly(A) binding protein, cytoplasmic 5 0.262 #N/A 0.135 
PACRG PARK2 co-regulated 0.291 #N/A 0.352 
PADI3 peptidyl arginine deiminase, type III 0.320 #N/A #N/A 
PAK1IP1 PAK1 interacting protein 1 #N/A #N/A 3.160 
PAQR5 progestin and adipoQ receptor family member 
V 
3.695 4.058 6.337 
PAQR8 progestin and adipoQ receptor family member 
VIII 
0.165 #N/A 0.292 
PAQR9 progestin and adipoQ receptor family member 
IX 
#N/A #N/A 3.945 
PARP4 poly (ADP-ribose) polymerase family, member 
4 
#N/A #N/A 0.301 
PAX8 paired box gene 8 #N/A 2.945 #N/A 
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  PGF Butaprost PGF & 
Butaprost 
PCDH9 protocadherin 9 #N/A 0.310 #N/A 
PCDHA2 protocadherin alpha 2 #N/A 0.345 #N/A 
PCDHA4 protocadherin alpha 4 #N/A 0.331 #N/A 
PCDHB14 protocadherin beta 14 0.332 #N/A #N/A 
PCDHB8 protocadherin beta 8 #N/A 0.348 #N/A 
PCDHGA6 protocadherin gamma subfamily A, 6 #N/A 0.293 #N/A 
PCDHGB6 protocadherin gamma subfamily B, 6 0.194 #N/A #N/A 
PCNXL3 pecanex-like 3 (Drosophila) 0.301 #N/A #N/A 
PCYT1B phosphate cytidylyltransferase 1, choline, beta #N/A #N/A 0.342 
PDE2A phosphodiesterase 2A, cGMP-stimulated 3.032 #N/A #N/A 
PDK2 pyruvate dehydrogenase kinase, isozyme 2 #N/A #N/A 0.243 
PDLIM2 PDZ and LIM domain 2 (mystique) #N/A #N/A 2.901 
PDLIM5 PDZ and LIM domain 5 4.986 2.853 5.777 
PDLIM7 PDZ and LIM domain 7 (enigma) 3.242 #N/A #N/A 
PDZK3 PDZ domain containing 3 0.340 0.279 0.295 
PEX11G peroxisomal biogenesis factor 11 gamma 0.335 #N/A #N/A 
PEX12 peroxisomal biogenesis factor 12 0.302 #N/A #N/A 
PFN4 profilin family, member 4 #N/A #N/A 0.216 
PGAM2 phosphoglycerate mutase 2 (muscle) 0.292 #N/A #N/A 
PHF2 PHD finger protein 2 #N/A #N/A 3.138 
PHF21A PHD finger protein 21A 0.252 0.305 #N/A 
PHIP pleckstrin homology domain interacting protein #N/A #N/A 0.205 
PHLDA1 pleckstrin homology-like domain, family A, 
member 1 
4.755 5.857 6.806 
PHLDB2 pleckstrin homology-like domain, family B, 
member 2 
4.476 2.980 3.686 
PI3 peptidase inhibitor 3, skin-derived (SKALP) 5.027 3.020 6.396 
PIK3AP1 phosphoinositide-3-kinase adaptor protein 1 0.334 #N/A #N/A 
PIM1 pim-1 oncogene 3.229 #N/A 3.310 
PIM3 pim-3 oncogene 4.051 #N/A 3.814 
PIN4 protein (peptidyl-prolyl cis/trans isomerase) 
NIMA-interacting, 4 (parvulin) 
0.264 #N/A #N/A 
PKP3 plakophilin 3 #N/A #N/A 0.326 
PLA2G1B phospholipase A2, group IB (pancreas) 0.262 #N/A #N/A 
PLA2G2E phospholipase A2, group IIE 0.327 #N/A #N/A 
PLA2G4F phospholipase A2, group IVF 0.328 #N/A #N/A 
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  PGF Butaprost PGF & 
Butaprost 
PLA2G7 phospholipase A2, group VII (platelet-
activating factor acetylhydrolase, plasma) 
0.265 #N/A #N/A 
PLAG1 pleiomorphic adenoma gene 1 0.348 #N/A #N/A 
PLAU plasminogen activator, urokinase 3.776 #N/A #N/A 
PLAUR plasminogen activator, urokinase receptor 13.711 4.154 15.528 
PLEC1 plectin 1, intermediate filament binding protein 
500kDa 
#N/A #N/A 0.331 
PLEKHA7 pleckstrin homology domain containing, family 
A member 7 
3.386 #N/A #N/A 
PLEKHC1 pleckstrin homology domain containing, family 
C (with FERM domain) member 1 
#N/A #N/A 3.082 
PLEKHG1 pleckstrin homology domain containing, family 
G (with RhoGef domain) member 1 
#N/A #N/A 0.286 
PLSCR4 phospholipid scramblase 4 0.217 0.277 0.228 
PLXDC2 plexin domain containing 2 #N/A #N/A 0.302 
PMAIP1 phorbol-12-myristate-13-acetate-induced 
protein 1 
#N/A #N/A 3.109 
POLR3G polymerase (RNA) III (DNA directed) 
polypeptide G (32kD) 
0.288 #N/A #N/A 
PPFIBP2 PTPRF interacting protein, binding protein 2 
(liprin beta 2) 
#N/A 0.308 #N/A 
PPP1R15A protein phosphatase 1, regulatory (inhibitor) 
subunit 15A 
3.151 #N/A 4.609 
PPP3CC protein phosphatase 3 (formerly 2B), catalytic 
subunit, gamma isoform (calcineurin A 
gamma) 
3.778 5.301 5.656 
PRAC small nuclear protein PRAC  0.348 #N/A #N/A 
PRICKLE2 prickle-like 2 (Drosophila) 0.207 #N/A #N/A 
PRKAG2 protein kinase, AMP-activated, gamma 2 non-
catalytic subunit 
5.307 3.246 4.073 
PRKCG protein kinase C, gamma 0.342 #N/A #N/A 
PRO0478 PRO0478 protein  0.318 #N/A 0.262 
PROC protein C (inactivator of coagulation factors Va 
and VIIIa) 
0.214 #N/A #N/A 
PROM1 prominin 1 3.021 #N/A #N/A 
PRPF38B PRP38 pre-mRNA processing factor 38 (yeast) 
domain containing B 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
PRSS12 protease, serine, 12 (neurotrypsin, motopsin) #N/A #N/A 0.005 
PRSS3 protease, serine, 3 (mesotrypsin) #N/A #N/A 0.019 
PRSS33 protease, serine, 33 #N/A #N/A 0.343 
PRTG protogenin homolog (Gallus gallus) 0.326 #N/A #N/A 
PSG4 pregnancy specific beta-1-glycoprotein 4 0.322 #N/A #N/A 
PSME2 proteasome (prosome, macropain) activator 
subunit 2 (PA28 beta) 
0.243 #N/A #N/A 
PSORS1C2 psoriasis susceptibility 1 candidate 2 #N/A #N/A 0.331 
PSRC1 proline/serine-rich coiled-coil 1 #N/A #N/A 0.280 
PTDSR phosphatidylserine receptor #N/A #N/A 2.975 
PTGER4 prostaglandin E receptor 4 (subtype EP4) 3.238 2.837 8.337 
PTGIR prostaglandin I2 (prostacyclin) receptor (IP) 0.325 #N/A 0.295 
PTGS2 prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase) 
6.245 3.923 10.906 
PTHLH parathyroid hormone-like hormone #N/A #N/A 3.316 
PTPRB protein tyrosine phosphatase, receptor type, B 2.986 #N/A 3.081 
PTPRU protein tyrosine phosphatase, receptor type, U 0.268 #N/A #N/A 
PTRF polymerase I and transcript release factor 3.291 #N/A 3.756 
PVALB parvalbumin 0.270 #N/A #N/A 
PVR poliovirus receptor #N/A #N/A 3.256 
PXDN peroxidasin homolog (Drosophila) #N/A #N/A 0.350 
PXK PX domain containing serine/threonine kinase 0.284 #N/A #N/A 
RAB11FIP4 RAB11 family interacting protein 4 (class II) #N/A #N/A 0.326 
RAB26 RAB26, member RAS oncogene family 0.254 #N/A #N/A 
RAB7B RAB7B, member RAS oncogene family 0.313 0.196 0.241 
RABGGTB Rab geranylgeranyltransferase, beta subunit #N/A #N/A 4.194 
RAFTLIN raftlin, lipid raft linker 1 3.144 3.422 4.340 
RAG1 recombination activating gene 1 0.330 0.349 #N/A 
RAI1 retinoic acid induced 1 #N/A #N/A 0.215 
RAI17 retinoic acid induced 17 0.327 0.262 0.292 
RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 
5 
#N/A 3.479 4.048 
RASAL1 RAS protein activator like 1 (GAP1 like) 0.296 #N/A #N/A 
RASAL2 RAS protein activator like 2 3.538 #N/A 3.817 
RASD1 RAS, dexamethasone-induced 1 27.066 11.275 14.339 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
RDH12 retinol dehydrogenase 12 (all-trans and 9-cis) 0.318 #N/A #N/A 
RDHE2 epidermal retinal dehydrogenase 2 0.339 #N/A #N/A 
RDM1 RAD52 motif 1 0.215 0.286 #N/A 
RECK reversion-inducing-cysteine-rich protein with 
kazal motifs 
#N/A #N/A 0.350 
RECQL5 RecQ protein-like 5 0.319 #N/A 0.347 
REG3G regenerating islet-derived 3 gamma #N/A #N/A 0.220 
RELB v-rel reticuloendotheliosis viral oncogene 
homolog B, nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 3 (avian) 
#N/A #N/A 2.969 
RGC32 chromosome 13 open reading frame 15 4.042 5.167 6.149 
RGR retinal G protein coupled receptor #N/A #N/A 0.041 
RGS16 regulator of G-protein signalling 16 5.391 4.172 6.796 
RGS20 regulator of G-protein signalling 20 #N/A #N/A 3.633 
RGS3 regulator of G-protein signalling 3 2.975 3.828 5.033 
RHBDL2 rhomboid, veinlet-like 2 (Drosophila) 0.271 0.317 0.329 
RHCG Rhesus blood group, C glycoprotein 0.309 #N/A #N/A 
RHOF ras homolog gene family, member F (in 
filopodia) 
5.316 4.791 6.335 
RHOH ras homolog gene family, member H 0.328 #N/A #N/A 
RHOU ras homolog gene family, member U 0.177 #N/A #N/A 
RIBC2 RIB43A domain with coiled-coils 2 0.296 #N/A #N/A 
RLN1 relaxin 1 #N/A 0.348 0.323 
RLN2 relaxin 2 0.219 #N/A #N/A 
RNASEL ribonuclease L (2',5'-oligoisoadenylate 
synthetase-dependent) 
0.217 0.246 0.332 
RND3 Rho family GTPase 3 3.132 #N/A 5.647 
RNF126 ring finger protein 126 2.956 #N/A 2.909 
RNF148 ring finger protein 148 0.256 #N/A #N/A 
ROBO4 roundabout homolog 4, magic roundabout 
(Drosophila) 
0.225 #N/A 0.314 
RPL19 ribosomal protein L19 0.320 #N/A #N/A 
RPL22 ribosomal protein L22 #N/A #N/A 2.926 
RPRM reprimo, TP53 dependent G2 arrest mediator 
candidate 
#N/A 11.899 7.764 
RPS6KA3 ribosomal protein S6 kinase, 90kDa, 
polypeptide 3 
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  PGF Butaprost PGF & 
Butaprost 
RSHL3 radial spokehead-like 3 0.153 #N/A 0.286 
RTP2 receptor (chemosensory) transporter protein 2 #N/A #N/A 0.255 
RUNX3 runt-related transcription factor 3 #N/A 2.927 #N/A 
SACS spastic ataxia of Charlevoix-Saguenay (sacsin) 2.914 3.877 11.779 
SALL2 sal-like 2 (Drosophila) 0.308 #N/A 0.130 
SAMD13 sterile alpha motif domain containing 13 #N/A 0.352 0.311 
SAT spermidine/spermine N1-acetyltransferase #N/A 5.938 7.465 
SBDS Shwachman-Bodian-Diamond syndrome #N/A #N/A 3.499 
SBDSP Shwachman-Bodian-Diamond syndrome 
pseudogene 
#N/A #N/A 2.839 
SBLF stonin 1 #N/A 0.285 #N/A 
SBP1 multiple EGF-like-domains 8 0.247 #N/A #N/A 
SBSN suprabasin 0.156 #N/A #N/A 
SCGB1D4 secretoglobin, family 1D, member 4 0.084 0.033 0.055 
SCHIP1 schwannomin interacting protein 1 6.344 3.527 8.078 
SCML4 sex comb on midleg-like 4 (Drosophila) #N/A #N/A 0.274 
SCN1A sodium channel, voltage-gated, type I, alpha 0.150 0.301 #N/A 
SCN3B sodium channel, voltage-gated, type III, beta 0.305 #N/A #N/A 
SDCBP2 syndecan binding protein (syntenin) 2 #N/A 3.640 #N/A 
SDF2L1 stromal cell-derived factor 2-like 1 #N/A 2.870 #N/A 
SDPR serum deprivation response (phosphatidylserine 
binding protein) 
23.088 22.710 25.532 
SECTM1 secreted and transmembrane 1 0.286 #N/A #N/A 
SEMA3B sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3B 
3.500 3.327 3.711 
SEMA3C sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3C 
2.929 #N/A 3.222 
Sept9 septin 9 #N/A #N/A 0.209 
SERINC4 serine incorporator 4 #N/A #N/A 0.313 
SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), 
member 1 
#N/A #N/A 2.964 
SERPINB8 serpin peptidase inhibitor, clade B (ovalbumin), 
member 8 
4.768 2.872 5.570 
SERPINB9 serpin peptidase inhibitor, clade B (ovalbumin), 
member 9 
7.090 7.240 9.681 
SERPINE2 serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1) 2 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
SFN stratifin 9.903 6.957 15.545 
SH3GL2 SH3-domain GRB2-like 2 3.077 #N/A #N/A 
SH3MD2 SH3 multiple domains 2 3.302 #N/A 3.759 
SIAH2 seven in absentia homolog 2 (Drosophila) 3.095 #N/A #N/A 
SLC16A13 solute carrier family 16 (monocarboxylic acid 
transporters), member 13 
#N/A #N/A 0.336 
SLC16A2 solute carrier family 16 (monocarboxylic acid 
transporters), member 2 
0.195 #N/A #N/A 
SLC17A2 solute carrier family 17 (sodium phosphate), 
member 2 
0.225 #N/A #N/A 
SLC19A2 solute carrier family 19 (thiamine transporter), 
member 2 
3.682 2.831 3.855 
SLC20A1 solute carrier family 20 (phosphate transporter), 
member 1 
#N/A #N/A 3.075 
SLC20A2 solute carrier family 20 (phosphate transporter), 
member 2 
8.839 3.029 5.453 
SLC22A6 solute carrier family 22 (organic anion 
transporter), member 6 
0.321 #N/A 0.343 
SLC24A1 solute carrier family 24 
(sodium/potassium/calcium exchanger), 
member 1 
0.275 #N/A #N/A 
SLC25A25 solute carrier family 25 (mitochondrial carrier; 
phosphate carrier), member 25 
4.001 3.050 4.566 
SLC25A27 solute carrier family 25, member 27 0.224 #N/A #N/A 
SLC25A32 solute carrier family 25, member 32 3.526 3.342 4.787 
SLC27A1 solute carrier family 27 (fatty acid transporter), 
member 1 
#N/A #N/A 0.350 
SLC35D3 solute carrier family 35, member D3 0.314 #N/A 0.276 
SLC36A2 solute carrier family 36 (proton/amino acid 
symporter), member 2 
0.306 #N/A #N/A 
SLC38A1 solute carrier family 38, member 1 2.899 #N/A #N/A 
SLC38A2 solute carrier family 38, member 2 4.247 #N/A 3.078 
SLC39A14 solute carrier family 39 (zinc transporter), 
member 14 
3.457 #N/A #N/A 
SLC40A1 solute carrier family 40 (iron-regulated 
transporter), member 1 
0.331 0.301 #N/A 
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  PGF Butaprost PGF & 
Butaprost 
SLC6A1 solute carrier family 6 (neurotransmitter 
transporter, GABA), member 1 
0.268 #N/A #N/A 
SLC6A13 solute carrier family 6 (neurotransmitter 
transporter, GABA), member 13 
#N/A 0.340 #N/A 
SLC6A15 solute carrier family 6, member 15 #N/A #N/A 3.248 
SLC6A16 solute carrier family 6, member 16 0.351 #N/A #N/A 
SLC7A1 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1 
3.874 5.601 5.950 
SLC7A10 solute carrier family 7, (neutral amino acid 
transporter, y+ system) member 10 
0.199 #N/A #N/A 
SLC7A4 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 4 
0.296 #N/A #N/A 
SLCO4A1 solute carrier organic anion transporter family, 
member 4A1 
5.798 4.136 5.463 
SLITRK1 SLIT and NTRK-like family, member 1 0.068 0.184 0.154 
SLITRK5 SLIT and NTRK-like family, member 5 #N/A 0.316 0.324 
SMAD3 SMAD, mothers against DPP homolog 3 
(Drosophila) 
3.143 #N/A 2.899 
SMP3 phosphatidylinositol glycan anchor 
biosynthesis, class Z 
#N/A #N/A 0.295 
SMURF2 SMAD specific E3 ubiquitin protein ligase 2 6.362 3.245 7.439 
SNAI3 snail homolog 3 (Drosophila) 0.339 #N/A #N/A 
SNF1LK SNF1-like kinase 8.053 7.748 5.656 
SOCS2 suppressor of cytokine signaling 2 3.149 3.253 4.582 
SORBS2 sorbin and SH3 domain containing 2 0.118 0.331 0.184 
SORCS2 sortilin-related VPS10 domain containing 
receptor 2 
#N/A 0.240 #N/A 
SORCS3 sortilin-related VPS10 domain containing 
receptor 3 
0.325 #N/A #N/A 
SOSTDC1 sclerostin domain containing 1 0.092 0.124 0.143 
SOX17 SRY (sex determining region Y)-box 17 4.541 4.203 5.067 
SOX4 SRY (sex determining region Y)-box 4 #N/A 2.883 #N/A 
SOX9 SRY (sex determining region Y)-box 9 
(campomelic dysplasia, autosomal sex-
reversal) 
#N/A 0.277 #N/A 
SPAG4 sperm associated antigen 4 #N/A 3.061 #N/A 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
SPATA7 spermatogenesis associated 7 0.188 #N/A 0.339 
SPHK1 sphingosine kinase 1 9.932 5.058 11.676 
SPRR4 small proline rich protein 4 #N/A #N/A 0.271 
SPRY2 sprouty homolog 2 (Drosophila) 13.016 6.642 15.883 
SRF serum response factor (c-fos serum response 
element-binding transcription factor) 
4.857 3.860 5.632 
SSFA2 sperm specific antigen 2 4.356 3.082 4.585 
SSPN sarcospan (Kras oncogene-associated gene) #N/A 0.315 #N/A 
ST3GAL1 ST3 beta-galactoside alpha-2,3-
sialyltransferase 1 
5.256 3.346 5.416 
STAMBPL1 STAM binding protein-like 1 5.367 4.572 9.026 
STARD6 START domain containing 6 0.310 #N/A #N/A 
STAU2 staufen, RNA binding protein, homolog 2 
(Drosophila) 
0.329 0.262 0.322 
STEAP2 six transmembrane epithelial antigen of the 
prostate 2 
#N/A #N/A 0.322 
STK17A serine/threonine kinase 17a (apoptosis-
inducing) 
3.863 5.962 10.187 
STK23 serine/threonine kinase 23 0.321 #N/A #N/A 
STK38L serine/threonine kinase 38 like 3.482 3.048 5.345 
STK40 serine/threonine kinase 40 0.350 #N/A #N/A 
STX11 syntaxin 11 8.884 5.916 11.956 
SUHW1 suppressor of hairy wing homolog 1 
(Drosophila) 
#N/A #N/A 0.322 
SULT1E1 sulfotransferase family 1E, estrogen-preferring, 
member 1 
0.277 0.346 #N/A 
SULT2B1 sulfotransferase family, cytosolic, 2B, member 
1 
0.264 #N/A #N/A 
SUSD3 sushi domain containing 3 0.308 #N/A #N/A 
SYNE1 spectrin repeat containing, nuclear envelope 1 0.234 #N/A 0.234 
SYNJ1 synaptojanin 1 #N/A #N/A 0.287 
SYT1 synaptotagmin I 0.334 #N/A #N/A 
TAF1A TATA box binding protein (TBP)-associated 
factor, RNA polymerase I, A, 48kDa 
#N/A #N/A 3.438 
TAF4B TAF4b RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
105kDa 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
TAGLN transgelin 11.127 #N/A 5.695 
TAIP-2 family with sequence similarity 130, member 
A2 
0.267 0.214 #N/A 
TA-PP2C PTC7 protein phosphatase homolog (S. 
cerevisiae) 
3.496 3.525 4.636 
TAS2R4 taste receptor, type 2, member 4 #N/A 0.267 #N/A 
TCAM1 testicular cell adhesion molecule 1 homolog 
(mouse) 
0.352 #N/A #N/A 
TCF7L2 transcription factor 7-like 2 (T-cell specific, 
HMG-box) 
3.139 #N/A 3.291 
TCL1A T-cell leukemia/lymphoma 1A 0.304 #N/A #N/A 
TCL6 T-cell leukemia/lymphoma 6 #N/A #N/A 0.326 
TEAD1 TEA domain family member 1 (SV40 
transcriptional enhancer factor) 
5.415 4.017 5.357 
TENC1 tensin like C1 domain containing phosphatase 
(tensin 2) 
#N/A 0.343 #N/A 
TEX14 testis expressed sequence 14 #N/A #N/A 3.432 
TFAM transcription factor A, mitochondrial #N/A 2.986 3.118 
TFDP3 transcription factor Dp family, member 3 0.332 #N/A #N/A 
TFF3 trefoil factor 3 (intestinal) 0.353 #N/A #N/A 
TFPI2 tissue factor pathway inhibitor 2 8.138 5.338 6.674 
TFRC transferrin receptor (p90, CD71) 3.043 #N/A 3.366 
TGFB2 transforming growth factor, beta 2 5.091 #N/A 3.451 
THAP2 THAP domain containing, apoptosis associated 
protein 2 
0.317 #N/A #N/A 
THBS1 thrombospondin 1 15.614 5.176 13.901 
THNSL1 threonine synthase-like 1 (bacterial) 0.305 #N/A #N/A 
THSD1P thrombospondin, type I, domain containing 1 
pseudogene 
#N/A #N/A 0.336 
THSD3 thrombospondin, type I, domain containing 3 0.314 #N/A #N/A 
TINAGL1 tubulointerstitial nephritis antigen-like 1 5.002 #N/A 4.403 
TIPARP TCDD-inducible poly(ADP-ribose) polymerase #N/A #N/A 2.932 
TLE3 transducin-like enhancer of split 3 (E(sp1) 
homolog, Drosophila) 
3.559 3.825 3.248 
TLN2 talin 2 #N/A #N/A 0.176 
TLX1 T-cell leukemia homeobox 1 #N/A #N/A 0.273 
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TMEM2 transmembrane protein 2 6.245 6.009 12.377 
TMEM22 transmembrane protein 22 3.840 2.884 3.115 
TMEM37 transmembrane protein 37 #N/A #N/A 0.176 
TMEM39A transmembrane protein 39A 2.865 #N/A #N/A 
TMEPAI transmembrane, prostate androgen induced 
RNA 
4.280 4.543 6.928 
TMPRSS11D transmembrane protease, serine 11D #N/A 0.339 #N/A 
TMPRSS2 transmembrane protease, serine 2 0.332 #N/A #N/A 
TNFAIP1 tumor necrosis factor, alpha-induced protein 1 
(endothelial) 
6.059 4.807 4.617 
TNFAIP8 tumor necrosis factor, alpha-induced protein 8 #N/A 0.286 #N/A 
TNFAIP8L1 tumor necrosis factor, alpha-induced protein 8-
like 1 
#N/A #N/A 0.330 
TNFAIP8L3 tumor necrosis factor, alpha-induced protein 8-
like 3 
0.313 0.283 #N/A 
TNFRSF10A tumor necrosis factor receptor superfamily, 
member 10a 
#N/A 3.881 #N/A 
TNFRSF11B tumor necrosis factor receptor superfamily, 
member 11b (osteoprotegerin) 
4.112 7.628 6.237 
TNFRSF12A tumor necrosis factor receptor superfamily, 
member 12A 
6.377 4.701 5.614 
TNFRSF19 tumor necrosis factor receptor superfamily, 
member 19 
0.323 #N/A #N/A 
TNFRSF21 tumor necrosis factor receptor superfamily, 
member 21 
3.609 3.061 3.726 
TNFSF15 tumor necrosis factor (ligand) superfamily, 
member 15 
0.219 #N/A 0.295 
TNFSF4 tumor necrosis factor (ligand) superfamily, 
member 4 (tax-transcriptionally activated 
glycoprotein 1, 34kDa) 
0.293 #N/A #N/A 
TNK2 tyrosine kinase, non-receptor, 2 #N/A #N/A 0.341 
TNN tenascin N 0.313 #N/A #N/A 
TNNC2 troponin C type 2 (fast) #N/A 0.331 #N/A 
TNRC6B trinucleotide repeat containing 6B #N/A #N/A 0.222 
TP53I11 tumor protein p53 inducible protein 11 0.274 0.306 0.235 
TP73 tumor protein p73 #N/A #N/A 0.318 
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  PGF Butaprost PGF & 
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TPM4 tropomyosin 4 3.925 #N/A #N/A 
TRFP Trf (TATA binding protein-related factor)-
proximal homolog (Drosophila) 
#N/A #N/A 0.337 
TRIB1 tribbles homolog 1 (Drosophila) 9.643 5.502 14.502 
TRIB3 tribbles homolog 3 (Drosophila) 3.340 #N/A #N/A 
TRIM38 tripartite motif-containing 38 0.301 #N/A #N/A 
TRIM45 tripartite motif-containing 45 0.307 #N/A 0.279 
TRIM51 tripartite motif-containing 51 #N/A #N/A 3.103 
TRIM6 tripartite motif-containing 6 #N/A 0.352 0.298 
TRPC6 transient receptor potential cation channel, 
subfamily C, member 6 
#N/A #N/A 6.694 
TRPS1 trichorhinophalangeal syndrome I #N/A 0.311 #N/A 
TRPV6 transient receptor potential cation channel, 
subfamily V, member 6 
#N/A #N/A 0.305 
TSGA10 testis specific, 10 #N/A 0.183 #N/A 
TSNARE1 t-SNARE domain containing 1 #N/A 0.296 #N/A 
TSPAN19 tetraspanin 19 0.284 #N/A #N/A 
TSSK3 testis-specific serine kinase 3 #N/A #N/A 0.218 
TTC25 tetratricopeptide repeat domain 25 0.352 #N/A #N/A 
TTC6 tetratricopeptide repeat domain 6 #N/A #N/A 3.036 
TU12B1-TY 5'-nucleotidase domain containing 3 3.361 #N/A 4.090 
TUBA2 tubulin, alpha 2 0.287 #N/A #N/A 
TUBE1 tubulin, epsilon 1 3.040 #N/A #N/A 
TXLNB taxilin beta 0.297 #N/A 0.332 
TXNIP thioredoxin interacting protein 0.179 0.119 0.101 
UAP1 UDP-N-acteylglucosamine pyrophosphorylase 
1 
#N/A #N/A 2.876 
UBE2H ubiquitin-conjugating enzyme E2H (UBC8 
homolog, yeast) 
#N/A #N/A 2.882 
UBIAD1 UbiA prenyltransferase domain containing 1 #N/A #N/A 0.350 
UBXD3 UBX domain containing 3 0.282 #N/A #N/A 
UCA1 urothelial cancer associated 1 4.959 3.493 4.452 
UGT1A10 UDP glucuronosyltransferase 1 family, 
polypeptide A10 
0.312 #N/A 0.270 
UGT2A1 UDP glucuronosyltransferase 2 family, 
polypeptide A1 
#N/A #N/A 0.208 
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  PGF Butaprost PGF & 
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USP1 ubiquitin specific peptidase 1 #N/A #N/A 2.897 
USP15 ubiquitin specific peptidase 15 #N/A #N/A 3.092 
USP16 ubiquitin specific peptidase 16 #N/A #N/A 2.921 
USP54 ubiquitin specific peptidase 54 #N/A #N/A 0.263 
VAV3 vav 3 oncogene 0.119 0.168 #N/A 
VCPIP1 valosin containing protein (p97)/p47 complex 
interacting protein 1 
3.262 #N/A #N/A 
VEGF vascular endothelial growth factor 5.351 6.048 8.186 
VGF VGF nerve growth factor inducible 4.008 7.001 6.959 
VIL1 villin 1 #N/A #N/A 0.331 
VLDLR very low density lipoprotein receptor 3.770 #N/A #N/A 
VMAC vimentin-type IF-associated coiled-coil protein  0.275 #N/A #N/A 
VMO1 vitelline membrane outer layer 1 homolog 
(chicken) 
8.842 19.813 0.143 
WDR36 WD repeat domain 36 #N/A #N/A 3.095 
WDR65 WD repeat domain 65 0.329 #N/A #N/A 
WDR71 WD repeat domain 71 #N/A #N/A 0.344 
WDR78 WD repeat domain 78 0.296 #N/A #N/A 
WFDC10A WAP four-disulfide core domain 10A #N/A 0.300 #N/A 
WFIKKN1 WAP, follistatin/kazal, immunoglobulin, kunitz 
and netrin domain containing 1 
3.549 #N/A 3.755 
WNT1 wingless-type MMTV integration site family, 
member 1 
#N/A #N/A 0.102 
WWTR1 WW domain containing transcription regulator 
1 
3.574 #N/A 4.269 
XKR5 X Kell blood group precursor-related family, 
member 5 
0.284 #N/A #N/A 
XKR5 X Kell blood group precursor-related family, 
member 5 
#N/A 0.322 #N/A 
XPNPEP1 X-prolyl aminopeptidase (aminopeptidase P) 1, 
soluble 
0.305 #N/A #N/A 
YOD1 YOD1 OTU deubiquinating enzyme 1 homolog 
( yeast) 
6.842 2.840 11.577 
YRDC yrdC domain containing (E.coli) 4.185 3.702 4.736 
ZBTB1 zinc finger and BTB domain containing 1 #N/A 2.868 #N/A 
ZC3H6 zinc finger CCCH-type containing 6 0.348 #N/A #N/A 
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  PGF Butaprost PGF & 
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ZHX2 zinc fingers and homeoboxes 2 3.126 #N/A #N/A 
ZIC5 Zic family member 5 (odd-paired homolog, 
Drosophila) 
2.979 3.301 3.679 
ZMYND17 zinc finger, MYND-type containing 17 0.210 #N/A #N/A 
ZNF165 zinc finger protein 165 7.478 2.906 5.551 
ZNF20 zinc finger protein 20 (KOX 13) 0.232 #N/A #N/A 
ZNF214 zinc finger protein 214 0.264 #N/A #N/A 
ZNF223 zinc finger protein 223 0.325 #N/A #N/A 
ZNF23|ZNF19 zinc finger protein 23 (KOX 16)|zinc finger 
protein 19 (KOX 12) 
#N/A 0.321 #N/A 
ZNF306 zinc finger protein 306 0.274 0.225 0.288 
ZNF307 zinc finger protein 307 0.310 #N/A #N/A 
ZNF323 zinc finger protein 323 #N/A 0.164 0.117 
ZNF333 zinc finger protein 333 0.304 #N/A #N/A 
ZNF337 zinc finger protein 337 0.289 0.293 #N/A 
ZNF396 zinc finger protein 396 0.189 #N/A #N/A 
ZNF404 zinc finger protein 404 #N/A #N/A 0.337 
ZNF418 zinc finger protein 418 0.340 #N/A #N/A 
ZNF433 zinc finger protein 433 #N/A 0.314 #N/A 
ZNF483 zinc finger protein 483 #N/A #N/A 0.059 
ZNF488 zinc finger protein 488 0.199 0.321 0.227 
ZNF499 zinc finger protein 499 0.303 #N/A #N/A 
ZNF503 zinc finger protein 503 #N/A #N/A 3.599 
ZNF512 zinc finger protein 512 0.302 #N/A 0.245 
ZNF545 zinc finger protein 545 #N/A #N/A 4.457 
ZNF546 zinc finger protein 546 0.353 #N/A #N/A 
ZNF564 zinc finger protein 564 0.275 #N/A #N/A 
ZNF568 zinc finger protein 568 0.337 #N/A #N/A 
ZNF575 zinc finger protein 575 0.323 #N/A #N/A 
ZNF596 zinc finger protein 596 0.340 #N/A 0.345 
ZNF606 zinc finger protein 606 0.258 0.200 #N/A 
ZNF610 zinc finger protein 610 #N/A #N/A 0.295 
ZNF621 zinc finger protein 621 #N/A 0.348 #N/A 
ZNF66 zinc finger protein 66 #N/A 0.343 #N/A 
ZNF676 zinc finger protein 676 0.321 0.345 #N/A 
ZNF681 zinc finger protein 681 0.228 #N/A #N/A 















Gene Name Fold Change 
  PGF Butaprost PGF & 
Butaprost 
ZNF702 zinc finger protein 702 #N/A 0.346 #N/A 
ZNF703 zinc finger protein 703 #N/A 3.279 3.040 
ZNF85 zinc finger protein 85 (HPF4, HTF1) 0.348 #N/A #N/A 
ZNRF1 zinc and ring finger 1 0.119 #N/A 0.246 
ZP1 zona pellucida glycoprotein 1 (sperm receptor) #N/A #N/A 0.321 
ZRF1 zuotin related factor 1 #N/A #N/A 3.173 
ZXDA zinc finger, X-linked, duplicated A 0.257 #N/A #N/A 
ZYG11B zyg-11 homolog B (C. elegans) 0.290 0.338 #N/A 













BUFFERS AND SOLUTIONS 
 
Agarose gel-loading buffer  
   0.25% w/v bromophenol blue 
  0.25% xylene cyanol FF 
  40% (w/v) sucrose in water   
 
Agarose gel tracking dye:  
  0.25 % w/v bromophenol blue   
  40% w/v sucrose 
  20mM (pH 8.0) EDTA   
 
Buffer I:    
140mM NaCl 





1mg/ml bovine serum  
10mM LiCl 
Laemmli buffer:   
125mM Tris-HCL pH 6.8  
4% SDS  
20% glycerol 
5% 2-mercapthoethanol  













10% Glycerol  
0.6% (v/v) NP-40  
50mM Tris/HCL pH 7.4  
10mM EDTA (add protease inhibitor cocktail before use) 
 
TAE electrophoresis buffer (50X 1litre): 
  242g Tris   
  57.1ml Glacial acetic acid 
  100ml EDTA (0.5M) adjust volume with distilled water  
 
Transfer Buffer:  
  25mM Tris/HCL,  
0.192M Glycine and  
20% Methanol  
 
Tris-EDTA (TE) buffer:  
  10mM Tris   
  1mM EDTA adjust to pH 7.6 with HCL 
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